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List of main abbreviations 
ACL  - antibodies to cardiolipin 
ALT - alanine aminotransferase 
AMCV - antibodies to modified citrulline vimentin 
ANA - antinuclear antibodies 
ANF - antinuclear factor 
ANCA - antineutrophilic cytoplasmic antibodies 
ANCA-SV - systemic vasculitis associated with antineutrophilic 
cytoplasmic antibodies 
ACE - angiotensin-converting enzyme 
ARD - autoimmune rheumatic diseases 
AST - aspartic aminotransferase 
APLA - antiphospholipid antibodies 
APS - atiphospholipid syndrome 
ACA - anticentromeric antibodies 
ACP - antibodies to citrulline proteins 
ACCP - antibodies to cyclic citrulline peptide 
DMARDs - basic anti-inflammatory drugs 
LA - lupus anticoagulant 
GEBD -genetic engineering biological drugs 
GCS - glucocorticosteroids 
GPA - granulomatous polyangiitis 
DM - dermatomyositis 
DNA - Deoxyribonucleic acid 
DS - diagnostic specificity 
DS - diagnostic sensitivity 
GIT - gastrointestinal tract 
IL - interleukin 
ELISA - enzyme-linked immunosorbent assay 
CPK - creatine phosphokinase 
IIF - indirect immunofluorescence 
NSAIDs - non-steroidal anti-inflammatory drugs 
MPO - myeloperoxidase 
MP - microscopic polyangiitis 
MRI - Magnetic resonance imaging 
PR-3  - proteinase 3 
PM - polymyositis 
RA - rheumatoid arthritis 
RF - rheumatoid factor 
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MCTD - mixed connective tissue disease 
SLE - systemic lupus erythematosus 
SS/SSD - systemic sclerosis / systemic scleroderma 
ESR - sedimentation rate of erythrocytes 
RP - C-reactive protein 
SS - Sjogren's syndrome 
TGF-β - transforming growth factor beta 
FER - function of external respiration 
FC - functional class 
TNF-α  - tumor necrosis factor alpha 
CNS - central nervous system 
COX-1 - cyclooxygenase type 1 
COX-2 - cyclooxygenase type 2 
EGPА  - eosinophilic granulomatosis with polyangiitis 
aβ2-GP 1 - antibodies to β2-glycoprotein 1 
аSS-A/Ro - antibodies to antigenic determinants on two nuclear 
proteins (61 and 52 kDa) (Sjogren syndrome A / Robert) 
аSS-B/La - antibodies to the antigenic determinant associated with 
the protein (43 kDa), forming a complex with RNA 
(Sjogren syndrome B / Lane) 
аSm - antibodies to the nuclear protein Sm 
аScl-70  - antibodies to topoisomerase I (Scl-70) 
аRNA polymerase 
III 
- antibodies to RNA polymerase III 
аCENP-A, CENP-
B, CENP-C 
- anti-acetromeric antibodies, antibodies to centromere 
antigens - Centromere protein-A (CENP-A), -B, -C 
anRNP (U1-RNP)  - antibodies to small nuclear ribonucleoprotein 




- antinucleolar autoantibodies 
аPCNA 
 
- antibodies to the nuclear antigen of proliferating cells 
(proliferating cell nuclear antigen 1) 
аJo-1, аPL-7, аPL-
12, аEJ, аOJ 
- antibodies to tRNA synthetases of cytoplasm 
ACR - American College of Rheumatology (American 
College of Rheumatologists) 
CD - cluster of differentiation 
CD20  - CD20 antigen - protein, coreceptor located on the 
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surface of B-lymphocytes 
DAS28 - Disease Activity Score 28– disease activity index 
dsDNA - double-stranded deoxyribonucleic acid 
EULAR - European League Against Rheumatism (European 
League Against Rheumatism) 
IgM, IgG, IgA, IgE, 
IgD 
- immunoglobulin (s) class A, G, E, D 
HLA - human leucocyte antigens  
SLICC - Systemic Lupus International Collaboratoring Clinics 
(criteria for systemic international joint clinics for 
systemic lupus erythematosus) 
SICCA - Sjogren’s International Collaborative Clinical Alliance 
(Sjogren’s International Clinical Clinical Alliance 
criteria) 
Th1Th2 - T-helper of the first type and second type 
Тreg - T-regulatory cells 
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1. CLASSIFICATION AND IMMUNOPATHOGENESIS OF 
AUTOIMMUNE RHEUMATIC DISEASES 
 
 
Autoimmune diseases are characterized by a high prevalence in the population, the 
difficulty of early diagnosis, and often cause the rapid disability of patients, reduce 
their life expectancy. Treatment of autoimmune diseases requires large financial 
costs and is characterized by low efficiency in some patients. 
Autoimmune diseases occur as a result of increased immune responses to the 
molecular components of their own cells, tissues, and organs that act as antigens. 
The recognition of "their own" molecules by cells of the immune system is 
disrupted, so autoantibodies and sensitized T-lymphocytes with specific T-cell 
receptors are formed. 
According to modern concepts, in the pathogenesis of autoimmune diseases, along 
with the activation of acquired immunity (hyperproduction of autoantibodies), a 
large role belongs to the innate link of immunity responsible for the formation of 
autoimmune inflammation. A key role in the activation of innate immunity is 
played by Toll-(Toll-like receptor, TLR) and NOD-like (Nod-like-receptor, NLR) 
receptors that recognize certain sequences (patterns) of microorganisms, core 
components released from cells subjected to apoptosis, uric acid crystals, 
cholesterol, etc. 
In 2006, a classification - a continuum of immuno-inflammatory diseases [28] - 
was proposed, which combines a group of clinically heterogeneous diseases with 
common pathogenesis mechanisms characterized by a combination of 
autoinflammation and autoimmunity processes, which are associated with 
genetically determined and induced by environmental factors defects in the 
activation of the innate and acquired immune response. The frequency of immuno-
inflammatory diseases in the population is 8% and has 100 nosological forms. 
The continuum of immuno-inflammatory diseases includes: 
1. Rare monogenic auto-inflammatory diseases: systemic Mediterranean fever, 
pyogenic sterile arthritis, etc. 
2. Polygenic auto-inflammatory diseases: Crohn's disease, ulcerative colitis, 
osteoarthritis, gout, etc. crystalline arthritis, giant cell arteritis, Takayasu disease, 
etc. 
3. Auto-inflammatory autoimmune diseases associated with HLA (human 
leucocyte antigens – human leukocyte antigens) class I: ankylosing spondylitis, 
psoriatic arthritis, Behcet's disease, uveitis, still's disease, multiple sclerosis. 
4. Classic polygenic autoimmune diseases (organ-specific and organ-specific): 
▪ organ-specific: celiac disease, primary biliary cirrhosis, type 1 diabetes, 
autoimmune diseases of the thyroid gland, myasthenia gravis, pemphigus, etc. 
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▪ organ-specific (systemic) autoimmune rheumatoid diseases: rheumatoid arthritis 
(RA), systemic lupus erythematosus (SLE); Sjogren's syndrome (SS); systemic 
sclerosis/systemic scleroderma (SS/SSD); dermatomyositis/polymyositis 
(DM/PM); systemic vasculitis associated with anti-neutrophil cytoplasmic 
antibodies (ANCA-SV), antiphospholipid syndrome (APS). 
5. Rare monogenic autoimmune diseases: autoimmune lymphoproliferative 
syndrome, autoimmune syndrome of polyendocrinopathy-candidiasis-ectodermal 
dystrophy. 
 
A heterogeneous group of autoimmune rheumatic diseases (ARD) is united by 
common genetic predisposition factors, immunopathogenesis, and similarity of 
clinical symptoms that reflect systemic inflammation [6, 19]. 
Combinations of factors that ensure the ARD development: 
• genetic predisposition associated with HLA-system genes, which is realized 
through the interaction of immune system cells, target cells and pathogenic 
antigens that share epitopes with autologous organ-specific molecules-
hormones, enzymes, and cytokines; 
• genetically determined presence of affine variants of variable chains and 
active receptor centers on T-and B-lymphocytes to organ-specific molecules, 
which increases the potential ability of lymphocytes to form clones of 
autoreactive cells; 
• presence of adverse factors-chemical, physical and biological (infections, 
Smoking, obesity, violation of the intestinal microbiota, etc.) that stimulate 
autoallergia. 
 
The immunopathogenesis of ARD is based on the concept of disruption of t-cell 
tolerance, which leads to an imbalance between Th (t-helpers) type 1, Th17 and 
Th2, resulting in the predominant synthesis of proinflammatory cytokines - TNF-α 
(tumor necrosis factor alpha), interleukin (IL)-1, IL-6, IL-8, IL-12, IL-17, IL-23, 
etc.over anti - inflammatory cytokines-IL-10, TFR-β (transforming growth factor 
beta) and Others. Defects of t-regulatory (tged) cells play a fundamental role in the 
violation of immune tolerance to their own proteins in ARD (figure 1). Th1 and 
TH17 are involved in the anti-infectious immune response and the development of 
autoimmune reactions, Th2-in the development of allergic reactions. Cytokines 
secreted by Th1 and Th2 have an opposite effect, and an imbalance between cells 
leads to the development of pathology. Thed cells play an important role in 
maintaining immune tolerance, influencing the functions of Th1 and Th2, 















T-bet, FoxP3, GATA-3 - transcription factors of Th1, T-regulatory and Th2 
cells. 















2. IMMUNODIAGNOSIS OF 
AUTOIMMUNE RHEUMATIC DISEASES 
 
Early diagnosis of ARD using only clinical and instrumental research methods is 
often difficult. Progress in the diagnosis of ARD is closely related to the 
determination of the spectrum of molecular and cellular biomarkers, including: 
autoantibodies, acute-phase inflammatory proteins, cytokines, chemokines, 
markers of vascular endothelial activation, components of the complement system, 
lymphocyte subpopulations, products of bone and cartilage metabolism, genetic, 
epigenetic, transcriptomic markers in blood, synovial fluid, urine, synovial 
membrane biopsies, kidneys, and others affected tissue. The study of molecular 
and cellular biomarkers makes it possible to assess the activity of the pathological 
process, determine the prognosis of the disease, and also predict the effectiveness 
of treatment, which is especially important in the case of pharmacotherapy using 
immunobiological drugs. 
Autoantibodies are the main diagnostic laboratory markers of ARD, allowing to 
evaluate the activity and prognosis of ARD. 
 
The group of autoantibodies detected in ARD includes: 
* Antinuclear antibodies (ANA). 
* Rheumatoid factor (RF). 
* Antibodies to citrullinated proteins (ACP). 
* Antineutrophilic cytoplasmic antibodies (ANCA). 
* Antiphospholipid antibodies (APLA). 
It is important to remember that the detection of autoantibodies in the absence of 
clinical signs is not sufficient for diagnosis. 
Autoantibodies are often detected out of association with ARD: 
• in the elderly and senile; 
• on the background of taking medicines; 
• for viral and bacterial infections; 
•  for malignant neoplasms; 
•  in healthy relatives of patients with autoimmune diseases. 
ARD is characterized by persistent and pronounced hyperproduction of 
autoantibodies, while in other cases - moderate transient formation of them. 
Immunological diagnostics of ARD is carried out in 2 stages: 1-performing 
screening tests; 2 - performing tests for differential diagnosis. 
Indications for the appointment of immunological studies and interpretation of 
their results in the manual are presented from the position of ACR/EULAR 
(American College of Rheumatology/European League Against Rheumatism-
American College of rheumatology/European League against rheumatism), 
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according to the recommendations for laboratory diagnostics proposed by the 
Association of rheumatologists in Russia (ARR) [1, 4], the clinical Protocol for the 
diagnosis and treatment of patients with rheumatic diseases in the Republic of 
Belarus [5]. 
 
Screening tests for the diagnosis of autoimmune rheumatic diseases 
 
Determination of antibodies to the nuclear structures of the cell-antinuclear 
autoantibodies 
ANA is a heterogeneous group of antibodies that react with various components of 
the cell nucleus and cytoplasm. 
Indications for use: SLE, SS, localized scleroderma, DM, PM, SS, mixed 
connective tissue disease (MCTD, Sharpe syndrome), juvenile chronic arthritis, 
autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, exclusion 
of ARD with an unclear clinical picture. 
To detect ANA, a combination of 2 tests is recommended: 
- Determination of antibodies that react with the components of the nucleus of 
epithelial cells of human laryngeal adenocarcinoma of the ner-2 line by indirect 
immunofluorescence (IIF). The antibodies detected by the IIF method were called 
antinuclear factor (ANF). 
- Determination of antibodies to extractable nuclear antigen - ANA-screening (or 
ENA- / ENA-screen, ENA - extractable nuclear antigen / ENA - extractible nuclear 
antigen) by enzyme-linked immunosorbent assay (ELISA). Antinuclear antibodies 
include ribonucleoprotein antigens SS-A, SS-B, Sm, U1-RNP, antibodies to 
topoisomerase I (Scl-70), Jo-1. 
This set of tests is used to reduce the frequency of false-negative results. 
Simultaneous detection of ANA-screen and ANF provides recognition of 
antibodies to soluble antigens (SS-A, Jo-1, RibP), which can be lost from the cell 
nuclei or diffuse into the cell cytoplasm. 1-10% of patients who do not have ANF 
are diagnosed with "ANF-negative SLE" based on IIF results. 
Interpretation of results 
ANA is missing. Negative result - no ANA. In 95% of cases, it allows you to 
exclude ARD. A negative test result in a patient with signs of an autoimmune 
process does not exclude the presence of an autoimmune disease. 
ANA are present. Positive result - ANA present. Most often, ANA is found in 
MCTD (in 99% of cases), SLE (93% -95%),SS (60% -95%), SS (95%), DM / PM 
(30-50%), RA (30 -40%). The content of antinuclear antibodies is quantified in + 
(from 1+ to 4+), and as a serum titer. A higher titer of ANA indicates a high 
probability of ARD, especially SLE. 
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Normal ANF titers in blood serum are < 1: 40 when using cryostat sections of the 
liver or kidneys of laboratory animals and <1:160 when using Hep-2 cells. There 
are levels of anf-HEp-2 positivity: low-positive titles-1: 160, moderately positive 
titles-1:320-1:640, high-positive titles-1:1280 or more. 
When performing the IIF, the type of core glow is described and the associated 
antigens are specified (table 1). 
 
Table 1 - Characterization of antinuclear factor 
Type of glow Type of autoantibodies Association with diseases 
Homogeneous Antibodies to 
deoxyribonucleic acid of 
DNA (two and one-chiral), 
histones (H1, H2A, H2B, 
H3, H4) 
SLE, medicinal lupus, any 
ARD and non-rheumatic 
diseases 
Peripheral Antibodies to double-
stranded, native DNA  
SLE 
(boundary) Antibodies Sm, RNP, SS-
A/Ro, SS-B/La, Jo-1  
SLE, MCTD, Sjogren's 
syndrome, PM/DM 
Mottled  Antibodies to Scl-70 S / SSD 
Netted speckled Anti-centromeric antibodies 
(ACA) 
CREST syndrome, Raynaud's 
syndrome 
Discrete speckled Antibodies to RNA 
polymerase 1, PM/Scl, U3-
RNP 
S / SSD 
 
The standardization and reproducibility of IIF results is significantly enhanced 
when using automated systems for interpreting research results. 
 
Type of glow 
 
 
Positive test result  
(in "+", titer, glow) 
          
 
 
ELISA, immunoblot, immunodiffusion, 
 counter immunoelectrophoresis, 





ANA by the IIF 
Type of glow, titer 
Antibodies to specific 
nuclear antigens 
Antibodies to ds-DNA, nucleosomes, Sm, U1RNP, SS-A / 





With a "+" result of tests revealing ANF or ANA, it is required to find the 
specificity of autoantibodies to individual nuclear antigens. The most informative 
method for identifying the specificity of ANA is an immunoblot, additionally, the 
ELISA methods, double immunodiffusion method, counter 
immunoelectrophoresis, etc. This sequence of immunological tests for suspected 
ARD is shown in Figure 2. 
 
Figure 2 - Algorithm of immunodiagnosis of ARD 
 
Some types of ANA (anticentromeric, PCNA-proliferating cell nuclear antigen 1, 
antibodies to the mitotic apparatus of the cell-NUMA, Golgi apparatus) are 
detected only by the NIF method on HEp-2 cells, which eliminates the need for 
further research. 
A positive ANF/ANA result in a patient without symptoms of an autoimmune 
process must be interpreted taking into account additional anamnestic, clinical and 
laboratory data, since ANA is detected in 3-5% of healthy people (10-37% aged 
over 65 years), as well as in infectious, inflammatory, oncological diseases, and in 
25-30% of relatives of patients with ARD. 
 
Immunological tests for differential diagnosis of autoimmune rheumatic 
diseases 
 
Immunoblot of antinuclear antibodies 
The method allows us to evaluate the specificity of antinuclear antibodies. 
Antibodies to autoantigens are detected: Sm, RNP/Sm, SS-A, SS-B, Scl-70, PM-
Scl, PCNA, CENT-B, dsDNA/Histone/Nucleosome, RibP, AMA-M2, Jo-1. 
Interpretation of results 
The result is presented as follows: 
"+" - low content of antibodies to autoantigen; 
"++"- the average content of antibodies to the autoantigen, 
"+++" - high content of antibodies to autoantigen; 
"–"- antibodies to the autoantigen were not detected. 
A positive test result that detects the presence of specific antibodies does not allow 
diagnosing ARD in the absence of a clinical picture. 
A negative result of the immunoblot does not exclude ARD in the presence of a 
characteristic clinical picture. In this case, it is recommended to conduct additional 
studies using a complex of highly sensitive immunological methods in dynamics. 
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In ARD, a different combination of autoantibodies is most often found.  
Based on international recommendations, standard autoantibody profiles have been 
developed for the diagnosis of ARD (table 2). 
The list of screening tests with high diagnostic sensitivity (DS) and confirming 
immunological tests with high diagnostic specificity (DS), as well as additional 
serological tests for the diagnosis of ARD, presented in table 3, is convenient for 
the clinician. 
Immunological studies contribute to the early diagnosis of ARD, allow assessing 
the activity and severity of the disease, and predict the effectiveness of therapy. 
However, the frequency of detection of autoantibodies differs significantly in 
ARD, many of them are not highly specific (table 4). 
The development of ARD immunodiagnostics is aimed at using multiplex analysis 
of biomarkers based on genetic, epigenomic, transcriptomic and proteomic 
technologies using DNA and protein microchips, polymerase chain reaction, and 
flow cytometry. 
 
Table 2-Autoantibodies included in the diagnostic and/or classification criteria of 
ARD 
Disease Autoantibodies Diagnostic and / or 
classificatory 
ARD criteria 
RA Rheumatoid factor (RF) Classification criteria 
ACR/EULAR (2010) 
SLE Antibodies to citrulline proteins (ACP) Classification criteria 
SLICC (2012) 




Antibodies to double-stranded (ds) DNA 
(anti-dsDNA) 
Classification criteria 
ACR (2012),  
SICCA (2012) 





Anti-SSA / Ro Preliminary 
classification criteria 
(1997) 
APS Anti-SSB / La Classification criteria 
(consensus; 2006) 
ANCA-SV Antiphospholipid antibodies: antibodies to 




glycoprotein 1 (aβ2-GP 1), lupus 
anticoagulant (LA), false positive 
Wasserman reaction 
PM / DM Antibodies to tRNA aminoacyl synthetases - 
Jo-1, PL-7, PL-12, EJ, OJ, KS; antibodies to 




1. ACR/EULAR - American College of Rheumatology/ European League Against 
Rheumatism-American College of rheumatology/ European League against 
rheumatism.  
2. SLICK-systematic Lupus International Collaborator and Clinics-criteria for 
systemic international joint clinics for systemic lupus.  
3. SICCA - Sjogren's International Collaborative Clinical Alliance-criteria for the 
Sjogren international collaborative clinical Alliance. 
 
Table 3-List of primary (screening) and secondary (confirming) immunological 















































































1 2 2 3 2   2    2 3 3  
Sjogren's syndrome 1 3 3  2   3    3  3  
Systemic sclerosis / 
systemic scleroderma 
1   2  2      3    
Mixed connective 
tissue diseases 
1 2 2 2    2    3  3  
Polymyositis / 
Dermatomyositis 
1   2   2         
Antiphospholipid 
Syndrome 
1           1 2   
Rheumatoid arthritis              1 1 
Vasculitis with 
predominant lesion of 
small-caliber vessels 
         1 2 2    
Connective tissue 
diseases 
1 3 3 3 2  2   1 3  1 2 1 
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Notes: 
1 - primary tests; 
2 - confirmatory tests; 
3 - additional tests. 
• ANA-IIF - antinuclear antibodies determined by indirect immunofluorescence 
test; 
• aDNA - antibodies to native DNA; 
• aSm - antibodies to the Sm nuclear protein; 
• aU1RNP - antibodies to aU1RNP; 
• aSSA / SSB - antibodies to SSA / SSB; 
• aScl-70 - antibodies to topoisomerase I; 
• aJo-1 - antibodies to histidyl tRNA synthetase; 
• ariboRNP - antibodies to riboRNP; 
• ANCA - antineutrophilic cytoplasmic antibodies (IIF method); 
• MPO-ANCA - antibodies to myeloperoxidase; 
• PR3-ANCA - antibodies to proteinase 3; 
• ACL - antibodies to cardiolipin; 
• aβ2-GP 1 - antibodies to β2-glycoprotein 1; 
• IgM RF - autoantibodies of the IgM class rheumatoid factor; 
• ACCP - antibodies to a cyclic citrulline peptide. 
 






MCTD РА Sjogren's 
syndrome 
SS DM 





















- - - >90 - - 
Anti Sm 10-
30 
- - - - - - 
Anti-RNP / Sm 10-
30 
- >90 - - - - 
Anti-scl-70 - - - - - >90 - 
Anti-Jo-1 - - - - - - 50-90 
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It should be remembered that the interpretation of these immunological tests 
should always be carried out in accordance with the clinical symptoms of the 
suspected  disease. 
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3. RHEUMATOID ARTHRITIS 
 
RA is a chronic autoimmune systemic connective tissue disease characterized by 
persistent progressive inflammation of mainly peripheral joints in the form of 
symmetrical erosive-destructive polyarthritis, often with extra-articular lesions of 
internal organs. 
• RA affects approximately 1% of the population (0.2% to 5.3%). 
• It affects people of all ages, but is most common in 40-60 years. There are 
three age peaks in the development of RA (the last one is 60-80 years old). 
• Women get sick 3 times more often than men. 
• Disability develops in 10 years in 30%, in 20 years-in 60-90% of patients. 
• Life expectancy is reduced by 3-7 years. 
• Increased mortality due to the rapid development of atherosclerosis against 
the background of immune inflammation. 
 
ICD-10 codes 
M05. Seropositive RA 
• M05. 0. Felty Syndrome 
• M05. 1. Rheumatoid lung disease 
• M05. 2. Rheumatoid vasculitis 
• M05. 3. RA with the participation of other bodies and systems 
• M05. 8. Other seropositive RA 
• M05. 9. Unspecified seropositive RA 
M06. Other RA 
• M06. 0. Seronegative RA 
• M06. 1. Still's disease in adults 
• M06. 2. Rheumatoid Bursitis 
• M06. 3. Rheumatoid node 
• M06. 4. Inflammatory polyarthropathy 
• M06. 8. Other specified RA 
• M06. 9. Unspecified RA 
 
Etiology of RA. There is a genetic predisposition to the disease, mediated by HLA-
DR4 or HLA-DR1 antigens, polymorphism of the T-cell receptor, IgG, receptors 
for cytokines TNF-α, IL-10, and others. Carrier of HLA-DR4 in seropositive RA 
reaches 70% (in the population - 25%). The relationship between the HLA-DR4 
locus and the severity of RA, hyperproduction of rheumatoid factor, and rapid 
development of erosive changes in the joints was revealed. 
The role of viruses (Epstein-Barr virus, lymphotropic T-cell virus, human B19 
parvovirus, retroviruses, rubella virus, herpes, cytomegalovirus), bacterial 
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infections (Mycoplasma, chlamydia, etc.), and microbiocinosis disorders are 
considered. 
Hormonal background and its disorders (sex hormones, prolactin) have a certain 
value. 
 
Immunopathogenesis of RA. T and B lymphocytes stimulated by an unknown 
antigen migrate from the postcapillary venules of the synovial membrane to the 
tissues. Then, synovial cells carrying abnormal class II HLA antigens and 
costimulatory molecules present an unknown arthritogenic peptide to T cells. After 
this, cytokines stimulate the activation of various cellular systems. B cells are 
activated by the mechanism of polyclonal stimulation, synthesize 
immunoglobulins (rheumatoid factors - immunoglobulins directed against IgG Fc 
fragments), which activate the complement system through immune complexes, 
which contributes to the development of vasculitis. Pro-inflammatory cytokines, 
especially TNF-a and IL-1, lead to increased proliferation and activation of 
fibroblasts. Chondrocytes activated by cytokines produce a large number of 
fibroblast growth factor and granulocyte-monocyte colony stimulating factor. All 
this causes the development of synovitis and the formation of a pannus, and, as a 
result, the destruction of the bone and joint. 
Along with T-lymphocytes, macrophages secreting TNF-α and IL-1 play an 
important role in the destruction of the joint. Macrophages are characterized by 
enhanced phagocytosis and chemotaxis. These cells make up about 30% of the 
cells in the inflamed synovial membrane. The regulatory (anti-inflammatory) 
cytokines of macrophages and T-regulatory cells (IL-10, TGF-β) cannot withstand 
pro-inflammatory cytokines. 
 
Rheumatoid arthritis has a staged development: 
• Preclinical stage (genetic risk, asymptomatic autoimmunity disorder, subclinical 
symptoms of joint damage detected by special studies). 
• Very early stage (disease duration <6 months). 
• Early stage (duration is from 6 months to 1 year). The treatment prescribed in the 
early period of RA is most effective, which is why this period is called the 
“window of opportunity”. 
• Advanced stage (disease duration> 1 year in the presence of a clinical picture of 
RA). After 2 years of illness, the presence of erosion in the joints is observed in 
90% of patients. 
• Late stage. The presence of proliferative changes in the joints, characteristic 




Clinical Symptoms of RA 
 
General clinical manifestations in RA can occur even before joint damage. These 
include weight loss, fever, generalized weakness, morning stiffness. 
Joint damage. In 70-80% of cases, the disease begins with polyarthritis, less often 
with monoarthritis and oligoarthritis. Joint syndrome is characterized by bilateral 
symmetrical damage to the joints. Small joints of the hands are usually involved in 
the pathological process: metacarpophalangeal, proximal interphalangeal 
(“exception” joints - distal interphalangeal joints of the fingers, 1st 
metacarpophalangeal joint, 5th proximal interphalangeal joint), foot joints 
(metatarsophalangeal), wrist joints, less commonly affected are the hip, knee, 
shoulder and spinal joints. A gradual increase in joint pain and morning stiffness 
lasting 1 hour or more is characteristic. Affected joints are hyperemic, swollen, 
painful on palpation, local hyperthermia is determined above the joints. Active and 
passive movements in the joints are limited. 
Joint lesions in RA can be reversible and irreversible. Reversible changes are 
associated with the development of synovitis, irreversible changes are caused by 
structural changes in the joints in the later stages. With a long course of the 
disease, ankylosis of the joints develops and their complete immobilization. 
"Rheumatoid hand" is a typical lesion of the joints of the hand that occurs with 
RA. Signs of a “rheumatoid wrist” are: symmetric swelling of the 
metacarpophalangeal, proximal interphalangeal joints of the hand (usually 2-4 
fingers are involved), in the wrist, deformation of the wrist like “boutonniere”, 
“swan’s neck”, development of amyotrafia and ulnar deviation (table 5). 
 
Table 5 - Picture of rheumatoid lesions of the hand 
Symptom Characteristic 
Symptom of the “buttonhole” 
or deformation of the fingers 
of the hand according to the 
type of “buttonhole” 
Re-extension of the distal interphalangeal joints in 
combination with flexion of the proximal 
interphalangeal joints of the hand 
Deformation of the fingers of 
the hand according to the type 
of "swan neck" 
Flexion of the distal interphalangeal joints, 
overextension in the proximal interphalangeal 
joints in combination with flexion contracture in 
the metacarpophalangeal joints 
Z-shaped deformation of the 
first finger of the brush 
Subluxation of the metacarpophalangeal joint with 
hyperextension of the interphalangeal joint of the 
first finger 
Symptom of "lorgnet" Due to the formation of flexion contracture of the 
fingers and limitation of extension in the distal 
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and proximal interphalangeal joints, the patient 
cannot fully extend his palm and touch it on a flat 
surface. This deformation is accompanied by 
almost complete inoperability of the brush 
Amyotrophy symptom Atrophy of the interosseous muscles of the rear of 
the hand 
Ulnar deviation Subluxations in the metacarpophalangeal joints 
with deviation of the fingers to the elbow side. 
This shape of the brush is called "walrus fin" 
 
Foot joints damage is accompanied by lateral deviation and deformation of the 
first toe (hallus valgus - valgus deformity), as well as the formation of subluxations 
in the metatarsophalangeal joints and hammer-like deformation of the toes of the 
foot. 
Damage to the elbow joint leads to the formation of a “symptom of a key,” which 
is characterized by a subluxation of the head of the ulnar bone due to damage to 
the ulnar collateral ligament and instability in the radiolar joint. This symptom is 
characterized by pathological mobility of the ulnar head. 
Damage to the shoulder joint is associated with synovitis and involvement in the 
pathological process of the distal third of the clavicle, muscles of the shoulder 
girdle, neck and chest. Pain syndrome is accompanied by restriction of movements 
in the shoulder joint and the development of muscle atrophy. Weakness of the 
articular bag leads to anterior subluxation of the humeral head. 
Arthritis of the knee joints is characterized by flexion and hallux valgus, as well as 
the formation of a Baker cyst (protrusion of the posterior inversion of the joint bag 
into the popliteal fossa). The development of synovitis of the joints leads to a 
configuration of the knee joints, palpation determines the ballot of the patella. 
Hallux valgus is characterized by strong lateral curvature. With this deformation, 
an open outward angle is formed between the lower leg and thigh. 
Damage to the ankle joint is rare and is accompanied by swelling in the ankle. 
With the involvement of the ligamentous apparatus, instability of the ankle joint 
with frequent subluxations develops. 
The involvement of the hip joint is observed with a prolonged course of the disease. 
The pain may radiate to the inguinal region or lower part of the gluteal region. The 
fixation of the thigh in the position of slight flexion is characteristic. With the 
development of aseptic necrosis of the head of the hip and protrusion of the 
acetabulum, there is a sharp restriction of active and passive movements in the 
joint. 
Damage to the joints of the spine can be observed in the late stage of RA. The 
cervical spine is most often involved in the pathological process. Subluxation of 
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the atlantoaxial joint (in 10% of cases) is accompanied by severe pain, neck 
stiffness, can be complicated by compression of the vertebral artery and spinal 
cord, leading to the development of neurological dysfunction. 
Involvement of the temporomandibular joint is accompanied by a restriction on the 
opening of the mouth and makes eating difficult. 
 
Extraarticular manifestations of RA. They are developed in the debut of RA, 
sometimes even prevail in the clinical picture of the disease (table 6). 
By the nature of the progression of destructive processes in the joints and extra-
articular manifestations, the following variants of the course of RA are 
distinguished: 
• prolonged spontaneous clinical remission (less than 10%); 
• intermittent course (15-30%); 
• progressive course (60-75%); 
• fast progressing course (10-20%). 
In 2007, the Association of Rheumatologists of Russia proposed the classification 
of RA, which consists of 8 headings (table 7) 
 






Fever, weight loss, general well-being, sweating, asthenia, 
generalized weakness, myalgia. Symptoms are associated with 
a high degree of inflammation activity, may develop before 
the onset of articular syndrome. 
Damage to the 
skin 
Rheumatoid nodules are found in 30-40% of patients with RA, 
more often with high disease activity. They are dense 
formations from 1-2 mm to 1.5-2 cm in diameter, painless on 
palpation, mobile, can be soldered with aponeurosis or 
underlying bone. They develop in places of increased 
traumatization (over small joints of the hands, in the region of 
the bag of the ulnar process, extensor surface of the forearm), 
can be single or multiple, located symmetrically or 
asymmetrically. Usually appear during an exacerbation of the 
disease and may disappear after the onset of remission. 
Thinning and dryness of the skin, especially at the fingertips. 
Hyperpigmentation of the skin develops on the lower 
extremities. Violation of trophic nails leads to their thinning, 
brittleness, longitudinal striation. Due to the development of 
cutaneous vasculitis, subcutaneous hemorrhages may occur, 
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accompanied by small focal necrosis of the soft tissues under 
the nail plates or in the area of the nail bed (digital arteritis) 
Muscle damage Muscle weakness amid the development of atrophy. Active 
RA can lead to the development of myositis, necrosis of 
muscle fibers, an increase in the level of creatine 
phosphokinase, transaminases, aldolases 
Lymphadenopathy In 20% of cases with high activity. During remission, a 
decrease in the size and number of lymph nodes 
Eye damage Scleritis, episiscleritis, dry keratoconjunctivitis, scleromalacia, 




10% of patients with RA develop keratoconjunctivitis 
(discomfort, itching, burning eyes, a feeling of “sand in the 
eyes”), xerostomia (dry mouth, associated with a decrease or 
complete cessation of salivation) 
Lung damage Dry and effusion pleurisy, interstitial pulmonary fibrosis, 
bronchiolitis, pulmonary vasculitis, rheumatoid nodules in the 
lungs 
Damage to the 
cardiovascular 
system 
With pronounced activity of RA - pericarditis, myocarditis, 
endocarditis, cardiomyopathy, damage to the conduction 
pathways of the heart, coronary arteritis, granulomatous 
damage to the heart valves, vasculitis 
Kidney damage Glomerulonephritis, with prolonged course and high activity 
of RA - amyloidosis (proteinuria, cylindruria, peripheral 
edema, arterial hypertension, decreased glomerular filtration 
rate, impaired renal excretory function of the kidneys) 
Damage to the 
nervous system 
Compression neuropathy, symmetric sensory-motor 




Less than 1%, prevails in men with highly active seropositive 
RA. Characterized by the development of palmar, plantar 
capillaritis, digital arteritis, obliterating endarteritis of large 
arteries 
 
Table 7 - Classification of RA (APP, 2007), [8] 
1. The main diagnosis 
Seropositive RA 
Seronegative RA 
Special clinical forms of RA: Felty's syndrome, Still's disease in adults 
Probable RA 
2. Clinical stage 
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Very early stage: disease duration <6 months 
Early stage: disease duration 6 months - 1 year 
Advanced stage: disease duration> 1 year in the presence of typical symptoms of 
RA 
Late stage: the duration of the disease is 2 years or more + pronounced destruction 
of small (III-IV radiological stage) and large joints, the presence of complications 
3. Disease activity score (DAS - Disease Activity Score - disease activity index) 
0 - remission (DAS28 <2.6), 1 - low (DAS28 = 2.6–3.2), 2 - medium (DAS28 = 
3.3–5.1), 3 - high (DAS28> 5.1 ) 
4. Extraarticular (systemic) manifestations 
Rheumatoid nodules 
Cutaneous vasculitis (ulcerative necrotic vasculitis, nail bed heart attacks, digital 
arteritis, live-angiitis) 
Vasculitis of other organs 
Neuropathy (mononeuritis, polyneuropathy) 
Pleurisy (dry, effusion), pericarditis (dry, effusion) 
Sjogren's syndrome 
Eye damage (scleritis, episiscleritis, retinal vasculitis) 
5. Instrumental characteristic 
The presence of erosion (according to x-ray, possibly magnetic resonance imaging, 
ultrasound): non-erosive, erosive 
X-ray stage (according to Steinbroker with modification): 
I - periarticular osteoporosis 
II - periarticular osteoporosis + narrowing of the joint space, there may be a single 
erosion 
III - signs of the previous stage + multiple erosion + subluxation in the joints 
IV - signs of a previous stage + bone ankylosis 
6. Additional immunological characteristic - anti-citrulline antibodies (ACCP) 
ACCP - positive, ACCP - negative 
7. Functional class (FC) 
I - self-service, unprofessional and professional activities are fully preserved 
II - self-service and professional activity are preserved, unprofessional activity is 
limited 
III - self-service is maintained, unprofessional and professional activity is limited 
IV - limited self-care, unprofessional and professional activities 
8. Complications 





Tunnel syndromes (carpal tunnel syndrome, compression syndromes of the ulnar, 
tibial nerves) 




Comments on Rheumatoid arthritis classification (Association of Rheumatologists 
of Russia, 2007) 
Heading "The main diagnosis." Seropositivity and seronegativity are diagnosed on 
the basis of a determination in the blood serum of the Russian Federation. Its 
identification must be performed using a reliable quantitative or semi-quantitative 
test (latex test, enzyme immunoassay, immunonefelometric method). 
The heading "Activity of the disease." To determine the activity of RA, it is 
recommended to use the DAS28 index. The following parameters must be 
considered: 
- the number of painful joints (CPJ); 
- the number of swollen joints (NSJ); 
- erythrocyte sedimentation rate (ESR); 
- the general state of health of the patient (GSHP). 
 
Formula for calculating DAS 28: 
DAS28 = 0.56 × √ CPJ + 0.28 × √ NSJ + 0.7 × lg ESR + 0.014 × GSHP 
 
CPJ and NSJ are diagnosed in evaluating 28 joints (shoulder, elbow, wrist, 
metacarpophalangeal, proximal interphalangeal, knee). GSHP is evaluated on a 
100 mm visual analogue pain scale. ESR is determined by the method of 
Westergren. It is possible to use other methods of counting activity, for which 
good compatibility with DAS28 is proved. 
 
Heading "Instrumental characteristic". 
Detailed description of the radiological stages: 
Stage I: 
- small periarticular osteoporosis; 
- single cystic enlightenment of bone tissue; 
- slight narrowing of the joint spaces in individual joints. 
II stage: 
- moderate (severe) periarticular osteoporosis; 
- multiple cystic enlightenment of bone tissue; 
- narrowing of the joint spaces; 
- single erosion of articular surfaces (1-4); 
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- slight bone deformities. 
Stage III: 
- moderate (severe) periarticular osteoporosis; 
- multiple cystic enlightenment of bone tissue; 
- narrowing of the joint spaces; 
- multiple erosion of articular surfaces (5 or more); 
- multiple pronounced bone deformities; 
- subluxations and dislocations of the joints. 
IV stage: 
- moderate / severe periarticular or common osteoporosis; 
- multiple cystic enlightenment of bone tissue; 
- narrowing of the joint spaces; 
- multiple erosion of bones and articular surfaces; 
- multiple pronounced bone deformities; 
- subluxations and dislocations of the joints; 
- single (multiple) bone ankyloses; 
- subchondral osteosclerosis; 
- osteophytes at the edges of the articular surfaces. 
Category "Functional class" 
- self-care: dressing, eating, personal care, etc. 
- unprofessional activity: elements of recreation, leisure, sports, etc., taking into 
account gender and age 
- professional activity: work, study, housekeeping (for patients working at home) 
taking into account gender and age. 
Determining the degree of activity of RA can also be carried out using the 
recommendations of the Association of Rheumatologists of Russia (ARP, 2003). 
To do this, it is necessary to assess the pain on a visual analogue scale (VAS), 
CRP, ESR, and also to clarify the duration of morning stiffness. Assessment of the 
degree of activity of RA in accordance with the recommendations of the 
Association of Rheumatologists of Russia (2003) is presented in table 8. 
 
Table 8 - Assessment of the degree of activity of rheumatoid arthritis 
(APP, 2003), [8] 
Indicator 
 
Degree of activity 
0 1 2 3 
Pain on a visual 
analogue scale (10 cm) 
0 ≤3 4-6 >6 






ESR (mm / h) ≤15 16-30 31-45 >45 
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CRP Норма (N) ≤2N ≤3N >3N 
Diagnosis of RA 
For the diagnosis of RA, the diagnostic criteria proposed by the American College 
of Rheumatology in 1987 are used (Table 9). 
 
Table 9 - Diagnostic criteria for RA (ACR, 1987), [15] 
Criterion Characteristic 
Morning stiffness Stiffness in the morning in the area of joints or 
periarticular tissues, which lasts at least 1 hour 
Arthritis of three 
joints and more 
Swelling of the periarticular soft tissues or the presence 
of effusion in the articular cavity in at least three joints. 
Possible damage to 14 joints on the right and left 
extremities (proximal interphalangeal, 
metacarpophalangeal, carpal, ulnar, knee and ankle) 
Arthritis of the joints 
of the hands 
Swelling of at least one group of joints of the following 
localization: proximal interphalangeal, 
metacarpophalangeal, wrist 
Symmetric Arthritis Simultaneous bilateral joint damage 
(absolute symmetry is not required) 
Rheumatoid nodules Subcutaneous nodules, localized mainly on protruding 
parts of the body, extensor surfaces or in the periarticular 
regions 
Rheumatoid factor Detection of an increase in the concentration of 
rheumatoid factor in serum by any standard method that 
gives positive results in no more than 5% of healthy 
people 
X-ray changes Diagnosis of radiological changes typical of RA in the 
hands and feet (erosion or periarticular osteoporosis, 
most pronounced in clinically affected joints) 
 
The diagnosis of RA is established in the presence of at least 4 of the 7 criteria 
presented above. The first four criteria should be maintained for at least six weeks. 
Certain difficulties in the early diagnosis of RA are associated with the fact that 
rheumatoid nodules and radiological changes usually appear in the late stages of 
the disease, and the RF in some patients may be negative. With this in mind, in 
2010 the American College of Rheumatologists, together with the European 
League against Rheumatism, proposed new diagnostic criteria (table 10). 
In order to diagnose RA according to new criteria, the following conditions must 
be fulfilled: to determine if the patient has at least one joint with swelling 
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(synovitis) according to physical examination; exclude other diseases that may be 
associated with the development of synovitis; score ≥6 points out of 10 in four 
positions (A-D). 
Patients who scored less than six points at the time of examination are considered 
to have no RA. It is recommended that their condition be reevaluated, since 
diagnostic criteria can cumulatively cumulate over time. 
 
Table 10 - Diagnostic criteria for RA (ACR / EULAR, 2010), [10] 
Diagnostic criteria Points 
A. Joint damage 
• 1 large joint 
• 2-10 large joints 
• 1-3 small joints (large joints are not counted) 
• 4-10 small joints (large joints are not counted) 







B. Serological data (at least one test is required for diagnosis) 
• Negative RF and ACCP 
• Weakly positive RF and slightly positive ACCP s (exceed the 
upper limit of the norm by three or less times) 
            • Sharp-positive RF and sharply positive ACCP s (exceed the 






C. Acute phase reagents (at least one test is required for diagnosis) 
• Normal erythrocyte sedimentation rate (ESR) and C-reactive 
protein (CRP) 





D. Duration of symptoms 
• <6 weeks 







• General blood test: increased ESR; hypochromic anemia; leukocyte shift to the 
left; leukocytosis, thrombocytosis, eosinophilia can be observed in severe RA; 
neutropenia is diagnosed with Felty's syndrome. 
• Biochemical blood test: increased CRP; an increase in the level of liver enzymes 
may be associated with therapy with basic anti-inflammatory drugs (DMARDs) 
and genetically engineered biological drugs (GEBD); hyperglycemia is diagnosed 
in the treatment of glucocorticosteroids (GCS); an increase in creatinine and uric 
acid is determined by the nephrotoxic effect of DMARDs and GEBD or the 
development of renal amyloidosis. 
 29 
• Diagnostic immunological biomarkers: simultaneous assessment of 
concentrations of RF IgM / IgA, levels of antibodies to cyclic citrulline peptide and 
antibodies to modified citrulinated vimentin increase diagnostic sensitivity to 90% 
in the early stage of RA, to 92% in the late stage. 
 
Rheumatoid factor 
• RF - IgM, IgG and IgA autoantibodies that react with the IgG Fc fragment. Of 
greatest importance is the definition of IgM RF. 
• The normal level of RF IgM when testing sera with latex agglutination is ≤1: 40, 
nephelometry ≤ 15 IU / ml, ELISA ≤20 IU / ml. Allocate negative (less than or 
equal to the upper limit of the norm); low positive (≤3 upper normal) and highly 
positive (> 3 upper normal) IgM RF levels. 
• A positive result of detection of RF IgM in serum confirms RA in case of 
symptoms of RA. A negative analysis result does not exclude RA. 
• In the early stages of RA, only high IgM RF titers are of diagnostic value. 
• RF IgM - sensitive (PM: 50-90%), but not specific enough (DS: 80-93%), a 
marker of RA. High titers of RF are determined for Sjögren’s disease, sarcoidosis, 
low titers for hepatitis, autoimmune thyroiditis, psoriatic arthritis, mononucleosis, 
Epstein-Barr infection and other IgM RF are determined in approximately 5% of 
healthy people, 5-25% of elderly people (table eleven). 
 
Table 11 - Frequency of occurrence of Rheumatoid factor in various diseases and 
in healthy people 
Groups surveyed RF detection frequency 
Rheumatoid arthritis 80% 
Sjogren's syndrome 70% 
SLE 30% 
Polymyositis 20% 
Systemic sclerosis 20% 
Cirrhosis of the liver 25% 
Infectious hepatitis 25% 
Tuberculosis 15% 
Syphilis 10% 
Healthy Less than 5% 
 
• RF has prognostic value in relation to clinical manifestations of RA severity. 
High concentration IgM RF is a predictor of rapidly progressive destructive joint 
damage and systemic manifestations in RA. An increase in the concentration of 
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IgM RF correlates with indicators of the acute phase of inflammation - ESR, CRP. 
Seroconversion in RF may be observed during RA treatment. 
 
Antibodies to citrulline proteins (ACPs) are a heterogeneous group of 
autoantibodies that recognize the antigenic determinants of phyllagrin and other 
proteins containing the atypical amino acid citrulline, resulting from post-
translational modification of arginine residues under the action of the 
peptidylarginin deiminase enzyme. The ACP family includes: antibodies to a 
cyclic citrulline peptide, antibodies to a modified citrulinated vimentin, 
antiperinuclear factor, antikeratin antibodies, antifillagrine antibodies, antibodies to 
citrulinated fibrinogen, antibodies to citrulliniron histrionins, citruliniron 
histrionins antibodies. Among ACPs, the most standardized marker for early 
diagnosis and assessment of prognosis of RA is the definition of ACCP. 
 
Antibodies to cyclic citrulline-containing peptide 
• Negative (≤ the upper limit of the norm, that is, from 5 to 25 U / ml, depending 
on the manufacturer of the reagents); low positive (≤3 upper limit of normal) and 
highly positive (> 3 upper limit of normal) ACCP level are distinguished. 
• The positive results of detecting ACCP in serum serve as a diagnostic criterion 
for RA. Only in 2% of cases, the level of ACCP is increased in SLE, SS, Sjögren’s 
syndrome, systemic vasculitis (Wegener's granulomatosis), autoimmune 
thyroiditis. 
• ACCP is a marker of RA at a very early stage (disease duration <6 months) and 
at an early stage (disease duration 6 months - 1 year), can be determined 1.5 years 
or more before the onset of symptoms of RA. 
• ACCP C is a highly specific diagnostic marker for RA (AF: 49-91%, DS: 73-
99%), especially at an early stage of the disease (AF: 39-71%, DS: 93-99%) 
compared with the RA IgM. The detection rate of ADC in IgM RF-negative 
patients with RA is 20–40%. 
• The detection of ACCP is predictive in relation to the development of joint 
destruction in patients with early RA. 
 
Antibodies to Modified Citrulline Vimentin (AMCV) 
• The upper limit of the norm in determining AMCV using ELISA is 20 IU / ml. It 
is recommended to highlight the negative (≤ the upper limit of the norm); low 
positive (≤3 upper bounds of the norm) and highly positive (> 3 upper bounds of 
the norm) levels of AMCV. 
• Positive results of determination of AMCV in blood serum serve as an additional 
diagnostic marker of RA with negative results of determination of RF IgM and 
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ACCP in blood serum. In patients with RA, negative in Rheumatoid factor, AMCV 
is detected in 50%. 
• AMCVs have a higher or similar sensitivity (PM: 77%), but less specificity (DS: 
89%) compared to ACCP. 
• Identification of AMCV predicts the development of severe erosive joint damage 
in patients with RA. AMCV is more associated with clinical and laboratory 
indicators of RA activity than ACCP. 
• The multiplicity of determining the level of AMCV in RA is similar to that for 
ACCP. 
 
At present, multiparametric research methods have been developed for diagnosing 
RA, evaluating activity, predicting the course of the disease and the effectiveness 
of therapy. The complex of defined immunological biomarkers includes: 
autoantibodies, acute phase inflammatory proteins, cytokines, chemokines, 
vascular endothelial activation markers, complement system components, 
lymphocyte subpopulations, markers of bone and cartilage tissue metabolism, etc. 
Promising diagnostic biomarkers of RA include: antibodies to carbamylated 
proteins (anti-CarrP); protein 14-3-3η, belonging to the family of regulatory 
molecules that affect the cell cycle, metabolic control, apoptosis, gene transcription 
control, adhesion. Both markers play an important role in the immunopathogenesis 
of RA, reflect the degree of joint damage and disease activity. 
Immunogenetic study: determination of HLA-DR4 (allele DRB 1 * 0401), which is 
a marker of severe RA and poor prognosis. 
Synovial fluid analysis: in patients with RA there is a decrease in synovial fluid 
viscosity, leukocytosis (> 6 × 109 / L), an increase in the number of neutrophils 
(25-90%), a loose mucinous clot). 
 
Instrumental research methods 
 
Radiography of the joints is carried out to confirm the diagnosis of RA, to 
determine the radiological stage, to assess the progression of destructive lesions of 
the joints. 
First of all, X-rays of the hands and feet are performed, since in RA small joints 
are initially affected. In patients with RA, periarticular osteoporosis, erosion 
(usury) of articular surfaces, narrowing of the joint spaces up to their complete 
disappearance and formation of joint ankylosis, dislocation and subluxation in the 
joints are revealed. There are 4 radiological stages of RA (table 7, p. 5). 
For the early diagnosis of RA, it is necessary to use ultrasonography (ultrasound) 
and magnetic resonance imaging (MRI). These methods have great diagnostic 
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capabilities in detecting joint pathology at the onset of the disease compared with 
radiographic examination. 
Joint MRI is most sensitive in detecting synovitis of joints and early changes in the 
articular surface of bones in comparison with radiography. 
Ultrasonography (ultrasound) of the joints allows us to assess the state of the 
articular surface of the joints, synovial membrane, joint capsule, cartilage and 
periarticular tissues. Using this method, it is possible at an early stage of RA to 
visualize inflammation of the synovial membrane, characterized by an 
accumulation of effusion in the cavity lined by it. 
 
Clinical and laboratory monitoring in RA. 
 
The definition of prognostic and pharmacotherapeutic biomarkers of disease 
activity and the rate of progression of RA is shown: DAS28 index, functional 
ability of the patient, radiological changes in the joints. 
Studies are being carried out on a general blood test, ESR, CRP, a biochemical 
blood test (liver enzymes, total protein and protein fractions, glucose, creatinine, 
urea), in the treatment with TNF-α inhibitors, the determination of antinuclear 
antibodies, antibodies to double-stranded DNA (development of other autoimmune 
diseases). 
 
Recommended multiplicity to determine RF IgM: 
• in seronegative patients at an early stage of RA, once every 3 to 6 months, at a 
developed stage - once a year, at a late stage, re-analysis is not carried out; 
• in low / highly seropositive patients at an early stage 1 time in 3 months, at a 
developed stage - 1 time in 3-6 months, at a late stage - 1 time per year. 
Recommended multiplicity to determine ACCP and AMCV: 
• to monitor the effectiveness of therapy with basic and symptomatic drugs, the 
definition of ACCP / AMCV is uninformative; 
• in patients who are seronegative for ACCP / AMCV, the recommended rate of 
determining indicators at an early stage of RA is 1 time in 6 months, at a 
developed stage - once. ACCP / AMCV are not exposed to seroconversion; 
• with a low level of ACCP / AMCV in the early stage of RA, their repeated 
determination should be carried out once every 3-6 months, at the expanded stage - 
once a year. 
• in case of revealing a high positivity on ACCP / AMCV at the early and 
developed stages of RA, repeated studies are not carried out; 





1. Rheumatoid arthritis, late stage, seropositive, ACCP-negative, activity 2 
degrees, stage IV, functional class III. 
2. Rheumatoid arthritis, early stage, seronegative, ACCP -positive, activity 3 
degrees (DAS28-5,4 points), stage I, functional class I. 
3. Rheumatoid arthritis, advanced stage, seronegative, ACCP -negative, activity 2 
degrees, stage II with systemic manifestations (rheumatoid nodules, digital 
arteritis), functional class I. 
 
Treatment of rheumatoid arthritis [5, 9, 7, 22] 
Tactics for treating patients with RA are presented in the international program 
“Treat to target” (“T2T, targeted therapy”), 2013 [22] - the concept of “Treatment 
to achieve the goal”, where the main goal is to achieve remission of RA, the 
alternative is to achieve low activity of RA. 
Tactics of early aggressive therapy are adhered to, since the highest degree of joint 
destruction, which determines the unfavorable prognosis of the disease, is observed 
precisely in the debut of RA. 
The principle of a personalized approach is used – choosing the therapy taking 
into account the individual characteristics of the patient. This takes into account: 
• The prevailing immunopathogenesis of RA. At present, RF IgM and antibodies to 
citrulline proteins are considered as different systems of autoantibodies, which 
allows us to distinguish two main clinical and laboratory subtypes of RA - ACP-
positive and ACP-negative. These RA subtypes have differences in pathogenesis, 
severity, and treatment approaches. 
• Stage (early, full, late). 
• The nature of the course of RA (rapidly or slowly progressing), etc. 
• Comorbid pathology. 
• Polymorphism of genes responsible for drug metabolism. 
• The nature of the metabolism. 
 
From the perspective of evidence-based medicine, pharmacotherapy of RA 
includes: 
• Pain Relief Medicines – Non-steroidal anti-inflammatory drugs (NSAIDs). 
• Glucocorticosteroids. 
• Basic synthetic anti-inflammatory drugs (or disease-modifying drugs). 
• Biological genetic engineering disease-modifying drugs (original, biosimilars). 
 
NSAIDs are prescribed for the relief of joint pain for a short time. As the pain in 
the joints decreases with the use of synthetic immunosuppressants, NSAIDs are 
canceled. Aceclofenac 200 mg / day by mouth, or diclofenac 100-150 mg / day, by 
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mouth or IM, or ibuprofen 1200-2400 mg / day by mouth, or meloxicam 15 mg / 
day, by mouth or IM, or nimesulide 200-400 mg are prescribed. / day inside, or 
celecoxib 400 mg / day inside or etodolac 600-1200 mg / day inside. 
More often than other side effects with NSAIDs, gastropathy and enteropathy 
develop. In order to prevent them, it is advisable to use selective type 2 
cyclooxygenase inhibitors (COX-2) (nimesulide, meloxicam). 
It should be remembered that highly selective COX-2 inhibitors (coxibs) increase 
platelet aggregation and increase the risk of cardiovascular complications. With a 
combination of risk factors from the gastrointestinal tract (GIT) and the 
cardiovascular system, it is advisable to use combinations: naproxen + proton 
pump inhibitors, or celecoxib + low doses of aspirin + proton pump inhibitors. 
 
Basic synthetic anti-inflammatory drugs (DMARDs): methotrexate, 
sulfasalazine, leflunomide, hydroxychloroquine, tofacitinib, azathioprine, 
cyclosporine, cyclophosphamide, D-penicillamine, gold salts. 
The principles of therapy: 
- Appointed from the moment of diagnosis of RA to each patient, regardless of 
age. 
- Reduce pain, swelling and joint destruction. 
- It takes 6 months to achieve the effect. Slow increase in the effect of DMARDs is 
compensated by small doses of corticosteroids. 
- When long-term remission is achieved, prolonged dose titration. 
- Monitoring of side effects is required. 
- Women of reproductive age with the use of DMARDs need reliable 
contraception. 
Methotrexate is a first-line drug in the treatment of RA. 2.5 mg tablet, 2.0 ml vials 
(5 and 50 mg) for intramuscular and intravenous administration. An early 
appointment in the form of monotherapy or in combination with immunobiological 
drugs is recommended, which allows achieving remission in more than half of 
patients. Treatment with methotrexate begins with a dose of 10-15 mg / week. 
Then the dose can be increased to 20-30 mg / week, 5 mg every 2-4 weeks, 
monitoring the effectiveness and tolerability of drugs. The effect is evaluated after 
3-6 months of therapy. If the patient notes poor tolerance to the oral form of 
methotrexate or the desired effect cannot be achieved, then it is administered 
subcutaneously. 
You should remember that you need to take folic acid at least 5 mg / week (on 
those days when the patient does not take methotrexate). 
It is necessary to monitor side effects (liver damage, pulmonary fibrosis, stomatitis, 
cytopenia), which are monitored once every 1-3 months, monitoring the level of 
hemoglobin, the number of leukocytes, platelets, creatinine level, activity of 
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aspartate aminotransferase (AST), alanine aminotransferase (ALT). In the case of 
an increase in the level of liver enzymes up to 3 times, methotrexate is not 
canceled, but the dose is reduced. Methotrexate is not canceled during surgical 
treatment. 
It is undesirable to combine methotrexate with DMARDs, aspirin. Methotrexate 
can be combined with leflunomide, sulfasalazine, hydroxychloroquine (but the risk 
of side effects increases). 
In the presence of factors of an unfavorable prognosis of RA, which include: 
identification of the RF and ACCP in the onset of the disease, high activity of the 
disease, early appearance and rapid progression of erosion in the joints, early 
impairment of joint functions, the presence of extra-articular manifestations, 
methotrexate are combined with GEBD. 
With contraindications to methotrexate, leflunomide, or sulfasalazine, is 
prescribed. With intolerance to methotrexate, it is possible to prescribe GEBD 
monotherapy or combination therapy of GEBD with other DMARDs. When 
planning pregnancy, methotrexate is canceled after 6 months. 
Leflunomide. Tablets, 10 and 20 mg. The initial dose of LF is 100 mg, taken daily 
for 3 days, then they switch to a maintenance dose of 10-20 mg / day. It is 
indicated for intolerance to methotrexate, high activity of RA, the presence of foci 
of chronic infection, with a seropositive variant of RA. It is necessary to monitor 
liver enzymes, a general blood test (cytopenia). It has a long elimination period. 
Women of reproductive age are not recommended to plan a pregnancy earlier than 
2 years after the withdrawal of leflunomide. 
Sulfasalazine. Tablets, 500 mg. The drug of choice with moderate activity, a 
seronegative variant of RA, with a combination of RA with chronic hepatitis, when 
planning pregnancy. Start therapy with 500 mg / day. The dosage is increased by 
500 mg once a week so that after four weeks the dose is 2-3 g / day in two divided 
doses. Contraindication for the appointment is a lupus erythematosus and a 
positive reaction to ANA. 
Hydroxychloroquine. Tablets, 200 mg. It is used to treat early lung RA, or as an 
adjunctive therapy with other DMARDs, or for differential diagnosis between 
undifferentiated arthritis and systemic connective tissue disease. It is prescribed in 
minimally effective doses - 200 or 400 mg / day. 
Azathioprine, cyclophosphamide, D-penicillamine, cyclosporine do not have 
proven effectiveness in preventing the development of destructive changes in the 
joints, but can be used for intolerance to methotrexate, sulfasalazine, leflunomide. 
An inhibitor of the Janus kinase family is a synthetic low molecular weight drug 
tofacitinib. Registered in Russia under the brand name Yakvinus for the treatment 
of RA, psoriatic arthritis, ulcerative colitis. Janus kinases are signaling membrane 
proteins that affect the activity of the predominantly T-cell component of the 
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immune system. Tofacitinib acts on intracellular signaling pathways, blocking IL-
6. Efficiency is comparable with biological drugs, but it is deprived of 
immunogenicity. Tofacitinib is used to treat patients with moderate to high activity 
RA with an inadequate response to one or more of the DMARDs. Tofacitinib can 
be used as monotherapy or in combination treatment with methotrexate or other 
DMARDs. The recommended dose of tofacitinib is 5 mg twice a day, it is possible 
to increase the dose to 10 mg twice a day. 
Baritinib is an inhibitor of Janus kinases (phase 3 clinical trials are conducted). 
 
Glucocorticosteroids 
- Do not prevent the development of joint destruction and are prescribed in the 
acute period of the disease to reduce the activity of RA before the development of 
the effect of taking DMARDs. Combined therapy of corticosteroids with 
DMARDs is also used to relieve exacerbation of RA. 
- Duration of taking GCS no more than 6 months. It is necessary to properly reduce 
the dose of corticosteroids as soon as it becomes clinically possible. 
- GCS can be prescribed in the form of monotherapy in case of inefficiency or 
inability to prescribe DMARDs and GEBD. 
- For elderly patients, corticosteroids (5-10 mg per prednisolone) may be 
prescribed with reduced sensitivity to NSAIDs. 
- To take per os (methylprednisolone, prednisone, dexamethasone) small (<7.5 mg) 
or medium doses are used ("bridge therapy") until the development of the effect of 
DMARDs. With high RA activity, medium or high doses are prescribed short-term 
(15 mg / day or more, usually 30-40 mg). 
- For intravenous administration (methylprednisolone) in the form of pulse therapy 
(1000; 500; 250 mg). GCS is administered 1 time per day for 3 days. The 
recommended dose is 15-20 mg / kg of the patient’s body weight or 1000 mg / m2 
of body surface per day; lower doses are administered to elderly patients. 
Methylprednisolone is diluted in 250 ml of isotonic sodium chloride solution or 
5% glucose solution and injected over 35-45 minutes. In severe RA with extra-
articular manifestations, combined pulse therapy of GCS with cyclophosphamide 
is recommended. Cyclophosphamide is added on the 2nd day of metipred 
administration (diluted in the same vial with metipred) at the rate of 15-20 mg / kg 
or 1000 mg / m2, administered once. 
- GCS are used for intraarticular injection (diprospan, Kenalog). Perform no more 
than two intraarticular injections of corticosteroids in one joint during the year. 
- GCS is associated with the development of many side effects that require careful 




Biological therapy is carried out by drugs that affect the cellular-molecular 
mechanisms of the disease. Biological drugs block specific pathways and signals 
of the inflammatory process, have a selective damaging effect on specific target 
cells, minimally negatively affecting normal tissues and organs of the host. 
According to the definition of the European Medicines Agency (EMA), 
biotechnological drugs are immunobiological drugs produced using genetic 
engineering methods of recombinant DNA technology, or the method of controlled 
expression of genes encoding the production of biologically active proteins, or the 
method of hybridization of monoclonal antibodies. 
 
Groups of immunobiological drugs for the treatment of RA 
 
TNF-α Inhibitors: 
• infliximab (Remicade) - chimeric monoclonal antibody to TNF- α; 
• adalimumab (Humira) - a humanized monoclonal antibody to TNF- α 
• golimumab (Simponi) - a fully human monoclonal antibody to TNF- α; 
• certolizumab pegol (Symzia) - pegylated Fab fragment for TNF- α; 
• etanercept (Enbrel) - a humanized soluble receptor for TNF- α. 
Anticytokines: 
• Anakinra (Kineret) - an antagonist of IL-1 receptor; 
• tocilizumab (Actemra) - humanized monoclonal antibody IgG1 to the soluble / 
fixed receptor IL-6; 
• sarilumab (Kevzara) - a human monoclonal antibody to the IL-6 receptor. 
 
Anti-B-cell therapy (anti-CD20) - rituximab (MabThera) - a chimeric monoclonal 
antibody. 
 
Anti-T cell blocker of co-stimulation molecules CTLA-4 (cytotoxic T-lymphocyte-
associated antigen 4) - abatacept (Orencia) - monoclonal antibody to CD80 / 
CD86. 
 
Indications for the appointment of the GEBD in RA 
GEBD are prescribed for the insufficient effect of monotherapy with methotrexate 
or combination therapy of methotrexate with other DMARDs, which must be used 
in adequate doses for ≥ 3 months. 
 
The effectiveness of immunobiological drugs. In 70-80% of patients, good disease 
control is achieved, in 50% of cases - clinical remission, reverse development of 
pathological changes in the joints. 
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Safety of immunobiological drugs. The purpose of the GEBD may be accompanied 
by: 
• inhibition of anti-infection immunity (development of bacterial and fungal 
infections, reactivation of latent tuberculosis); 
• inhibition of antitumor immunity; 
• the development of allergic reactions; 
• an increase in the risk of developing autoimmune syndromes and autoimmune 
diseases (about 50 nosological forms of autoimmune diseases have been described 
with the use of GEBD). 
To enhance the effect of drug therapy and reduce the immunogenicity of GEBD, it 
is advisable to combine with methotrexate. 
 
Inhibitors of TNF- α 
• They are the main GEBD used in the treatment of RA. TNF- α is a pro-
inflammatory cytokine produced by monocytes, macrophages, mast cells activated 
by T-lymphocytes. TNF- α has the following biological effects in patients with 
RA: it stimulates the synthesis of IL-1, IL-6, IL-8; induces angiogenesis; promotes 
intensive proliferation and pannus growth; triggers an immune response that 
induces the transformation of b-lymphocytes into plasma cells producing 
immunoglobulins; induces the formation of granulocyte macrophage colony 
stimulating factor; promotes mast cell degranulation; stimulates the synthesis of 
metalloproteinases, which have a destructive effect on the intraarticular cartilage 
and articular surfaces of bones; activates osteoclasts that damage bone tissue. 
• Used either as monotherapy or in combination with methotrexate. 
• Have a fast onset of action, which is already observed within the first 2-4 weeks. 
The full effect of the use of TNF- α inhibitors develops within 3-6 months. 
• Contraindicated in patients with active infection, hypersensitivity to these drugs, 
in the presence of chronic hepatitis B. 
Infliximab is a chimeric monoclonal antibody against TNF- α, 25% consists of 
mouse and 75% of human IgG1. Infliximab has a high affinity for TNF- α and 
forms a stable complex with both soluble and membrane-associated forms of 
human TNF- α, which is accompanied by inhibition of its functional activity. 
Also, the effect of infliximab is associated with the activation of apoptosis of 
activated T-lymphocytes. Infliximab is administered intravenously once for two 
hours at a dosage of 3 mg / kg body weight. Then infliximab is prescribed after 2, 
6 and 8 weeks, then every 8 weeks. Duration of use is set individually, depending 
on the indications and regimen of the therapy. 
Adalimumab is a fully humanized monoclonal antibody to TNF- α. Adalimumab 
can be prescribed as monotherapy, and it is also possible to prescribe a 
combination of adalimumab with DMARDs. Adalimumab is administered 
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subcutaneously in the abdomen or anterolateral thigh at a dosage of 40 mg once 
every 1-2 weeks. 
Certolizumab pegol is a pegylated Fab fragment of a fully humanized monoclonal 
antibody against TNF- α. Tsertolizumab pegol is prescribed at the beginning of 
therapy at a dose of 400 mg (two subcutaneous injections of 200 mg per day on the 
1st, 2nd and 4th week of treatment). Then 200 mg every two weeks or 400 mg 
every four weeks. 
Golimumab is a fully human monoclonal antibody of class IgG1 to TNF- α. 
Golimumab has a high affinity for the soluble form of TNF- α, which is 2.4 and 
7.1 times higher in comparison with infliximab and adalimumab, respectively. It is 
used in a dosage of 50 mg once a month on the same day. In patients weighing 
more than 100 kg, if there is no adequate therapeutic effect after performing 3-4 
injections, it is possible to increase the dosage to 100 mg per month. If the effect is 
also absent at a dosage of 100 mg for 12-14 weeks, then it is necessary to consider 
the feasibility of further use of golimumab. 
Etanercept is a soluble p75 receptor for TNF- α, which is coupled to the Fc 
fragment of human IgG1 immunoglobulin. Unlike other inhibitors, TNF- α can 
block not only TNF- α, but also TNF-β (lymphotoxin). Etanercept does not form 
strong complexes with membrane molecules and does not cause apoptosis of the 
corresponding cells (T-lymphocytes, macrophages) on which these molecules are 
located. In this regard, when using etanercept, the risk of developing pulmonary 
tuberculosis is significantly reduced. Etanercept in RA is administered 
subcutaneously at 25 mg twice a week (twice a week with an interval of 3-4 days) 
or 50 mg once a week. The administration of etanercept twice a week is associated 
with the achievement of two times higher equilibrium concentrations. 
 
Anticytokines 
Anakinra is an artificially synthesized selective IL-1 receptor antagonist. Blockade 
of the IL-1 receptor is accompanied by a decrease in inflammation and destruction 
of cartilage in rheumatoid arthritis. Anakinra is administered subcutaneously at 
100 mg once a day. The duration of therapy is currently not known. 
Tocilizumab is a recombinant humanized monoclonal antibody to the human IL-6 
receptor. Tocilizumab is administered intravenously at a dose of 8 mg / kg 1 time 
per month. Each patient's dose is calculated individually depending on body 
weight. It is not recommended to exceed the dose of tocilizumab more than 800 
mg per infusion in patients whose body weight is more than 100 kg. before 
administration, the drug is diluted in a solution of 0.9% sodium chloride, 
administered within one hour. Tocilizumab is used when there is an inadequate 




Rituximab is a chimeric monoclonal antibody that is specific for CD20 
transmembrane receptors. Rituximab refers to IgG1. Its molecule contains murine 
variable fragments of light and heavy chains and a human constant segment. The 
CD20 receptor is involved in the regulation of all stages of B-lymphocyte 
maturation. The mechanism of action of rituximab unfolds due to the interaction of 
the Fab fragment with the CD20 antigen on lymphocytes, then immunological 
reactions are induced with the participation of the Fc domain, which are 
accompanied by lysis of B cells. The administration of rituximab leads to the rapid 
depletion of CD20-positive B cells in peripheral blood. After 6–9 months, the 
number of B-lymphocytes begins to recover, returning to normal by 12 months 
after completion of rituximab treatment. The use of rituximab is associated with 
the development of persistent hypogammammaglobulinemia after repeated 
courses, but this does not lead to a sharp increase in the frequency of infectious 
complications. Rituximab is administered intravenously in a dosage of 1000 mg on 
days 1 and 15. Further, the infusion is repeated once every six months. 
The administration of rituximab is carried out after premedication with 
methylprednisolone (100-250 mg methylprednisolone intravenously 30-60 minutes 
before the rituximab infusion) and antihistamines (chloropyramine hydrochloride 
20 mg intramuscularly) to reduce the risk of developing a “cytokine release 
syndrome”. 
Contraindication for the appointment of rituximab is the presence of a positive 
intradermal tuberculin test, infection with hepatitis B virus, a decrease in serum 
IgG, neutropenia. 
 
Anti-T Cell Therapy 
Abatacept is a protein molecule consisting of the outer domain of a cytotoxic 
antigen – 4 T-lymphocytes (cytotoxic T-lymphocyte-associated antigen 4 — 
CTLA-4) bound to an Fc-modified fragment of human IgG. Abatacept is a 
modulator of costimulation of the interaction of CD80 and CD86 on antigen-
presenting cells with CD28 on T-lymphocytes. The binding of CTLA4-Ig to CD80 
/ 86 provides a negative feedback mechanism that leads to T cell deactivation. 
Abatacept is used to treat RA in the event of an inadequate response to therapy 
with TNF- α inhibitors. Abatacept is prescribed 500-1000 mg (depending on body 
weight) intravenously in the form of infusion for 30 minutes at the 1st, 2nd and 4th 






Principles of GEBD treatment  
- If the first TNF- α inhibitor is not effective enough, then another TNF - α 
inhibitor, or methotrexate, is prescribed (in patients who have not previously taken 
methotrexate).  
- If two drugs from the group of TNF- α inhibitors were not effective enough, then 
they are prescribed GEBD with a different mechanism of action (abatacept, 
rituximab, tocilizumab). 
- Abatacept, or rituximab, or tocilizumab, for patients who are resistant to standard 
DMARDs, can be prescribed as the first GEBD. 
- In the case of resistance to abatacept, rituximab, or tocilizumab, it is possible to 
prescribe any GEBD or DMARDs that has not been previously used. 
- Patients with RA who have rheumatoid factor and/or ACCP, extra-articular 
manifestations of RA, or contraindications to the appointment of TNF- α 
inhibitors the rituximab is to be prescribed better. To maintain the effect, repeated 
courses of rituximab should be carried out 6 better months after the previous 
course. 
- With the development of multidrug resistance, simultaneous therapy with low 
doses of rituximab and TNF-α inhibitors (etanercept and adalimumab) can be used. 
 
Prognostic markers for assessing the effectiveness of biological drugs 
Currently, the concentration of a number of biomarkers is being actively studied to 
predict the response to GEBD therapy in RA, which contributes to its personalized 
choice. Thus, a high basal level of RF IgM is associated with a good response to 
rituximab, tocilizumab. With ACCP-positive RA, the best effects of methotrexate, 
abatacept, infliximab, tocilizumab, rituximab were obtained compared with ACCP-
negative RA. A profile of 24 autoantibodies and cytokines was identified to predict 
the response to etanercept therapy in patients with RA. The efficacy of etanercept 
and golimumab therapy is higher in patients with high basal serum CRP; basal 
serum levels of C3, hyaluronic acid, IL-6, IL-8, myeloperoxidase are associated 
with the effectiveness of golimumab. 
 
Duration of RA Therapy 
• It is necessary to regularly evaluate data on disease activity: 
- In patients with moderate / high degree of activity - monthly, 
- In patients with persistent low activity or in remission once every 3-6 months. 
• RA treatment aims to achieve remission or low disease activity. Revision of 
therapy should be carried out at least 1 time in 3 months. 
• When RA remission is achieved, GCS is first canceled, then the dose of 
biological drugs is reduced with their complete cancellation, then the volume of 
basic therapy is reduced by titrating a dose of or DMARDs. 
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Prospects for the treatment of autoimmune rheumatic diseases 
For the treatment of RA, biosimilars (bio analogs, similar biological medicinal 
product) are used - these are biotechnological drugs that are similar, but not 
identical in molecular structure to the original GEBD. They are registered after the 
expiration of the patent of the original drug. Biosimilars are not copies of the 
original biological drugs, since GEBDs contain a large molecule with a complex 
composition that cannot be exactly repeated. According to the definition of the 
World Health Organization, “a bioanalogue is a biotherapeutic product similar in 
quality, safety and effectiveness to a licensed “reference” biotherapeutic product.” 
The cost of treating 1 patient per year of GEBD is from 10 to 30 thousand dollars, 
while biosimilars are approximately 30% cheaper. At different stages of clinical 
trials, bioanalogs of infliximab, etanercept, adalimumab, rituximab are currently 
located. In 2013, the first bioanalog of infliximab, Flammagis, was registered in 
the Republic of Belarus. 
New biological drugs are being developed for the treatment of autoimmune and 
autoinflammatory diseases. Some of new biological drugs are already used to treat 
psoriasis, psoric arthropathy (ustekinumab (Stelara) - an anti-IL-12 / IL-23 
monoclonal antibody; secukinumab (Cosentix) - an anti-IL-17A monoclonal 
antibody), ankylosing spondylitis (secukinumab), youth (juvenile) arthritis, gout 
(kanakinumab (Ilaris) - a fully human monoclonal antibody against IL-1beta). 
The development of parenteral and oral immunotherapy with antigens with the aim 
of inducing Foxp3 + T-regulatory cells in RA, systemic sclerosis, ulcerative colitis, 
type  1diabetes. 
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4. SYSTEMIC LUPUS ERYTHEMATOSUS 
 
Systemic lupus erythematosus is a chronic systemic autoimmune connective tissue 
disease of unknown etiology with a genetic predisposition, characterized by the 
hyperproduction of numerous autoantibodies to various structures of the cell 
nucleus and immune complexes, and the development of an immuno-inflammatory 
process in various organs and tissues. 
* The prevalence of SLE is 4-250 cases per 100,000 population. 
* Ratio of women with SLE to men: 8:1-10: 1. 
* Onset of the disease at the age of 14-40 years. 
* Peak incidence occurs at the age of 15-25 years. 
 
Code according to ICD-10 
* M. 32 Systemic lupus erythematosus 
- M32. 0 Medicinal systemic lupus erythematosus 
- M32. 1 Systemic lupus erythematosus with lesions of other organs or systems 
- M32. 8 Other forms of systemic lupus erythematosus 
- M32. 9 Systemic lupus erythematosus, unspecified 
 
Etiology and immunopathogenesis of SLE 
- HLA-A1, B8, HLA-DR2, HLA-DR3, etc., IG and T-cell receptor genes.  
- immunological factors-violation of the regulatory mechanism and disruption of 
peripheral tolerance: 
- genetically determined polymorphism of T-cell receptors and IgG Fc receptors 
(FcyRIIA);  
- violation of the function of T-regulatory cells; 
- violation of lymphocyte apoptosis; 
- accumulation of antibodies against cell antigens, leading to the development of 
antibody-dependent cytotoxic reactions;  
- formation of immune complexes and, as a result, the development of vasculitis;  
- deficiency of early complement components-C2, C4.• Hormonal factor. 
- environmental factors (UV exposure). 
- microbial factors (viruses, vaccination). 
- medications (hydralazine, isoniazide, procainamide). 
 
SLE clinic 











manifestations of SLE 
Weakness, fever, weight loss (80% of cases) 
Skin and mucous 
membranes  
Often (20-50% of cases): butterfly rash, 
photosensitization, chronic discoid lesions, alopecia, 
petechiae, finger vasculitis; 
less common (5-20%): ulcers on the mucous 
membranes and extremities, urticaria, 
hyperpigmentation, rarely (less than 5%) - panniculitis, 
itching, jaundice, periorbital edema, bullae, etc. 
Musculoskeletal 
symptoms 
Arthralgia, arthritis (90-100%), morning stiffness 
(50%), tendinitis, synovitis (10%), myalgia (60%), 
myositis (5%) 




Adhesive pericarditis (20%), exudative pericarditis 
(50%), myocarditis (15%), Libman-Sachs endocarditis 
(abacal), coronariitis, myocardial infarction 
Gastrointestinal signs Hepatomegelia (25%), splenomegaly (10%), 
gastropathies (10-20%), peritonitis (rarely), pancreatitis 
(rarely), mesenteric vascular thrombosis 
 
Kidney damage Jade (50%) 
Damage to the 
nervous system 
Migraine (40%), psychosis, convulsions (5-10%), 
Cerebro-vascular lesions, sensory peripheral 
neuropathy, cranial nerve damage, organic brain 
syndrome 
Defeat of the 
hematopoietic system 
Hemolytic anemia (10-20%), leukopenia and 
lymphopenia (50%), thrombocytopenia 
Other symptoms Sjogren's syndrome, Raynaud's phenomenon, 
lymphadenopathy 
 
There are variants of the course of SLE: acute, subacute, chronic. 
Acute flow is characterized by rapid onset, marked fever, polyarthritis, massive 
skin lesions and internal organs with the development of renal, cardiac and 
pulmonary insufficiency, damage to the nervous system, the development of 
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polyserositis, a sharp decline in body weight, the presence of polycythemia and 
high ESR, high immunological activity with the formation of large amounts of 
antibodies characteristic of SLE. With a high degree of SLE activity, lupus crisis 
can develop, which is characterized by the occurrence of functional insufficiency 
of organs and systems. 
In the subacute course, there is a gradual development of SLE over several years. 
Initially, constitutional symptoms develop - weight loss, general weakness, a slight 
increase in temperature. Multiple organ failure develops 2-3 years after the onset of 
the disease. 
Chronic course of the disease development for 5-10 years. There are one or more 
symptoms-mono / oligoarthritis, Raynaud's syndrome, Sjogren's syndrome, 
hematological changes, damage to the kidneys, nervous system, cardiovascular, 
respiratory system.  
 
Diagnosis of SLE 
Table 13 presents the diagnostic criteria for SLE of the American College of 
rheumatologists (1997), [25].  
Immunological tests for the diagnosis of SLE  
 
Determination of antinuclear antibodies. ANA are detected in SLE in the indirect 
immunofluorescence response to human laryngeal epithelial cell culture (IIF-HEp-
2) in 95% of patients with a high titer of 1:1280 or more (in a low positive titer of 
1:160 or higher in 3-5% of healthy people, and in 10-37% of those over 65 years of 
age). 
 
Antibodies to double-chiral deoxyribonucleic acid (dsDNA) 
- DsDNA antibodies are a highly specific marker of SLE. In other cases, ARD are 
detected very rarely (≤5% of cases) and in low titers. 
- The detection rate of dsDNA antibodies in SLE is 70-90%, and a positive result is 
associated with a high risk of kidney damage. High titers of the antibody to 
dsDNA can be detected before the development of a detailed picture of SLE. 
- Characterized by a homogeneous type of glow of the nucleus of Hep-2 cells in 
the detection of antinuclear factor. The norm for detecting antibodies by the IIF 
method (the simplest microorganism Crithidia lucilliae is used as a substrate) is < 
1: 10, by the ELISA method < 10-20 IU / ml; DH-57.3%, DS-97.4%.  
- Often is correlated with disease activity. Monitoring the concentration of dsDNA 
antibodies is important for monitoring the effectiveness of therapy for SLE (1 time 






Table 13-Criteria of the American College of rheumatologists for the diagnosis of 
systemic lupus erythematosus, 1997 (abbreviated version) 
Criterion Brief description 
Rashes in the 
zygomatic area  
Spotty or papular rash on both cheeks and the bridge of the 
nose 
Discoid rash  Erythematous convex spots with areas of keratosis and 
atrophic scars that occur primarily in open areas of the skin 
Increased sensitivity to 
light 
A rash that appears quickly when exposed to sunlight 
(photosensitization)  Painless ulcers of the mouth or nasopharynx 
Ulceration of the oral 
cavity  
Arthritis (without erosions) in at least 2 peripheral joints 
(stiffness, swelling, effusion) 
Arthritis  One of the following changes is detected: 
- pleurisy (pleural pain and / or pleural friction noise, and / or 
pleural effusion, and/or thickening of the pleural leaflets) 
- pericarditis (noise of pericardial friction during auscultation 
and / or signs of pericarditis during echocardiography). 
The effusions Stable proteinuria (>0.5 g / day) and / or cylindruria (hyaline 
cylinders, granular and erythrocyte conglomerates) 
Impaired kidney 
function  
Convulsions or psychoses that are not related to metabolic 
causes or the effects of medications 
Neurological 
disorders  
Hemolytic anemia (reticulocytosis, positive Coombs test) and 
/ or leukopenia <4×109/l, and / or lymphopenia <1.5×109/l, 
and / or thrombocytopenia 100×109/l) 
Hematological 
disorders  
A positive test result for LE cells or the presence of anti-
dsDNA antibodies, or anti-Sm antibodies, or a false positive 
reaction to syphilis 
Immunological 
disorders  
Abnormally high titer of antinuclear antibodies (ANA) in a 
patient who has not taken medications that can cause lupus-
like syndrome 
The presence of 4 of the 11 criteria simultaneously or their occurrence sequentially 
during observation is the basis for diagnosing SLE. 
The identification of a smaller number of criteria does not exclude the diagnosis of 
SLE.  
To make a diagnosis, it is mandatory to identify one of the characteristic 
immunological markers (usually antibodies to dsDNA or anti-Sm antibodies), but it 
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is necessary to combine it with some clinical symptom of SLE. 
Antibodies to the Sm (Smith) antigen 
- Antibodies to Sm (Smith)-nuclear antigen - a highly specific marker of SLE, the 
norm for ELISA <25 U / ml; DH-8-20%; DS-99%. 
- Occur in approximately 20-30% of patients with SLE. The presence of antibodies 
is associated with the aggressive course of SLE, Central nervous system (CNS) 
damage, and the development of pulmonary fibrosis of kidney damage.  
- A single detection of sm-antigen antibodies is recommended, since they do not 
reflect the dynamics of SLE activity. 
 
Antibodies to SS-A / Ro (Sjogren syndrome A / Robert) 
- SS-A/Ro antibodies are found in the sera of 30-50% of SLE patients, 40-80% of 
SS patients, and 30-40% of RA patients.   
- In SLE, positive test results are found in patients with photosensitization, SH, RF 
hyperproduction, lung damage, and lymphopenia. 
- Antibodies to the SS-A/Ro antigen are found in 98% of mothers whose children 
suffer from congenital SLE (discoid lupus, transverse atrioventricular block, 
hepatitis, hemolytic anemia, thrombocytopenia). All pregnant women with 
suspected ARD should be tested for the presence of antibodies to SS-A / Ro-52 
kDa and SS-B/La-48 kDa. 
 
Antibodies to SS-B/La (Sjogren syndrome B/Lane) 
- SS-B/La antibodies are found in 20% of SLE patients and 40-50% of SS patients. 
Most often observed in combination with antibodies to SS-A/Ro. The combination 
of antibodies occurs in 60% of patients with cross syndrome (SH+SLE). 
- In SLE, SS-B/La antibodies are associated with a low incidence of kidney 
damage. 
- During pregnancy, an increase in the level of SS-B/La antibodies serves as a 
prognostic marker for the development of complete transverse heart block in the 
fetus. 
 
Antibodies to small nuclear ribonucleoprotein (RNP/U1-RNP)  
- Occur in 30% of patients with SLE (often together with Sm antigen), in 5% of 
cases of SS, in 10% - with polymyositis. 
- Isolated detectionof antibodies to U1-RNP in high titers is typical for MCTD 
(DH 95-100%, DS 98%), (see the section "Antiphospholipid syndrome").  
- U1-RNP antibody detection is used to predict the adverse course of SLE with the 
development of severe internal organ damage. 
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- U1-RNP-positive mothers have a high risk of having a child with congenital 
lupus erythematosus syndrome. 
Antibodies to phospholipids (cardiolipin, β2-glycoprotein 1, lupus anticoagulant, 
false positive Wasserman reaction within 6 months in the absence of syphilis) - in 
1/3 of patients with SLE, markers of antiphospholipid syndrome are detected (see 
the section "Antiphospholipid syndrome"). 
 
Antibodies to nucleosomes are highly specific markers of SLE, drug lupus. 
- The cumulative detection rate of antibodies to nucleosomes in SLE is 60-90%. 
- High antibody titers to nucleosomes are characteristic only for patients with 
active SLE accompanied by nephritis, their level is positively correlated with 
indicators of disease activity. 
 
Antibodies to histones 
- In 80% of patients with SLE antibodies to histones are detected. 
- These antibodies are often detected in patients with drug-induced lupus in the 
absence of anti-dsDNA or Sm antibodies. Simultaneous detection of anti-dsDNA, 
Sm-antibodies, and histone antibodies allows for differential diagnosis of SLE and 
drug lupus. Drug lupus syndrome is often developed when treated with phenytoin, 
quinidine, hydralazine, methyldopa, procainamide, isoniazide. Cancellation of the 
drug leads to a gradual decrease and disappearance of antibodies within 6 months.  
- High-titer histone antibodies can be found in patients with systemic scleroderma 
and autoimmune hepatitis. 
 
Antibodies to PCNA (proliferating cell nuclear antigen 1) 
 -PCNA antibodies are found in 2-5% of patients with SLE, rarely in RA. 
Detection in SLE is associated with kidney damage, central nervous system, and 
thrombocytopenia. 
- In SLE with the nervous system damage, PCNA antibodies are found in isolation 
without dsDNA antibodies. 
- Antibody content correlates with SLE activity. 
 
Antibodies to Ribo P 
- Antibodies to ribosomal protein P are highly specific for SLE, found in 10-20% 
of patients, often together with antibodies to Sm-antigen. 
- Typical (50-80% of cases) for SLE with CNS damage (depression, lupus 
psychosis).  
There was a correlation with skin and mucous membrane lesions in SLE (discoid 
rashes, photosensitization, aphthous stomatitis), and liver damage. 
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Antibodies to the C1q complement system protein-increased levels are 
associated with lupus nephritis. A decrease in C3, C4, and total complement 
hemolytic activity indicates SLE activity. 
LE cells (lupus cells, lupus erythematodes cells – are neutrophilic white blood cells 
containing phagocytic homogeneous nuclear material.) and antibodies to single-
chiral DNA-non-specific markers for SLE, often found in other ARD, infections, 
tumors, etc. 
 
Immunological tests to assess prognosis and monitor SLE activity:  
• DsDNA antibodies-often correlate with disease activity. 
• Antibodies to C1q-increased levels are associated with lupus nephritis. 
• The total hemolytic activity of complement may be reduced during the 
active period of SLE. 
 
Diagnosis of organ pathology in SLE includes the following studies: 
• General blood test. 
• General urine analysis, Zimnitsky test, Rehberg test, determination of daily 
proteinuria. 
• Biochemical blood analysis: CRP, fibrinogen, total protein and protein 
fractions, bilirubin, cholesterol, urea, creatinine, electrolytes.  
• Coagulogram. 
• Chest x-ray. 
• Radiography of affected joints. 
• Electrocardiography (ECG), echocardiography. 
• Spirometry. 
• Ultrasound of the pleural, abdominal cavities, liver, spleen, and kidneys. 
• MRI or other types of brain tomography. 
• Skin and muscle flap biopsy, kidney biopsy. 
In 2012, SLICC (systematic Lupus International Collaborating Clinics) diagnostic 
criteria were proposed, consisting of 11 clinical and 6 immunological criteria (table 
14). 
 
Table 14 - Diagnostic criteria for SLE (SLICC, 2012), [14, 20] 
Clinical criteria 
1.Acute, active lesions of the skin 
• Lupus rash on the cheekbones (discoid rashes are not taken into account) 
• Bullous rashes 
• Toxic epidermal necrolysis  
• Maculopapular lupus rash 
• Photodermatitis (in the absence of dermatomyositis) 
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• Subacute cutaneous lupus (non-indurative psoriaform and / or ring-shaped 
polycyclic lesions that resolve without scarring, sometimes post-
inflammatory depigmentation or telangiectasia may remain) 
2. Chronic lesions of the skin 
• Classic discoid rash: localized (above the neck), generalized (above and 
below the neck) 
• Hypertrophic (warty) skin lesions 
• Panniculitis 
• Mucosal lesions 
• Edematous erythematous plaques on the torso 
• Capillaritis (lupus erythematosus of frostbite, Gatchinson, manifested by 
lesions of the fingertips, ears, heel and calf areas) 
• Discoid lupus erythematosus by type of lichen planus or overlap syndrome 
(cross syndrome) 
3. Ulcers of the oral mucosa (palate, cheeks, tongue), nasal cavity (in the 
absence of other causes, such as vasculitis, Behcet's disease, herpes virus, 
inflammatory bowel diseases, spicy food, reactive arthritis) 
4. Alopecia that does not lead to scar formation (diffuse hair loss or short-lived 
hair with visible damage), with the exception of side effects of drugs, 
intoxication, androgen alopecia 
5. Arthritis: synovitis of two or more joints characterized by effusion and 
swelling or morning stiffness for more than 30 minutes 
6. Serositis: pleurisy (pleural effusion or pleural friction noise) for more than 1 
day; pericarditis (pericardial pain-lying down, increased when the body is lifted, 
pericardial effusion or pericardial friction noise, or ECG-signs of pericarditis) 
for more than 1 day  
7. Kidney damage: persistent proteinuria more than 0.5 g / day or cylindruria 
(erythrocyte, tubular, granular, mixed), hematuria>5 red blood cells in p/HR 
8. Central nervous system damage: convulsions, psychosis, 
mononeuritis/polyneuritis, myelitis, peripheral or Central neuropathy, acute 
impairment of consciousness 
9. Hemolytic anemia 
10. Leukopenia: less than 4, 0x109/l in the absence of other causes-Felty 
syndrome, medications, portal hypertension, lymphopenia less than 1, 0x109/l in 
the absence of GCS, medications, infection 
11. Thrombocytopenia: less than 100 x109/l once in the absence of other 
known causes-medications, portal hypertension, thrombocytopenic purpura 
Immunological criteria 
• ANA-level above the reference values of the laboratory 
• Anti-dsDNA is a level above the reference values of the laboratory  
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• Anti-Sm –antibodies against nuclear antigen Smith 
• Positive antiphospholipid antibodies identified in any of the following 
cases: 
• positive lupus anticoagulant test 
• false positive ELISA for syphilis 
• medium or high titer of lupus antibodies (IgA, IgG, or IgM) 
• positive test to anti-β2-glycoprotein 1 (IgA, IgG, or IgM) 
• Low complement fractions: low C 3, low C 4, low CH 50 
• Positive direct Coombs reaction in the absence of hemolytic anemia 
 
To establish a SLE diagnosis, there must be 4 criteria:  
 1st option: one clinical and one immunological (any of: antibodies to 
dsDNA, ANF, Sm, ACL, C3, C4); 
 2 option: nephritis, confirmed by biopsy, with the presence of ANF or 
dsDNA antibodies. 
Determining the activity of the disease is a mandatory component when 
prescribing treatment. When calculating the SLE activity index, the degree of 
organ damage and patient's quality of life are evaluated, and the presence of 
concomitant diseases and side effects of immunosuppressive therapy are taken into 
account. 
According to EULAR recommendations of (2010), validated questionnaires are 
used to standardize the activity of SLE: 
• Systematic Lupus Erythematosus Disease Activity Index (SLEDAI), 1992; 
• Systemic Lupus Activity Measure (SLAM), 1989; 
• European Consensus Lupus Activity Measurement (ECLAM), 1992; 
• Lupus Activity Index, (LAI) 1992; 
• Classic British Isles Lupus Assessment Group Index (BILAG Classic), 
1993. 
The SLEDAI activity index is most often used, which includes 24 indicators (16 
clinical and 8 laboratory parameters). Each attribute is assigned from 1 to 8 points, 
depending on its significance. The maximum number of points is 105. When 
evaluating activity on this index, it is necessary to note the signs of SLE that the 
patient had during the previous 10 days before the examination. 
 
The following degrees of SLE activity are distinguished according to the SLEDAI 
activity index: 
•  no activity – SLEDAI score of 0; 
•  low level of activity-SLEDAI 1-5 points; 
•  the average level of activity – SLEDAI 6-10 points; 
•  high degree of activity-SLEDAI 11-19 points; 
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•  very high level of activity-SLEDAI >20 points. 
If the patient on the next visit on the SLEDAI activity index scores 3-12 points 
more than on the previous one, this indicates the presence of a moderate 
exacerbation, and if more than 12 points, this is regarded as a severe exacerbation. 
Table 15 shows the clinical and laboratory characteristics of the degrees of SLE 
activity proposed by V. A. Nasonova. 
 
Examples of diagnosis formulation 
1. Systemic lupus erythematosus, acute course, grade III activity (SLEDAI 16), 
with skin lesions (butterfly, capillaritis, discoid lupus), joints (polyarthritis), serous 
membranes (bilateral pleurisy, pericarditis), heart (diffuse myocarditis, Libman-
Sachs endocarditis, chronic heart failure IIA, functional class II), kidneys (diffuse 
glomerulonephritis, nephrotic syndrome, chronic kidney disease, C3A), the 
nervous system (cerebral vasculitis with epileptiform syndrome). 
2. Systemic lupus erythematosus, subacute course, grade II activity (SLEDAI 
8), with skin lesions ("butterfly", capillaritis), joints (arthralgia), heart (mitral valve 
insufficiency of grade I, chronic heart failure I, functional class I), kidneys 
(glomerulonephritis with minimal urinary syndrome (subclinical proteinuria), 
chronic kidney disease, stage C1). 
3. Systemic lupus erythematosus, chronic course, activity of Ist degree, with 
skin lesions (discoid lupus), joints (arthralgia), Sjogren's syndrome, Raynaud's 
syndrome. 
 
Table 15-Clinical and laboratory characteristics of the degrees of activity of 
systemic lupus erythematosus (Nasonova V. A., 1972-1986) 
Indicator 
 
Degree of activity 
III II I 
Body temperature  38°C and above  Below 38°  Normal  
Losing weight Expressed Moderate Minor 





Polyarthritis Acute Subacute Deforming, 
arthralgia 
Pericarditis Exudate Dry Adhesive 
Myocarditis Diffuse Focal Cardiosclerosis, 
myocardial 
dystrophy 
Endocarditis Damage to many 
valves 






Pleurisy Exudate Dry 
 
Adhesive 
Pneumonitis Acute (vasculitis) Chronic (inter-
daily) 
Pneumofibrosis 












+ - - 
Hemoglobin, g / l Less than 100 100-110 120 or more 
ESR, mm / h 45 or more 30-40 16-20 
Fibrinogen, g / l 6 or more 5 5 
Albumins, % 30-35 40-45 48-60 










LE cells 5: 1000 white blood 
cells or more 
(1-2): 1000  
leukocytes' 
Single or absent 
Antinuclear  
antibodies, titers 
1:128 and higher 
 
1:64 1:32 










High Medium  Low  
 
Treatment of SLE [5, 7, 9, 23, 25] 
General recommendation 
• Photoprotection: use of creams with sun protection factor SPF15 (Sun 
Protection Factor) or more. 
• Foods high in polyunsaturated fatty acids, calcium, and vitamin D. 
• Treatment of concomitant infections, vaccination. 
• Refusal of smoking. 
• Oral contraceptives and hormone replacement therapy are not recommended. 
• Avoid stressful situations. 
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• Maintain a normal body weight. 
Drug therapy 
Therapy of SLE is performed with the use of corticosteroids, cytostatics, and 
biological drugs aminohinolinovogo.  
There are two types of induction and maintenance therapy. 
 
Glucocorticosteroids 
- GCS prescription is mandatory in SLE. 
-Induction therapy of GCS is carried out in different doses, the choice of which is 
determined by the degree of activity of SLE: 
• < 10 mg / day of prednisone at low activity; 
• 10-40 mg/day - with moderate activity for at least 3-4 weeks; 
• 1 mg / kg / day or more-with high activity for 4-12 weeks. 
- If the activity decreases, they switch to maintenance therapy of GCS, gradually 
reducing their dose after improving the patient's well-being and normalizing 
laboratory parameters. Reduce the dose by 1 mg in 7-10 days, aiming to receive 5-
7, 5-10 mg/day. Treatment is long-term (many years). 
- GCS pulse therapy is indicated for high SLE activity, severe visceral lesions, and 
catastrophic antiphospholipid syndrome: 
• МЕТ methylprednisolone 15-20 mg / kg (usually 500-1000 mg of 
methylprednisolone) is diluted in 100-250 ml of 0.9% sodium chloride 
solution or 5% glucose, injected intravenously for 30 minutes 3 days in a 
row;  
• on day 2: cyclophosphamide 0.5-1.0 g / m2 intravenous drip 1 time per 
month for 6 months, then 1 time every 3 months for 18-24 months. 
- Combination pulse therapy of corticosteroids and cytotoxic agents is the lack of 
effectiveness of monotherapy with high doses of corticosteroids:  
• on the 2nd day of GCS pulse therapy: cyclophosphamide 0.5-1.0 g / m2 
intravenously for 35-45 minutes; 
• program combined pulse therapy is performed 1 time per month for 6 
months according to the pulse therapy method, then 1 time every 3 months 
for 2 years. 
 
Aminoquinoline drugs 
Aminoquinoline drugs are prescribed to all patients with SLE, if they do not have 
contraindications for this therapy. 
They are used for long-term use with low activity of the inflammatory process, 
chronic SLE, with predominant skin and joint damage. Reduce the activity of the 
disease, the risk of developing cardiovascular lesions, kidney lesions. They are 
prescribed to prevent relapses when reducing the dose of GCS or canceling 
 55 
cyclosporine. In combination with antiplatelet agents, they are prescribed for the 
prevention of thrombotic complications. 
• Hydroxychloroquine (immard) 200-400 mg/day. Hydroxychloroquine can be 
used for probable SLE. 
• Chloroquine (delagil) 250-500 mg per day for 6-12 months. 
 
Cytostatics 
Cytostatics are prescribed in addition to GCS for progressive course, high activity 
of the disease (nephritis, CNS lesion, polyserositis, pneumonitis, alveolitis). 
Induction therapy is carried out for 3-6 months, after achieving the effect, they 
proceed to taking maintenance doses. One of the following drugs or a combination 
of them is assigned: 
• Cyclophosphamide 1-2 mg /kg/day orally or intravenously at a dose of 0.5-
0.75 mg/m2 for administration once every 2 weeks, or 500-1000 mg/m2 for 
administration once/month., or at a dose of 15 mg/kg for administration once 
every 2 weeks, a maintenance dose of 50-100 mg per day for a long time. It 
is necessary to monitor General clinical laboratory parameters 7-9 days after 
each intravenous injection, and 1 time every 7 days when taken orally. If the 
number of leukocytes in the peripheral blood is less than 2,5x109/l, platelets 
less than 100x109/l, increasing the concentration of ALT/AST more than 3 
times from the upper limit of the norm, treatment is stopped. The appearance 
of signs of hemorrhagic cystitis is an absolute contraindication for 
continuing treatment with cyclophosphamide. 
• Azathioprine 2-4 mg/kg/day, a maintenance dose of 2 mg/kg/day.  
• Mycophenalate mofetil 2-3 g/day, supporting dose 1-2 g/day. It is used for 
moderate or high SLE activity. 
• Methotrexate-7.5-15 mg / week.  
• Less frequently, cyclosporine < 5mg/kg of body weight per day. 
Cytostatics are used as maintenance therapy in combination with oral 
administration of GCS. It is prescribed for non-severe, non-renal variants of SLE 
with resistant skin and muscle-joint syndromes to achieve remission more quickly. 
The use of cytostatics allows the use of low doses of GCS. 
 
Non-steroidal anti-inflammatory drugs with a short course are indicated for 
arthralgia, myalgia, and serositis. Choose NSAIDs with a low risk of 
complications, take into account the comorbid pathology of the patient, the 
presence of APS. 
 
Anticoagulants, antiaggregants are prescribed for secondary antiphospholipid 
syndrome (see the section "Antiphospholipid syndrome"). 
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Immunoglobulins for intravenous administration 
Indications for use: CNS lesions, thrombocytopenia, bacterial infections, APS, 
decreased Ig levels in the treatment of rituximab, resistance to GCS therapy in 
combination with immunosuppressants with high SLE activity. 
Dose: 1-2 g/kg of body weight per course, for the treatment of infectious 
complications-in a dose of 0.4–0.5 g/kg per course. 
 
Biological Medicines 
• Indications: uncontrolled activity of SLE (inefficiency of GCS in 
combination with immunosuppressants in hemorrhagic alveolitis, rapidly 
progressive kidney damage, Central nervous system, thrombocytopenia, and 
other life-threatening conditions); 
• Rituximab (Mabtera) – antibodies to the CD20 receptor of B lymphocytes. 
Dose: 375 mg/m2 intravenous drip 1 time per week for 4 weeks, or 750mg / 
m2 at 2-week intervals.  
• Belimumab (Benlista) - human monoclonal antibodies to BLyS (B-
lymphocytic stimulator or B-cell activation factor), block the activation of B 
cells. The first 3 infusions (0-14-28 days) of 10 mg/kg of weight, then 10 
mg/kg monthly for at least 6 months. 
• Anakinra-Il-1 receptor antagonist is used for symptoms of arthritis. 
 
Extracorporeal therapies (plasmapheresis, rarely hemosorption) are indicated for 
rapidly progressive glomerulonephritis, APS, generalized vasculitis with skin and 
internal organ damage, thrombotic thrombocytopenic purpura, and severe CNS 
lesions. 
Synchronous intensive care: plasmapheresis + combined pulse therapy (GCS in 
combination with cytostatics). Plasmapheresis (3-6 procedures) is performed daily 
or every other day, with exfusion of 20-30 ml/kg of plasma weight. After the end 
of plasmapheresis, it is recommended to administer intravenous immunoglobulin 
in doses of 0.5-1.0 g/kg. 
If there is no effect during the first 3-4 days from the beginning of synchronous 
intensive therapy for life-threatening CNS lesions, Rituximab is additionally 
prescribed 500-1000 mg weekly (the maximum total dose is 2000 mg). 
Additionally, when SLE is used according to the indications: 
• broad-spectrum antibiotics, 
• antiviral drugs,  
• anabolic hormone,  
• diuretic drugs,  
• antiotensin converting enzyme (ACE) inhibitors), 
• peripheral vasodilators, etc. 
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Pregnancy in patients with SLE. You can use hydroxychloroquine, low-dose 
aspirin, prednisone. Methotrexate, cyclophosphamide, cyclosporine, 
mycophenolate mofetil have a teratogenic effect. The teratogenic effect of 
azathioprine in doses of no more than 2 mg/ kg is considered minimal. 
Evaluation of the effectiveness of therapy in SLE. It is performed in 1 week, 1 and 
3 months, then every 6 months. At any stage of treatment, the therapy should be 
corrected if it is ineffective and/or intolerant. 
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5. ANTIPHOSPHOLIPID SYNDROME 
 
 
Antiphospholipid syndrome (APS) is an autoimmune disease caused by an increase 
in the formation of autoantibodies to phospholipid-binding proteins, which is 
characterized by recurrent arterial and / or venous thrombosis, and / or pregnancy 
pathology (habitual miscarriage, fetal death, intrauterine development delay, 
preeclampsia, etc.), thrombocytopenia, stroke, and other clinical symptoms. 
In 1-5% of healthy people, antiphospholipid antibodies (APLA) are detected, in 
high titer – less than 0.2%. 
The prevalence of APS is 40-50 cases per 100,000 population. APS is more 
common in women than in men (5:1), usually at the age of about 35 years.  
During pregnancy, antiphospholipid antibodies are detected in 2-11% (on average, 
5%) of healthy women. Habitual miscarriage is associated with APS in 27-42% of 
cases. 
 
Classification of APS 
The following forms of APS are distinguished:  
• primary APS 
• secondary APS 
• catastrophic APS 
• seronegative APS 
• probable or prefix 
 
Primary APS is an independent nosological form. 
Secondary APS occurs in diseases accompanied by hyperproduction of 
autoantibodies-SLE, SS/SSD, RA, etc., malignant neoplasms, lymphoproliferative 
diseases, on the background of acute and chronic infections, when taking certain 
drugs (oral contraceptives, psychotropic drugs, etc.). Most often, APS is associated 
with SLE – about 30% of patients have antibodies to cardiolipin, and 25% have a 
lupus anticoagulant. APS in SLE may be the first manifestation of the disease in 
approximately 8% of patients. 
The catastrophic version of APS is characterized by widespread thrombosis with 
damage to many internal organs, with a mortality rate of about 50%. 
Seronegative APS is established in the presence of clinical manifestations 
associated with APS, but not included so far in the diagnostic criteria (reticular 
livedo, skin ulcers, thrombocytopenia, hemolytic anemia, heart valve lesions, 
nephropathy, cognitive disorders, etc.). Seronegativity can be explained by 
imperfect laboratory diagnostics, or disappearance of antibodies to phospholipids 
over time, or the presence of other coagulopathies. 
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Probable APS (or preAPS), described in 2005, is characterized by asymptomatic 
carriers of antiphospholipid antibodies. APS is excluded if only antiphospholipid 
antibodies without clinical manifestations are detected for less than 12 weeks or 
more than 5 years, or there are clinical manifestations of APS without antibodies to 
phospholipids. 
 
ICD code 10: D68. Other blood clotting disorders. 
D68. 6. Other thrombophilia. Antiphospholipid syndrome. 
 
Etiology and pathogenesis of APS 
The role of various bacterial and viral infections as the cause of APS is considered. 
There is a genetic predisposition to hyperproduction of antibodies to 
phospholipids, associated with the carrier of HLA antigens DR7, DR6, DR4, and 
genetic polymorphism of β2-glycoprotein I. 
In APS, antibodies appear to phospholipids, which are components of the cell 
membranes of platelets, endothelial cells, and nervous tissue, as well as to 
phospholipid-binding proteins, which normally prevent excessive activation of 
blood clotting. 
 
Antiphospholipid antibodies include: 
 
- Lupus anticoagulant-antibodies of the IgG or IgM class that can in vitro suppress 
phospholipid-dependent coagulation reactions by interacting with the phospholipid 
component of the prothrombinase activator complex. In SLE, the production of 
lupus anticoagulant is associated, unlike in vitro results, not with bleeding, but 
with a paradoxical increase in the frequency of thrombosis. 
 
- Antibodies to cardiolipin – a heterogeneous population of antibodies (IgG, IgM, 
IgA) that react with a negatively charged phospholipid-cardiolipin, which is the 
main antigen of the Wasserman reaction. 
 
- Antibodies to β2-glycoprotein 1-inhibit the natural anticoagulant and 
antiaggregant activity of β2-GP 1. β2-glycoprotein 1 acts as a cofactor 
(autoantigen) necessary for binding APLA to phospholipids. 
 
- Antibodies that react with various phospholipids, antithrombin antibodies, 
antiplatelet antibodies, antiendothelial antibodies, etc. 
Antiphospholipid antibodies affect the vascular, cellular and humoral components 
of the coagulation system, which leads to a violation of the balance between 
prothrombotic and antithrombotic processes and the development of 
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hypercoagulation. When antiphospholipid antibodies interact with phospholipids 
on cell membranes, systemic endothelial dysfunction and dysregulation in the 
hemostatic system develop, manifested by adhesion and platelet aggregation, a 
violation of the balance between the synthesis of the antiplatelet prostacyclin and 
the synthesis of thromboxane, which increases platelet aggregation. APLA reduces 
the activity of natural anticoagulants (protein C, S, and antithrombin III) and 
contributes to the development of thrombotic and immune thrombocytopenia. The 
basis of pathology of pregnancy in APS is thrombosis of the vessels of the placenta 
and trophoblast. 
In the development of thrombosis in APS, additional risk factors are important: the 
patient has arterial hypertension, diabetes, obesity, as well as smoking, pregnancy, 
and surgical interventions. 
 
The clinical picture of APS is presented in table 16. 
Catastrophic antiphospholipid syndrome (CAPS) is a rare complication of APS 
that developed in a relatively short period of time (less than one week) due to 
diffuse thrombosis of small and medium vessels, and leads to acute multi – organ 
failure. 
Infections, injuries, surgical interventions, autoimmune diseases (SLE, SSD, RA), 
cancer, pregnancy, the withdrawal of warfarin in APS, the use of certain drugs 
(vaccines, oral contraceptives, thiazide diuretics, danazol, etc.) are considered to be 
the provoking factors of APS. KAPS can develop in the absence of a history of 
antiphospholipid antibodies and clinical symptoms of APS. 
 
Table 16-Clinical picture of antiphospholipid syndrome 
Venous 
thrombosis 
Recurrent deep vein thrombosis of the lower extremities, 
pulmonary embolism, small vascular thromboembolism of 
the lungs with the development of pulmonary hypertension; 
hepatic, splenic, renal, mesenteric vein thrombosis, Central 
adrenal vein, subclavian vein, retinal vein 
Arterial 
thrombosis 
Recurrent strokes, transient ischemic attacks, aortic arch 
syndrome, lesion of mesenteric arteries (intestinal ischemia), 
peripheral arteries (ischemia and gangrene of the lower 
extremities), ocular artery occlusion 
Hematological 
manifestations 
Thrombocytopenia, hemolytic anemia (positive Coombs 
test), Evans syndrome (combination of thrombocytopenia 
and hemolytic anemia), microangiopathy 
Obstetric Habitual miscarriage, recurrent spontaneous abortions, 
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pathology intrauterine fetal death, late pregnancy toxicosis, 
preeclampsia, eclampsia, delayed fetal development, 
premature birth, HELLP syndrome: H-hemolysis 
(hemolysis), EL – elevated liver enzymes (increased activity 
of liver enzymes in the blood serum), LP – low level platelet 
(thrombocytopenia), usually occurs in the 3rd trimester of 
pregnancy at 33-35 weeks, in 30% of cases, develops on 1-3 
days after delivery 
Skin lesion Reticulated livedo, hemorrhagic rash, hemorrhages in the 
subarachnoid bed, skin necrosis, chronic leg ulcers 
Lesion of lungs Pulmonary embolism, pulmonary hypertension 
Heart failure Heart valve damage, formation of intracardiac blood clots, 
myocardial infarction, arterial hypertension 
Liver damage Hepatic vein thrombosis (Budd-Chiari syndrome), arterial 
damage with the development of a liver infarction 
Kidney damage Thrombosis (stenosis) of renal arteries, infarction of kidney, 
vnutrikletochnyi the mikrotromboza 
CNS defeat Transient ischemic attacks, strokes, convulsive syndrome, 
dementia, mental disorders, less often-migraine, chorea, 
transverse myelitis 
 
Clinical manifestations of CAPS: 
• impaired kidney function (80%), 
• acute respiratory distress syndrome and respiratory failure (25%), 
• pulmonary embolism, 
• acute cerebral distress syndrome (60%), 
• heart lesions (50%) - reduced myocardial contractile activity (aortic and 
mitral insufficiency, cardiogenic shock, myocardial infarction), development 
of catecholamine-refractory hypotension, 
• gastrointestinal thrombosis, 
• DIC-syndrome (bleeding, thrombocytopenia, microthrombosis); atypical 
thrombosis (pancreatic, prostate, bone marrow, adrenal, spleen, etc.). 
 
Classification criteria of KAPS (2002), [30, 34] 
• Clinical manifestations of vascular occlusion of 3 or more organs and 
systems. 
• Development of clinical manifestations simultaneously or with an interval of 
no more than a week. 
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• Histological confirmation of vascular occlusion in at least one organ. 
• Serological confirmation of the presence of APA: lupus anticoagulant, and / 
or antibodies to cardiolipin, and / or antibodies to beta-2-glycoprotein 1. 
• The diagnosis of CAPS corresponds to the presence of all four specified 
criteria. If the patient has only 3 of the 4 criteria, a diagnosis of probable 
CAPS is made. 
 
Diagnosis of antiphospholipid syndrome 
International criteria for APS have been developed, including clinical and 
serological features (table 17). 
Antiphospholipid antibodies are a heterogeneous group of autoantibodies that 
recognize antigenic determinants of phospholipids, and epitopes formed during the 
interaction of phospholipids and phospholipid-binding proteins in blood plasma. 
 
APLA includes: lupus anticoagulant, antibodies to cardiolipin of IgG/IgM classes, 
and antibodies to β2-glycoprotein 1 of IgG/IgM classes. 
-ACLs occur in 30-40% of patients with SLE, in patients with systemic vasculitis, 
appear against the background of infections (HIV infection, hepatitis B and C, 
malaria, herpes zoster, syphilis), cancer, chronic intoxication, myocardial 
infarction, deep vein thrombosis, taking drugs (penicillin, procainamide, 
phenytoin, chlorpromazine, minocycline) , etc. 
 
Table 17 - Diagnostic criteria for APS (2006), [29] 
1. Vascular thrombosis 
One or more clinical episodes of arterial, venous, or small vessel thrombosis in 
any tissue or organ. Thrombosis must be confirmed by image reproduction or 
Doppler examination, or morphologically, with the exception of superficial 
venous thrombosis. Morphological confirmation should be provided without 
significant inflammation of the vascular wall. 
2. Pathology of pregnancy 
a) one or more cases of intrauterine death of a morphologically normal fetus after 
10 weeks of gestation (normal morphological signs of the fetus are documented 
on ultrasound or by direct examination of the fetus) or 
b) one or more cases of premature birth of a morphologically normal fetus before 
34 weeks of gestation due to severe preeclampsia or eclampsia, or severe 
placental insufficiency, or 
C) three or more consecutive cases of spontaneous abortions before 10 weeks of 
gestation (exceptions are anatomical defects of the uterus, hormonal disorders, 
maternal or paternal chromosomal disorders). 
Laboratory criteria 
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• Antibodies to cardiolipin IgG or IgM detected in serum in medium or high 
titers at least 2 times during 12 weeks with the help of the ELISA. 
• Antibodies to β2-glycoprotein 1 IgG and / or IgM isotype detected in serum 
in medium or high titers at least 2 times during 12 weeks with the help of 
the ELISA. 
• Lupus anticoagulant in plasma in two or more studies with an interval of at 
least 12 weeks, determined according to the recommendations of the 
International society of thrombosis and hemostasis: 
a) prolongation of plasma clotting time in phospholipid-dependent coagulological 
tests: activated partial thromboplastin time, kaolin test, Russell Viper venom test; 
b) prolongation of blood clotting time (in screening tests) is preserved when 
mixed with donor plasma without platelets; 
c) normalization of blood clotting time when adding phospholipids; 
d) exclusion of other coagulopathies (presence of a blood coagulation factor VIII 
inhibitor or heparin). 
Notes: 
1. APS is diagnosed when there is one clinical and one serological criterion.  
2. APS is excluded if antibodies to phospholipids without clinical manifestations 
or clinical manifestations without antibodies to phospholipids are detected for 
less than 12 weeks or more than 5 years.  
3. The presence of congenital or acquired risk factors for thrombosis does not 
exclude APS. Patients should be stratified for: a) the presence of risk factors for 
thrombosis; 
b) with no risk factors for thrombosis. 
 
• For differential diagnosis of transient and persistent ACL products, the test 
(ELISA) is repeated after 6-12 weeks. In APS, IgG / IgM antibodies to 
cardiolipin should be detected in serum in 2 or more studies at intervals of at 
least 12 weeks. The result of the analysis should be evaluated together with 
additional laboratory data (antibodies to β2-glycoprotein 1 of IgG/IgM 
classes, lupus anticoagulant) and instrumental studies. 
• Antibodies to β2-glycoprotein 1 are detected in primary or secondary APS 
(ELISA). 
• Lupus anticoagulant is detected in SLE, APS, RA, multiple myeloma, 
ulcerative colitis, malignant tumors, after taking some drugs. 
 
To make a diagnosis of APS, it is sufficient to have one of 3 laboratory criteria: 
ACL, or antibodies to β2-GP 1 of IgG/IgM classes, or VA of IgG/IgM classes.  
• LA and antibodies to β2-GP 1 are more specific but less sensitive diagnostic 
markers of APS compared to ACL. 
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• For predicting the risk of thrombotic complications or obstetric pathology in 
APS, the most useful markers are LA, IgG ACL, and IgG to β2-GP 1. 
• Recommended multiplicity of determination of LA, IgG / IgM ACL, IgG / 
IgM to β2-GP 1 in APS is 1 every 3-6 months. 
 
Depending on positivity for antibodies to phospholipids, it is recommended to 
divide patients with APS into the following categories: 
•  I-detection of more than one laboratory marker (in any combination);  
•  IIa – only LA;  
•  IIb-ACL only;  
•  IIc-only antibodies to β2-glycoprotein 1. 
There is a high and low risk of subsequent thrombosis (table 18). 
 
Table 18-High and low risk of various antiphospholipid antibodies for subsequent 
thrombosis [21] 
High risk  
Positivity for lupus anticoagulant  
Positivity of three types of antiphospholipid antibodies (LA + antibody to 
cardiolipin + antibody to β2-glycoprotein 1)  
Isolated constant ACL positivity at high and medium levels for systemic lupus 
erythematosus 
Low risk 
Isolated periodic increase in each of the antiphospholipid antibodies at medium 
and low levels 
 
Diagnosis example 
1. Antiphospholipid syndrome, recurrent femoral vein thrombosis, recurrent 
fetal loss syndrome (intrauterine fetal death and spontaneous abortions), category I 
(positive anti-cardiolipin antibodies and antibodies to β2-glycoprotein 1). 
2. Antiphospholipid syndrome, category I, thromboembolism of small branches 
of the pulmonary artery (date). 
3. Probable antiphospholipid syndrome, category IIA, migraine, retinal livedo. 
4. Thrombocytopenia associated with antiphospholipid antibodies, category 
IIA (LA, antibodies to β2-glycoprotein 1). 
 
APS treatment 
Patients with APS should exclude causes that may complicate the course of the 
disease: 
• quitting Smoking and other bad habits, 
• the decrease in body mass index, 
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• exclude the use of estrogens-containing contraceptive drugs, 
• secondary APS requires treatment of the underlying disease, 
• in the presence of arterial hypertension, it is necessary to select 
antihypertensive therapy. 
 
Anticoagulants are used in APS treatment. Usually, heparins are first prescribed: 
unfractionated (normal), or low-molecular (most preferred), or pentasaccharides, 
followed by transfer to vitamin K antagonists (warfarin). 
There is no universal treatment regimen for APS due to the variability in the course 
of APS, the severity and prevalence of thrombotic processes. General 
recommendations for the management of patients with APS in table 19. 
 
Tactics of APS maintaining in women 
• A history of pregnancy complications, moderate/high afla titer — low doses 
of aspirin (75-100 mg/day). Against the background of therapy, gestation is 
50%. 
• Women with APS who have a history of thrombosis in previous pregnancies 
are treated with low-dose aspirin before, during pregnancy, and for 6 weeks 
after delivery. 
 
Table 19-Management tactics for patients with APS 
Symptoms Management tactics 
Asymptomatic 
course  
If the APL titer is low, follow-up is recommended,  
low doses of aspirin (75-100 mg/day) are prescribed for 
medium or high afla titers), 
(+ hydroxychloroquine 100-200 mg / day for secondary APS, 
such as SLE) 
Venous thrombosis  Warfarin (INR-international normalized ratio = 2.0-3.0) 
Arterial 
thrombosis  
Warfarin (INR = 3.0-3.5) 
Recurrent 
thrombosis 
Warfarin (INR = 3.0-4.0) + low-dose aspirin (75-100 mg / 
day) 
Catastrophic APS Anticoagulants, GCS, intravenous immunoglobulin or 
plasmapheresis with replacement of a single group of freshly 
frozen plasma, on the background of SLE+ cyclophosphamide 
Thrombocytopenia Mild to moderate-recommended observation 
Heavy (less than 50x109/l) — GCS, intravenous 
immunoglobulin 
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Refractory APS Some patients may experience recurrent thrombosis during 
warfarin therapy. For the treatment of refractory APS use: 
• direct thrombin inhibitors (dabigatran etexilate); 
• low molecular weight heparins (dalteparin sodium, 
enoxaparin sodium, nadroparin); 
• direct inhibitors of factor Xa (rivaroxaban, edoxaban, 
betrixaban, apixaban); 
• hydroxychloroquine; 
• statins (atorvastatin, rosuvastatin). 
 
• For APL and pregnancy, a combination of low-dose aspirin and low-molecular-
weight heparin is recommended: dalteparin 200 u / kg subcutaneously in 1 or 2 
injections, or enoxaparin 1 mg / kg every 12 hours or 1.5 mg/kg every 24 hours, or 
nadroparin 171 / u/kg subcutaneously in 1 or 2 injections). Low-molecular-weight 
heparin is the anticoagulant of choice, since it does not pass through the placenta. 
It does not cause osteoporosis and thrombocytopenia in the mother, which may 
develop due to prolonged (≥6 months) use of unfractionated heparin. Cancellation 
of low-molecular-weight heparins is performed 2-3 days before cesarean section, 
and in the postpartum period is resumed, then switch to taking indirect 
anticoagulants. Warfarin is not prescribed because it penetrates the placenta and 
can cause fetal abnormalities or death. 
In APS, warfarin, a vitamin K antagonist, is used to maintain hypocoagulation and 
prevent the development of thrombosis. 
Each patient's dose of warfarin is selected individually depending on the level of 
international normalized ratio (INR). The scheme for selecting the dose of warfarin 
depending on the level of INR is presented in table 20. 
 





Adjusting the warfarin dose 
1-2 days Inside, 1 time a day 5 mg 
Day 3 
 
МНО<1,5 Increase the daily dose by 1/2 tablet.  
Then determine the INR after 1-2 days. 
МНО=1,5-
2,0 
Increase the daily dose by 1/4 tablet.  
Then determine the INR after 1-2 days. 
МНО=2,0-
3,0 
Leave the daily dose unchanged.  
Determine the INR in 1-2 days. 
МНО=3,0-
4,0 
To reduce the daily dose by a quarter pill.  
Then determine the INR after 1-2 days. 
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МНО>4,0 Skip one appointment. Then reduce the dose by ¼ 
tablet. Determine the INR in 1-2 days. 
4-5 days In the morning, determine the level of INR. The actions correspond 
to the scheme of the 3rd day. If you need more than 5 days to select 
a dose, the multiplicity of determining the INR dose is 1 every 2-3 
days using the 3-day scheme. 
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6. SYSTEMIC SCLEROSIS/SYSTEMIC SCLERODERMA 
 
Systemic sclerosis/Systemic scleroderma – progressive systemic sclerosis, 
characterized by connective tissue fibrosis with lesions of the skin, blood vessels, 
musculoskeletal system and internal organs (lungs, heart, digestive organs, 
kidneys). 
 
ICD code 10 
• M 34-Systemic sclerosis 
• M34. 0-Progressive systemic sclerosis 
• M34. 1-CREST Syndrome 
• M34. 2-Systemic sclerosis caused by drugs and chemical compounds 
• M34. 8-Other forms of systemic sclerosis  
 
Classification of systemic scleroderma 
There are clinical forms of SS/SSD (table 21). 
 
Etiology and pathogenesis 
- The disease occurs mainly in women (M:F=1:4). 
- There is a genetic predisposition: HLA-antigens of type B35 and Cw4. 
- Inductors and triggers of systemic sclerosis: 
• unknown RNA-containing virus, parvovirus B19; 
• long-term professional contact with benzene, polyvinyl chloride, silicon dust, 
epoxy resins, toxic oils, paraffin;  
• working under intense vibration conditions; 
• drugs: tryptophan, bleomycin, cocaine. 
In systemic scleroderma, activation of CD4+T cells that infiltrate mainly the 
connective tissue zone and the area around the vessels leads to the secretion of 
proinflammatory (IL-1, IL-6, IL-8, etc.) and fibrosis-inducing cytokines (IL-17, 
IL-4, IL-6). Endothelial cells and fibroblasts produce cytokines and type I and III 
collagen. Growth factors – platelet growth factor, TFR-β, released from platelets 
and lymphocytes, and tryptase, histamine, and eosinophilic cationic protein of mast 
cells are involved in the process of fibrogenation. Muscle fiber degeneration, 
perivascular lymphoplasmocytic infiltration, and interstitial fibrosis develop. 
 
Table 21-Clinical forms of systemic scleroderma (Guseva N. G., 2008), [2] 
Clinical form Characteristic feature 
Prescleroderma Raynaud's syndrome, capillaroscopic changes, ANA 
(antibodies to topoisomerase 1-Scl-70, anticentromeric, 
antinucleolar) 
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The diffuse form • Development of skin changes within 1 year after 
the appearance of Raynaud's syndrome 
•  Involvement of the skin of the distal and proximal 
(above the elbow and knee joints) parts of the 
limbs and trunk 
• The presence of a symptom of the friction of the 
tendons 
• Early development intestinalnogo lung disease, 
oligonicella renal lesions, diffuse lesions of the 
gastrointestinal tract and the involvement of the 
myocardium 
• Antibodies to topoisomerase 1 
A limited form • Raynaud's symptom precedes other symptoms of 
the disease for many years 
• Skin involvement is limited to the distal parts of the 
extremities (distal to the elbow and knee joints) and 
the face 
• Late development of pulmonary hypertension with 
or without interstitial lung disease, calcifications, 
gastrointestinal tract damage 
• Expansion of the capillaries of the nail bed, usually 
without reduction 




• Raynaud's Syndrome + 
• No skin tightening 
• Onset of the disease with pulmonary fibrosis, 
scleroderma renal crisis, heart damage and 
gastrointestinal tract 




Combination of clinical signs of scleroderma and one or 
more ARD 
Juvenile form • Onset of illness before age 16 
• The skin lesion is often the type of focal or linear 
(hemiform) scleroderma 
• Tendency to form contractures, possible 
abnormalities of limb development 
• Moderate visceral pathology according to 
instrumental methods 
Induced SSD Common, often diffuse skin lesions (induration), 
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sometimes in combination with vascular pathology, 
developed after exposure to chemical and other 
environmental factors 
 
There is a thickening of the intima walls, mainly vessels of the microcirculatory 
bed, which leads to vasculopathy: occlusion of the vascular lumen, adventitia 
fibrosis, thrombosis. Fibrous and vascular changes occur in the skin, 
gastrointestinal tract, lungs, heart, kidneys, nervous and endocrine systems, and the 
musculoskeletal system. This leads to thickening of the skin, violation of the 
functions of internal organs and heart attacks associated with vascular obliteration. 
At the onset of the disease, Raynaud's syndrome develops – a violation of the 
microcirculation of the distal parts of the limbs, accompanied by painful swelling 
of the fingers, often ulceration of the fingertips. 
Characterized by Hyper-production of antinuclear autoantibodies. 
 
Clinical picture of systemic scleroderma 
The localization of lesions and symptoms of systemic scleroderma are presented in 
table 22. 
 
Table 22-Clinical symptoms of systemic scleroderma 
Localization of lesions Symptoms 
Skin and vascular 
lesions 
In local skin scleroderma-morphea (ring-shaped, 
teardrop-shaped, linear), unlike SSD, there is no 
vascular spasm and damage to internal organs.  
In SSD-Raynaud's syndrome in 95% of patients, dense 
skin edema, induration, atrophy, hyperpigmentation, 
depigmentation, digital ulceration, telangiectasia 
Defeat of the 
musculoskeletal system 
Polyarthritis with contractures, polymyositis, 
calcinosis, osteolysis of the nail phalanges 
Defeat of the 
gastrointestinal tract 
In terms of the frequency of visceral lesions, it ranks 
first. Reduced motility of the esophagus, small 
intestine, colon, esophagitis, stomach ulcers, 
duodenitis, malabsorption syndrome, colitis 
Lesion of lungs Second place by frequency after lesions of the 
gastrointestinal tract. Fibrosing alveolitis, and diffuse 
bilateral basal pulmonary fibrosis, adhesive pleurisy, 
pulmonary hypertension 
Heart failure Interstitial myocarditis, cardiosclerosis with rhythm 
and conduction disorders, endocarditis with the 
 71 
formation of a heart defect, pericarditis 
Kidney damage Acute nephropathy (sclerodermic renal crisis), chronic 
nephropathy 
Damage to the nervous 
system 
Neuritis of the trigeminal nerve, carpal tunnel 
syndrome, polyneuritis 
Defeat of the endocrine 
system 
Hypothyroidism 
Other defeats Sjogren's syndrome, primary biliary cirrhosis, fibrosis 
of the cavernous arteries 
 
The limited form of scleroderma includes CREST syndrome (Calcinosos, 
Raynaud's syndrome, Esophagitis, Sclerodactyly, Teleangiectasia) - calcinosis, 
Raynaud's syndrome, decreased esophageal motility, sclerodactyly, telangiectasia. 
Anti-centromeric antibodies are detected in 70% of patients with CREST 
syndrome. Patients with CREST syndrome often have primary biliary cirrhosis. 
Variants of the course: acute (rapidly progressive), subacute (moderately 
progressive), chronic (slowly progressive). 
 
Stages of SSD: initial (the number of localizations of lesions of organs and systems 
from 1 to 3), generalized (polysyndromic nature of the process), terminal (failure 
of one or more organs). 
 
Evaluation of SSDS activity in accordance with the recommendations of the 
European group for the study of SSDS is carried out in points. An alternative 
option is to evaluate the degree of SSD activity according to Guseva N. G. (2004), 
taking into account the localization of clinical manifestations, the severity of the 
course and laboratory markers of inflammation (table 23). At the first initial stage 
of SS, treatment is most effective, at the second (generalization stage) it is reduced, 
and at the third (terminal) symptomatic and supportive therapy is performed. 
 
Table 23-Degree of activity of systemic scleroderma (Guseva N. G., 2004), [3] 
Degree of activity Characteristic 
Minimum (I) •  Prevalence of functional vasospastic (Raynaud's 
syndrome), dystrophic, and sclerotic changes of various 
localization in the disease picture 
•  Usually a chronic course of the disease 
•  ESR<20 mm / h, level of γ-globulins up to 25% 
Moderate (II) •  Prevalence of proliferative changes (skin induration, 
indurative-proliferative polyarthritis, adhesive pleurisy, 
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interstitial myocarditis, cardiosclerosis, esophagitis, 
duodenitis, etc.) 
• For acute, sub-acute or exacerbation of chronic 
• ESR - 20-35 mm / h, the level of γ-globulins up to 25-
30% 
Maximum (III) • Fever, predominance of exudative phenomena (dense 
edema of the skin, capillaries, exudative polyarthritis, 
pneumonitis, myocarditis, duodenitis, acute 
sclerodermic nephropathy, etc.) 
• Usually acute current 
• ESR>35 mm / h, PSA>4 g / l fibrinogen >50 g / l, 
CIC>30 units, gamma globulin level >30% 
 
Diagnostics of SSD 
American rheumatological Association's clinical criteria for recognizing 
systemic scleroderma (1980) 
 
• "Large" criteria: 
-Proximal scleroderma – bilateral, symmetrical thickening, compaction, induration, 
sclerosis of the dermis of the fingers, skin of the extremities proximally from the 
metacarpal and metatarsophalangeal joints, involvement of the skin of the face, 
neck, chest, and abdomen. 
• "Small" criteria: 
- Sclerodactyly-induration, sclerosis, osteolysis of the terminal phalanges, 
deformity of the fingers of the hands. 
- scars, tissue defects on the fingertips of the hands. 
- basal pulmonary fibrosis on both sides. 
For the diagnosis of systemic scleroderma, either one "large "or 2 "small" criteria 
must be present. 
 
Laboratory and instrumental studies  
• General analysis of blood, urine, biochemical analysis of blood, creatinine 
clearance (Rehberg test, glomerular filtration rate). 
• Biopsy of the skin and muscle flap: obliterating vasculitis of small vessels, fibrotic 
sclerotic changes.  
• Puncture biopsy of the thyroid gland: identification of morphological signs of 
autoimmune thyroiditis, vasculitis of small vessels, fibrous atrophy of the organ.  
• Research of thyroid hormones. 
• X-ray examination (for the early diagnosis of interstitial lesions of the lung - 
computed tomography high resolution): 
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- calcinates in the tissues of the end phalanges of the fingers, elbows, and knees;  
- osteolysis of the distal phalanges of the fingers; 
- osteoporosis, narrowing of the joint gap, sometimes ankylosis of the affected 
joints.  
- chest - interpleural adhesions; basal, diffuse, often cystic (cellular lung) 
pneumofibrosis.  
- chest x-Ray with esophageal contrast (act of swallowing). 
• Fibrogastroduodenoscopy (FGDs). 
• Study of external respiratory function (ERF). 
• ECG, echocardiography. 
• Capillaroscopy. 
• Tests for malabsorption diagnosis: determination of fecal fat, xylose absorption, 
Shilling test to assess the absorption of vitamin B12, secretin test, serum carotenes, 
vitamin A, prothrombin time, radiography and biopsy of the small intestine, etc. 
 
Immunodiagnosis of SSD 
 
• Screening test for the presence of ANF positive. For differential diagnostics 
with other ARD, RF, dsDNA antibodies, antimitochondrial antibodies, and 
cryoglobulins are determined. 
• In SS, the presence of sclerodermic antibodies is determined, which include 
anti-centromeric antibodies (CENP-A, CENP-B, etc.), antibodies to Scl-70, and 
anti-nucleolar antibodies. 
• ACA (antibodies to the CENP-B protein) are detected in a limited form of 
scleroderma-CREST syndrome in 50% of patients, in systemic sclerosis-in 5-20%, 
in idiopathic Raynaud's syndrome in combination with arthralgias - in 20% of 
cases, in isolated Raynaud's syndrome - in 10%. ACA in Raynaud's syndrome is a 
precursor to scleroderma in a few years. In healthy individuals, they are not 
detected even in low titles. ACAS do not reflect the activity of the disease, it is 
recommended to determine them once. 
• Antibodies to Scl-70 (topoisomerase I-the main non-histone chromosomal 
protein) are a serological marker of SS with proximal scleroderma and diffuse 
lesions of the skin and internal organs. They are present in 70% of patients with 
SS, 30% of patients with CREST syndrome, and 10% of patients with localized 
forms of scleroderma. A single detection of Scl-70 antibodies is recommended. 
• Antinucleolar antibodies - antibodies to PM-Scl, to U3-RNP (fibrillarin), to 
Th/To, to the family of RNA polymerases I, II, III. They have high specificity (94-
98%), but low sensitivity (12-50%). 
- Antibodies to PM-Scl100 and to PM-Scl75 are often detected (50%) in cross-
syndrome (CC+PM), and may occur in idiopathic polymyositis. PM in 
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combination with SS is characterized by myalgia, skin lesions (periorbital edema, 
Gottron papules), Raynaud's syndrome, sclerodactyly, interstitial pneumonitis. 
- Antibodies to fibrillarin (U3-RNP) are found in 5-15% of patients with SS, 
indicating the involvement of internal organs, the progressive course of the disease. 
- Antibodies to RNA polymerases I, II, and III occur in isolation without antibodies 
to centromeres and to Scl-70 in 20% of patients with SS, CREST syndrome, and 
cross syndrome. Indicate a high risk of involvement of internal organs. 
- Antibodies to the Th/To antigen are found in 5% of cases in SS. They are detected 
in limited skin forms of scleroderma, there is a relationship with lung damage. 
• Antibodies to the Ku / Ka antigen are rarely detected in SS (<5%). They are 
a marker of a combination of scleroderma and polymyositis. There are SLE in 10-
40% of patients, primary pulmonary hypertension in 20%, diffuse toxic goiter 
(graves ' disease) - in 30%, less often in Sjogren's syndrome, PM, RA. 
 
SSD monitoring 
• General blood, urine, biochemical blood analysis, creatinine clearance. 
• Computed tomography of the lungs. 
• External respiration functions. 
• Echocardiography. 
• Research of thyroid hormones. 
• Tests for the diagnosis of malabsorption. 
 
Diagnosis Examples 
1. Systemic scleroderma, diffuse form, acute course, grade III activity, stage III, 
with skin lesions (swelling and induration of the skin of the trunk, shoulder girdle, 
sclerodactyly), joints (polyarthritis, functional insufficiency II), blood vessels 
(Raynaud's syndrome, telangiectasia), lungs (interstitial pneumonia, II), 
gastrointestinal tract (esophagitis, duodenitis), nervous system (polyneuropathy). 
2. Systemic scleroderma, diffuse form, subacute course, grade II activity, stage II, 
with skin lesions (sclerodactyly, "pouch" mouth), blood vessels (Raynaud's 
syndrome), lungs (diffuse pneumosclerosis, respiratory failure I), gastrointestinal 
tract (esophagitis, stomach ulcers), Sjogren's syndrome. 
3. Systemic scleroderma, limited form, chronic course, activity of the first degree, 
stage I, with skin lesions (edema and induration of the hands), blood vessels 
(Raynaud's syndrome). 
 
The treatment of SSD 
• Anti-fibrosis therapy. D-penicillamine (penicillamine, cuprenil) - 500-1000 
mg/day for 6-12 months, then gradually reduce to 250-500 mg/day, take for 
a long time (2-5 years); lidase, ronidase, dimexid, colchicine, unitiol.  
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• GCS. Prednisone 15-20 mg/day in acute, subacute course, exacerbation of 
the chronic course of SSD. When the clinical effect is achieved, the dose of 
GCS is reduced to the maintenance dose (5-10 mg/day). The course of 
treatment is long in acute and subacute course, in chronic form-short (1-2 
months). In the presence of fibrosis of various organs, GCS is combined 
with D-penicillamine and cyclophosphamide. 
• Immunosuppressants. Methotrexate 15 mg / week, or cyclosporine 2-3 mg / 
kg / day; or cyclophosphamide in the pulse therapy scheme, or 
aminoquinoline drugs (chloroquine, plakvenil). 
• Immunoglobulins for intravenous administration in the active course, the 
addition of severe infections in a dose of 0.4-2G/kg / day for 2-5 days daily, 
then monthly. 
• NSAIDs are prescribed to relief the joint syndrome, muscle pain: selective 
COX-2 inhibitors (meloxicam, nimesulid); in the absence of gastrointestinal 
pathology-non-selective Cox-1 and COX-2 inhibitors. 
• Vasodilator therapy: 
- calcium antagonists (dihydropyridine-nifedipine group; nifedipine 30-60 mg/day, 
or amlodipine 5-10 mg/day inside), with poor tolerance-benzodiazepine group);  
- angiotensin converting enzyme inhibitors (captopril, enalapril, ramipril, 
perindopril, spirapril, lisinopril); 
- prostaglandin E1 (alprostadil);  
- the prostacyclin (iloprost, beraprost, epoprostenol); 
- endothelina receptor antagonists (bosentan, sitaxentan); 
- phosphodiesterase type 5 inhibitors (sildenafil);  
- antiplatelet agents (acetylsalicylic acid, dipyridamole); 
- angioprotectors (emoxipin). 
• Antioxidant therapy (Actovegin, N-acetylcysteine). 
• Extracorporeal treatment methods. 
• Physiotherapy (electro -, heat -, balneo -, ultrasound -, laser therapy courses 
number 7-10 sessions), massage. 
 
Differential treatment of lesions in SSD 
 
• Raynaud's syndrome-prostaglandins, calcium antagonists, prostacyclines, if 
ineffective – finger sympathectomy. 
• Skin lesions in diffuse SSD-methotrexate.  
• Interstitial lung disease – penicillamine, cyclophosphamide, corticosteroids. 
• Pulmonary arterial hypertension-prostacyclines (iloprost, beroprost, 
epoprostenol), endothelin I receptor antagonists (bosentan, syntaxentan), 
type V phosphodiesterase inhibitor (sildenafil), anticoagulants.  
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• Renal crisis – ACE inhibitors, slow calcium channel blockers, prostacyclin, 
an antagonist of transforming growth factor beta (pirfenidone); hemodialysis 
in the progression of renal failure. 
• Gastrointestinal disorders-procinetics, proton pump inhibitors, rotating 
antibiotics, pancreatic enzymes, nutritional support, surgical treatment for 
esophageal strictures, fecal incontinence. 
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7. DERMATOMYOSITIS, POLYMYOSITIS 
 
 
Dermatomyositis or polymyositis (DM/PM) belongs to a group of autoimmune 
inflammatory myopathies, the main manifestation of which is progressive muscle 
weakness of the proximal extremities associated with inflammation of the striated 
muscles, skin, small vessels, and replacement of affected tissues with fibrous 
structures. 
 
Classification of inflammatory myopathies [16] 
• Primary idiopathic polymyositis 
• Primary idiopathic dermatomyositis (polymyositis with skin lesions) 
• Juvenile polymyositis/dermatomyositis. 
• Myositis, combined with MCTD (cross syndrome, frequency is 20%) 
• Myositis, combined with malignant tumors (20-30%) 
• Myositis with intracellular inclusions (15-28%) 
• Rare forms of inflammatory myopathies (granulomatous, eosinophilic, 
myositis in vasculitis, focal (nodular), orbital) 
DM/PM is most common among myopathies. 
 
ICD code 10: M33-Dermatopolymiositis; M33. 2-Polymyositis. 
 
Epidemiology, pathogenesis 
The peak incidence is 45-60 years. Women get sick 2 times more often in myositis, 
combined with cancer, and 5 times more often in childbearing age. 
• Infiltration of the muscle with CD4-lymphocytes, B-lymphocytes, 
macrophages, activation of complement and, as a result, vascular damage 
(vasculopathy) of the muscles in DM. tissue Ischemia leads to necrosis of 
perivascular muscle fibers.  
• Due to a genetic predisposition or as a result of exposure to an unknown 
factor, HLA class I antigens are expressed on the surface of muscle fibers. 
The result of this abnormal expression is infiltration of the muscle by 
cytotoxic CD8 lymphocytes, their secretion of perforins, and necrosis of the 
muscle fiber in PM. 
• In the later stages of DM / PM, muscle fibrillation, fibrosis, and adipose 






The clinical picture of PM/DM is shown in table 24. 
 
Table 24 - Clinical symptoms of PM/DM 
Symptoms  Signs 
Common Weakness, weight loss, fever (40%), Raynaud's syndrome 
Myositis Muscle weakness of the proximal muscles of the lower 
extremities (thighs), pelvic girdle, neck muscles, shoulders, 
trunk; shortness of breath - with weakness of the intercostal 
muscles and the diaphragm 
Myalgia (50%), muscle pain on palpation 
Muscle atrophy, contractures 
Skin lesion Heliotropic rash (30-60% of cases) - purple staining of the 
skin of the periorbital zone, often with edema 
Macular spots (Gottron sign) or erythematous papules or 
plaques on the skin of the extensor surface of the hands, elbow 
and knee joints (gottron papules) - 80% 
V-syndrome-macular rashes at the base of the neck and a 
"shawl" symptom on the back of the neck and shoulders 
Rarely in juvenile DM, skin vasculitis, ulceration 
Peeling and cracking of the skin of fingers and palms 
("mechanic's hand») 
Injuries of the 
musculoskeletal 
system 
Arthropathy (remember RA), strain, calcification of 
subcutaneous or connective tissue in the areas of 
microtraumatic 
Lesion of lungs Interstitial fibrosis (20%), aspiration pneumonia, respiratory 
failure, rarely-pulmonary vasculitis, pulmonary hypertension, 
hypersensitive pneumonitis, opportunistic infections 
Heart lesions Cardiomyopathy (5%), pericarditis (20%), blockages and 
arrhythmias 
Lesions of the 
gastrointestinal 
tract 
Dysphagia (30%), dysfunction of striated muscle tissue, 
cricopharyngeal dysfunction, lower esophageal dysfunction, 
impaired motility of the stomach and intestines 
Kidney damage Proteinuria, nephrotic syndrome, myoglobulinuria (very rare) 
Tumors High risk in men over 45 years of age with DM without 
autoantibodies 
In 15% of patients with DM, in 9% - with PM 
 
Diagnostics and monitoring of DM / PM 
• General analysis of blood and urine. 
• Biochemical blood analysis: bilirubin, AST, ALT, creatine phosphokinase (CPK), 
MB fraction of CPK, glucose, total protein, CRP, creatinine, urea, electrolytes;  
• Serum myoglobin, myoglobin in the urine.  
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• External respiration functions 
• Computed tomography – cancer search, diagnosis of interstitial lung diseases.  
• MRI muscles. 
• Electromyography. 
• Muscle biopsy. 
• Additional research methods for the diagnosis of cancer: examination of the 
rectum, prostate-specific antigen in men, fecal examination for hidden blood; 
smear from the cervix, mammography, pelvic ultrasound, CA-125 in women-
ovarian tumor antigen. 
• Immunological diagnostics of inflammatory myopathies includes determination of 
ANA, myositis-specific antibodies to extracted nuclear antigens-Jo-1, RNP, Mi-2, 
etc.  
- Myositis-specific antibodies-a group of autoantibodies (to tRNA synthetases (Jo-
1, PL-7, PL-12, EJ, OJ), to the Mi-2 protein, to the SRP-signal recognition 
particle) detected in 40% of inflammatory myopathies. 
- Antisynthetase antibodies are found in 20-30% of patients with PM/DM and are 
markers of antisynthetase syndrome, a form of myositis. It is characterized by the 
presence of anti-Jo-1 antibodies directed to histidyl-tRNA synthetase. Clinical 
manifestations of antisynthetase syndrome are interstitial lung disease, arthritis, 
Raynaud's disease, skin manifestations, fever and muscle weakness, and low 
effectiveness of immunosuppressive therapy.  
- Antibodies to the Mi-2 protein are found in DM in 10% of patients, characterized 
by a favorable course of the disease. 
- Antibodies to the SRP signal-recognizing particle are detected in 3% of cases in 
PM, and have a severe course with damage to the myocardium and respiratory 
muscles. 
- In 20-30% of patients with cross syndrome (PM+SS). Myositis-associated 
antibodies are detected - antibodies to PM-Scl, U1-RNP, SS-A. 
 
• Monitoring of indicators for DM/PM: General blood test, creatinine, 
electrolytes, MRI (muscle). 
 
International criteria for diagnosing DM/PM [17] 
1. Skin lesions: heliotropic rash, a sign of Gottron, erythema on the skin of the 
extensor surface of the elbow and knee joints. 
2. Proximal muscle weakness of the upper and lower extremities. 
3. Myalgia or muscle pain on palpation. 
4. Increased activity of CPK and / or aldolase in blood serum. 
5. Myogenic changes on the electromyogram (short polyphase potentials with 
spontaneous fibrillation potentials).  
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6. Antibodies to histidyl-tRNA synthetase-ajo-1 (detected in 50% of patients, 
other antisynthetic antibodies-in 5%). 
7. Non-destructive arthritis or arthralgia. 
8. Signs of systemic inflammation: body temperature above 370C, increase in 
CRP or ESR more than 20 mm / hour. 
9. Morphological examination of the skin-muscle flap: infiltrates in skeletal 
muscles with degeneration or necrosis of fibers, active phagocytosis or signs of 
active regeneration.  
The presence of at least one type of skin lesion and at least 4 signs from 2 to 9 p. 
correspond to the diagnosis of DM (DH-94.1%, DS-90.3%). 




1. Idiopathic dermatomyositis, acute course, grade 3 activity with muscle damage 
(proximal myositis), skin (paraorbital edema, Gottron syndrome in the 
metacarpophalangeal and proximal interphalangeal joints, neck erythema), heart 
damage (myocarditis with rhythm and conduction disorders by type of atrial 
fibrillation, H2A, 2 functional class by NYHA (classification of chronic heart 
failure of the new York cardiological Association), lesions of the lungs 
(pneumonitis, DN II), the nervous system (polyneuropathy), joints (polyarthritis, 
functional class II). 
2. Idiopathic dermatomyositis, chronic course, activity of 1 degree with damage to 
the joints (polyarthralgia, functional class I), lungs (fibrotic alveolitis, respiratory 
failure II). 
3. Paraneoplastic polymyositis against the background of bladder cancer, subacute 
course, activity of the 1st degree with damage to the muscles of the upper and 
lower extremities, pharyngeal muscles, diaphragm, and skin (Gottron syndrome in 
the metacarpophalangeal joints). 
 
Treatment of PM/DM 
• First – line GCS: prednisone at a dose of 1 mg/kg/day, if there is no effect for 4 
weeks-2 mg/kg/day; treatment for 2-3 months or more until clinical effect is 
achieved. Reduce by ¼ tablet in 30 days. 
• Immunosuppressants in combination with GCS: methotrexate 7.5-15 mg/week or 
cyclosporine 2.5-3.5 mg/kg/day, or azathioprine 2-3 mg/kg/day, or mycophenolate 
mofetil 1g /day. 
• Combined pulse therapy for progressive lung damage: GCS 1g/day 
+cyclophosphamide 2 mg/kg/day. 
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• Aminoquinoline compounds: plakvenil 200-400 mg/day (for skin manifestations of 
DM).  
• Immunoglobulin for intravenous administration (for refractory course).  
• Rituximab, infliximab (effectiveness is being studied).  
• Plasmapheresis (4-5 procedures for severe, refractory to therapy). 
• NSAIDs (for muscle and joint pain). 
• Improvement of muscle metabolism (retabolil, Riboxin, ATP). 
• Treatment of calcification (disodium salt of ethylenediaminetetraacetic acid, 
colchicine). 
• Physical therapy, massage, physiotherapy. 
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8. MIXED CONNECTIVE TISSUE DISEASE 
 
Mixed connective tissue disease (MCTD), or Sharpe's syndrome is characterized 
by the presence of symptoms of various autoimmune diseases - SLE, scleroderma, 
PM/DM, RA, Sjogren's syndrome. It has a more favorable course and forecast in 
comparison with other ARD. To date, there is no clear answer as to whether the 
SPST is an independent nosological form or a variant of a single disease in a group 
of autoimmune systemic connective tissue diseases. 
 
Code according to ICD-10:  
M. 35 Other systemic connective tissue lesions.  
M 35.1 Other cross syndromes. Mixed connective tissue disease. 
 
Etiology and pathogenesis. Mostly women get sick, the peak of the incidence is 
observed in 20-30 years. The role of infectious antigens and genetic predisposition 
is assumed in the occurrence of MCTD. 
Immune inflammation develops in blood vessels and tissues, mediated by the 
formation of anti-nuclear antibodies, mainly to the nuclear antigen-
ribonucleoprotein U1-RNP, as well as hypergammaglobulinemia, 
hypocomplementemia, and an increased content of circulating immune complexes.  
 
Clinical symptoms 
• More often reminds SLE, SSD, PM. 
• Skin lesions: scleroderma-like changes-mild swelling of the hands-in 88%, rare 
therapeutic induration, skin atrophy and flexor contractures; telangiectasia, 
erythematous and Hypo - or hyperpigmented spots, discoid lupus, alopecia, 
periorbital pigmentation. 
• Arthritis (erosive in 30%) and arthralgia in 96%. 
• Raynaud's syndrome-in 84%, is an early symptom, but less pronounced than in 
MCTD. 
• Myositis (myalgia, muscle weakness mainly in the proximal extremities, increased 
CPK, aldolase, AST) - in 72%  
• Enlarged lymph nodes - in 68%. 
• Fever, serositis (effusion pericarditis, pleurisy), hepatosplenomegaly-in 20-33%.  
• In 75% of cases, lung damage develops (diffuse fibrosis with impaired restrictive 
function and pulmonary hypertension), or esophageal hypokinesia. 
• Secondary Sjogren syndrome - in 50%. 
• Kidney damage (glomerulonephritis) is rare-in 10%. 





• Presence of characteristic clinical symptoms of SS, SLE, and PM that appear 
simultaneously or sequentially. 
• High antibody titer to the soluble nuclear antigen - ribonucleoprotein U1-RNP 
(more than 1:100,000) is detected in 100% of cases, high titer of ANA (more than 
1:1000) of speckled glow type. Anti-nuclear antibodies to other soluble nuclear 
antigens (anti-dsDNA, Scl-70, Ro, La) are negative, and RF antibodies to 
nucleosomes can be detected.  
• There is an increase in ESR and CRP, hypergammaglobulinemia, 
hypocomplementemia, and an increased content of circulating immune complexes.  
• The presence of signs of myositis, kidney and lung damage requires CT, MRI, 
electromyography, and muscle biopsy. 
 
Diagnostic criteria for MCTD [27] 
• Serological criteria: high (>1:2000) antibody titers to the nuclear 
ribonucleoprotein-U1-RNP antigen (DH: 95-100%, DS: 98%). 
• Clinical criteria:  
  2A-Raynaud's syndrome;  
  2B-synovitis;  
  2C-myositis; 
  2D - swelling of the fingers. 
To make a diagnosis of MCTD, you must have a serological criterion, criteria 2A 
and 2-3 criteria from 2b to 2d (DS-62.5%; DS-86.2%). 
 
Diagnosis examples 
1. Mixed connective tissue disease: Raynaud's syndrome, swelling of the skin of 
the hands, esophagitis, myopathy, exudative pleurisy, pericarditis. 




• In the mild form of the disease - NSAIDs and aminoquinoline drugs, in some 
cases - low doses of GCS (prednisone at a dose of 5-15 mg per day). 
• In a moderately severe and severe form of MCTD, prednisone is prescribed at a 
dose of 1 mg/kg / day orally, then the dose is gradually reduced to a maintenance 
dose (5-10 mg/day). 
• The use of immunosuppressants (cyclophosamide, azathioprine, methotrexate) or 
the appointment of combination therapy with corticosteroids and 
immunosuppressants is possible. 
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• If signs of myositis or systemic scleroderma appear, they should be treated 
accordingly. 
The ten-year survival rate is 80%. The main causes of death are pulmonary 
hypertension, renal failure, myocardial infarction. 
 
Cross-forms of systemic connective tissue diseases 
The term “cross-sectional forms of MCTD - cross syndrome” is used when a 
patient has two or more systemic connective tissue diseases. The most common 
are: SS and DM / PM, SS and RA, SLE and RA, SLE and PM, RA and PM, RA 
and systemic vasculitis. 
Diagnosis is based on the identification of clinical, laboratory, immunological and 
other diagnostic criteria for both diseases. Treatment is determined by the 
predominance of the symptoms of one of the diseases, the activity and prognosis of 
its course. 
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9. Sjögren’s syndrome 
 
Sjögren’s syndrome is an autoimmune systemic inflammatory disease of unknown 
etiology, in which exocrine glands are affected and other organs are involved. 
Distinguish between primary and secondary secondary school. 
Primary secondary or Sjogren’s disease is an independent noslogic form. 
Sjogren's syndrome (secondary Sjogren's syndrome in foreign literature) develops 
in about 30% of cases with ARD (RA, SLE, SSD, PM / DM, MCTD), as well as 
with Hashimoto's thyroiditis, primary biliary cirrhosis, chronic autoimmune 
hepatitis. 
The incidence of secondary infections ranges from 4 to 250 cases per 100,000 
population, most often between the ages of 35-50. The ratio of women to men with 
secondary school is 8-10 / 1. 
 
ICD-10 code: M 35.0 - dry syndrome (Sjogren) 
 
Etiology, pathogenesis 
The relationship of the disease with HLA antigens DR3, DQ1, DQ2, B8 and others 
was revealed. Viral infections (herpes viruses, retroviruses, cytomegaloviuses), 
dysregulation of the immune response, and imbalance of sex hormones 
(androgens/estrogens) are important in Sjögren’s syndrome development. There is 
lymphocytic infiltration of exocrine glands - lacrimal, salivary and others, the 
result of which is their inflammation and destruction. T-lymphocytes, infiltrating 
glandular tissue, produce pro-inflammatory cytokines (IL-1, IL-2, IL-6, IFN-γ, 
etc.), activate B-cells. In turn, polyclonal B-cell activation is accompanied by the 
synthesis of autoantibodies against Ro (SS-A) and La (SS-B), RF, antinuclear 
antibodies antigens. The proliferation of cells of the exocrine gland ducts, 
obstruction of their ducts occurs, in the future - atrophy of the glands and a 
pronounced violation of their function. There is dryness of the mucous membranes 
of the eye, oral cavity, gastrointestinal tract, etc., a third of patients develop 
extragranular lesions of internal organs (arthritis, Raynaud's syndrome, 
lymphadenopathy, interstitial pneumonia, etc.). 
 
Clinical symptoms of SS associated with glandular lesions 
• Due to a decrease in production of tears and mucins, changes in the quality of the 
tear fluid (the content of lysozyme, lactoferrin, secretory IgA, etc. decreases), dry 
keratoconjunctivitis develops. The patient is concerned about dry eyes - 
xerophthalmia (dry eye syndrome), sensations of "sand" in the eyes, photophobia, 
pain and burning in the eye area, the appearance of discharge in the form of long 
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mucous filaments. With the development of keratitis, vision deteriorates, ulcers 
and perforation of the cornea develop. 
• Damage to the salivary glands - chronic sialadenitis, accompanied by a decrease in 
salivation (xerostomia), impaired chewing, swallowing, formation of calculi of the 
salivary ducts, and decrease in the perception of smell and taste. The parotid 
salivary glands, sublingual, small salivary, submandibular glands are affected. A 
characteristic sign of the disease is recurrent mumps. Approximately 30% of 
patients have an increase and slight pain on palpation of the parotid/submandibular 
salivary glands, which have a dense texture and a smooth contour. Violation of the 
qualitative composition of saliva leads to a decrease in local anti-infection 
protection of the mucous membranes of the oral cavity and lips, the development 
of recurrent aphthous/fungal stomatitis, multiple caries, cheilitis. 
• Dry skin and mucous membranes of another location might be developed - the 
nose, larynx, pharynx (dry subatrophic/atrophic rhinopharyngolaryngitis), bronchi, 
vulva and vagina, the occurrence of chronic arthrophic gastritis with secretory 
insufficiency, chronic pancreatitis. 
• In Sjögren’s disease, three main symptoms are detected: parenchymal sialadenitis 
with xerostomia, dry keratoconjunctivitis, and morphological changes in the small 
salivary glands. 
• In Sjögren’s syndrome, one, two, or three symptoms may be present at the same 
time (sialodenitis, dry keratoconjunctivitis, arthritis/arthralgia, lymphocytic 
infiltration of exocrine glands). 
 
Clinical out-of-body (systemic) manifestations of Sjogren's Syndrome 
• Weakness, fatigue, fever, often associated with exacerbations of mumps. 
• Arthralgia occurs in approximately 70% of patients, and in 33% of patients - 
arthritis with localization, as in RA, but without erosion. 
• Raynaud's syndrome is often detected. 
• Generalized lymphadenopathy. 
• Interstitial pneumonia, alveolar pulmonary fibrosis. 
• Biliary damage to the liver, pancreas. 
• A third of patients have vasculitis (lymphocytic, leukocytoclastic) with damage to 
the skin and mucous membranes, peripheral nerves, central nervous system, and 
kidneys. 
• Kidney damage - interstitial nephritis, tubular acidosis, the formation of calculi in 
the kidneys. 
• Perhaps the development of pseudolymph (accumulation of lymphoid cells 
without histological signs of malignancy), malignant lymphomas, Waldenstrom 
macroglobulinemia. The likelihood of developing non-Hodgkin lymphomas in SS 
is 40 times higher than in healthy people. 
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Diagnosis of Sjogren's syndrome [13] 
Tests that determine the level of secretion of the lacrimal glands. The function of 
the lacrimal glands can be assessed by the Schirmer test: the degree of wetting of a 
strip of filter paper placed on the lower eyelid is determined in 5 minutes. 
Normally, the wetting is 15 mm, while the SS is less than 10 mm. 
A more highly specific test is eye staining when instilling a 0.1% solution of 
fluorescein or lissamine green. Determine the time of rupture of the fluorescent 
film by the appearance of a "dry spot" after the last blink. Normally, it is 10 
seconds, while the time indicator is significantly reduced. 
Ophthalmoscopy at different stages of SS reveals dystrophy of the conjunctival 
and corneal epithelium of the I-III degree, filamentous keratitis, corneal xerosis, 
and corneal ulcer. 
Tests that determine the level of salivary gland secretion. Sialometry is used to 
objectify the degree of xerostomia. When the salivary glands are affected, the 
unstimulated saliva flow is less than ≤1.5 ml for 15 minutes, the stimulated (lemon 
juice, 5% ascorbic acid, 40% ethyl alcohol) saliva secretion is also reduced - <2.5 
ml/5 min. 
Sialography - examination of the salivary gland ducts with x-ray contrast material 
allows detecting the expansion of the ductal system. Cavities >1 mm in diameter 
are found, which is typical for parenchymal mumps. 
Salivary gland scintigraphy reflects the rate of saliva release by determining the 
capture and secretion of the radioactive technetium nuclide (Tc99) within 60 
minutes after its intravenous administration. 
Ultrasound and MRI of the salivary glands allow us to assess the structure, size of 
the glands, localization and degree of gland damage. 
 
Presence of autoantibodies  
Antibodies to the Ro nuclear antigen (SS-A) or to La (SS-B) are detected in 85-
100% of patients with SS: simultaneously, both antigens are detected in 40-50% of 
cases, to one Ro antigen (SS-A) - much more often than to La (SS-B). 
Antibodies to the Ro antigen (SS-A) have limited sensitivity and specificity, they 
are found in other ARD, whereas to the La antigen (SS-B) they are more specific 
for SS. 
The antibody titer to the soluble nuclear antigens Ro (SS-A) and La (SS-B) does 
not reflect the activity of the pathological process. 
ANA and RF are determined in 95-100% of patients. High RF numbers are typical 
for patients with cryoglobulinemic vasculitis and morphological signs of MALT-
tissue formation (mucosa-associated lymphoid tissue) in the salivary/lacrimal 
glands and lungs. MALT lymphomas are the most common form of non-Hodgkin's 
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lymphoma in Sjogren's disease. Cryoglobulins are detected in a third of patients 
with SS, while there is no link between the disease and hepatitis b and C viruses. 
 
Other laboratory indicators. In 50% of cases, antithyroid antibodies are detected, 
and hypothyroidism often develops. In 70% of cases, there is an increase in ESR, 
total protein, hypergammaglobulinemia (due to an increase in IgG and IgA, less 
often IgM). Monoclonal secretion of immunoglobulins (more often IgM) is 
detected in 20%, while in half of cases non-Hodgkin's lymphomas are diagnosed. 
In 33% of cases, anemia is detected, in 25% - leukopenia. 
 
A biopsy of salivary glands. In complex diagnostic cases, a salivary gland biopsy is 
performed, revealing characteristic histological changes – 
lymphohistioplasmocytic infiltration, multiple large clusters of lymphocytes (often 
follicle-like) with acinus atrophy. 
 
European-American criteria for SS diagnosis [12] 
- Eye symptoms (1 of 3): 
• dry eyes for more than 3 months; 
• feeling of a foreign body in the eyes; 
• using artificial tears more than three times a day. 
- Oral symptoms (1 of 3): 
• dry mouth for more than 3 months; 
• swelling of the salivary glands; 
• the need to wet the mouth. 
- Eye tests (1 of 2): 
• unstimulated Schirmer test <5 mm/5 min; 
• vitally colored spots on the cornea. 
- Positive labial biopsy (number of foci >1 in 4 mm2). 
- Oral tests (1 of 3): 
- unstimulated salivary secretion <0.1 ml / min; 
- deviation from the norm on the sialogram of the parotid salivary gland and the 
salivary Scintigram. 
- Positive Ro (SSA) and/or La(SSB) antibodies are detected during immunological 
blood tests. 
 
Classification criteria for Sjogren's syndrome (Sjogren's International 
Collaborative Clinical Alliance [13] 
- Presence of anti-SS-A/Ro and/or anti-SS-B/La anti-nuclear antibodies or positive 
RF and ANF. 
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- Focal lymphocytic infiltration is detected in the biopsy of small salivary glands – 
≥1 focus in 4 mm2 (focus is a cluster of at least 50 lymphoid cells in 4 mm2 of the 
surface of the salivary gland, the average focus is estimated for 4 small salivary 
glands). 
- Dry keratoconjunctivitis - ≥3 points on the scale of color of the eye epithelium 
with fluorescein and lissamine green (exclude the use of anti-glaucoma eye drops 
that inhibit the production of intraocular fluid, corneal surgery and blepharoplasty).  
The disease can be classified as Sjogren's syndrome if two of the three criteria 
points are met, excluding head and neck radiation, hepatitis C, HIV infection, 




1. Sjogren disease, acute period, severe stage, the activity of III degree, with 
the defeat of the salivary glands hypofunction III degree (Cialdini, xerostomia, 
grade II stomatitis, cervical caries with loss of teeth), with damage to the lacrimal 
glands with hyponatremia III degree, the eyes (dry keratoconjunctivitis, corneal 
dystrophy II degree), joints (non-erosive arthritis, functional class II), 
gastrointestinal tract (atrophic gastritis, pancreatic insufficiency), generalized 
lymphadenopathy. 
2. Sjogren's disease, subacute course, grade II activity with lesions of the 
salivary glands (bilateral mumps, paradontosis, cervical caries with tooth loss), 
lacrimal glands (dry keratoconjunctivitis), joints (polyarthritis, functional class II), 
with vascular lesions (Raynaud's syndrome), and the gastrointestinal tract (atrophic 
gastritis). 
3. Sjogren's disease, chronic course, initial stage, activity of I degree, with 
damage to the salivary glands with hypofunction of I degree, (stomatitis), with 
damage to the lacrimal glands with hypolacrimia of I degree, eyes (dry 
keratoconjunctivitis), joints (polyarthralgia, functional class I). 
 
Treatment of Sjogren's syndrome 
 
General recommendation. Avoid factors that lead to dryness of the mucous 
membranes of the eye and mouth (air conditioning, cigarette smoke, strong wind, 
prolonged visual, speech or psycho-emotional load), alcohol consumption, 
Smoking, taking drugs that reduce salivation (antidepressants, antihistamines, 
anticholinergics). 
If the oral mucosa is dry, it is recommended to drink the liquid in small sips and 
chew sugar-free chewing gums. Careful oral hygiene and regular dental 
supervision are necessary. 
 90 
 
Treatment of dry keratoconjunctivitis  
• Artificial tears containing 0.1-0.4% sodium hyaluronate, 0.5-1% 
hydroxypropylmethylcellulose, 0.5-1% carboxymethylcellulose, 0.1-3% dextran 
70, apply 3-4 or more times a day. 
• Eye drops are recommended on the basis of blood serum of cattle (of Adgelon). 
Assign 1-2 drops to the conjunctival SAC 3-6 times a day for 14 days. Drainage of 
the lacrimal ducts is performed. 
• The use of NSAIDs (0.1% indomethacin, 0.1% diclofenac) reduces discomfort in 
the eyes, but may provoke corneal damage. 
• Drugs that increase the amount of mucin-like substances and lacrimal fluid – 2% 
ophthalmic emulsion of rebamipid, 2% solution of dikvafozol-an agonist of purine 
P2Y2 receptors. 
• Cyclosporine-0.05% eye drops 2 times a day for 6-12 months. 
• GCS in low doses in short courses (up to two weeks) with exacerbation of dry 
keratoconjunctivitis. 
In case of dryness of the mucous membrane of the oral cavity is recommended: 
• Use of artificial saliva substitutes based on mucin and carboxymethylcellulose in 
the form of mouthwash. 
• Cholinergic drugs-pilocarpine (inside 5 mg 3-4 times a day) or cevimelin 
hydrochloride 30 mg 3 times a day to stimulate salivation. Contraindicated in 
bronchospasm and angle-closure glaucoma. 
• Warm compresses, analgesics, and NSAIDs are used to relieve pain caused by 
swelling of the salivary gland. 
• When infection develops, local and systemic antifungal treatment (nystatin, 
clotrimazole, fluconazole), and antibacterial therapy are indicated. 
If the upper respiratory tract is dry (rhinitis, sinusitis, laryngitis, bronchitis), 
Bromhexine or acetylcysteine is prescribed. 
If the skin and vagina are dry, lubricants are used. 
 
Treatment of extra-vascular manifestations of SS 
• To reduce arthralgia, NSAIDs, hydroxychloroquine 200-400 mg/day, small doses 
of GCS (prednisone 5 mg/day or every other day) are prescribed. 
• In the absence of severe systemic manifestations of SS, but there are moderate and 
significant changes in laboratory indicators of disease activity, small doses of GCS 
are prescribed in combination with leuceran 2-4 mg/day for 12 months, with the 
transition to a dose of 6-14 mg/week for several years. 
• In vasculitis, when there are no life-threatening systemic manifestations, low doses 
of GCS are prescribed in combination with cyclophosphane 200 mg/week for 3 
months, with a transition to 400 mg/month. 
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• For vasculitis with severe systemic manifestations, GCS therapy (20-60 mg/day) is 
performed in combination with leuceran (6-10 mg/day), or cyclophosphan (0.8-3.0 
g/month) and intensive therapy (pulse therapy of GCS in combination with 
cyclophosphan and extracorporeal methods). 
• Treatment with rituximab is performed in severe systemic manifestations of SS 
and in cases of resistance to therapy. 
• Intravenous immunoglobulin is prescribed for autoimmune thrombocytopenia, 
hemolytic anemia, agranulocytosis, sensory neuropathy resistant to therapy. 
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VASCULITIS ASSOCIATED WITH ANTINEUTROPHILIC CYTOPLASMIC 
ANTIBODIES (ANCA-VASCULITIS) 
 
ANCA-associated vasculitis belongs to the group of systemic vasculitis (SV) - a 
heterogeneous group of diseases that are based on generalized immuno-
inflammatory damage to blood vessels of different calibers with subsequent 
involvement in the pathological process of organs and tissues supplied by the 
corresponding vessels. 
 
Classification of systemic vasculitis 
• Primary (as independent nosological units). 
• Secondary vasculitis or vasculopathy associated with infections, tumors, systemic 
diseases of connective tissue, drugs, deficiency of components of the complement 
system, organ transplantation. 
The current classification of SV takes into account the caliber of affected vessels 
and the mechanisms of their damage (table 25). 
ANCA-associated SV vasculitis includes 3 nosological forms: granulomatous 
polyangiitis (GPA), formerly known as Wegener's granulomatosis; microscopic 
polyangiitis (MP), eosinophilic granulomatosis with polyangiitis (EGPA), formerly 
– Churge-Strauss syndrome. 
GPA occurs in about one in 25,000 people, and can occur at any age, most often at 
40. 
MP is rare (approximately 13-19 cases per million), and the average age of onset is 
50 years.  
The incidence of EGPA is approximately 3 cases per million, and the average age 
for the onset of the disease is 48 years. 
 
Code according to ICD: 
M 30.1-Eosinophilic granulomatosis with polyangiitis 
M 31.1-Granulomatous polyangiitis 
M 31.7-Microscopic polyangiitis 
 
Etiology and pathogenesis of SV 
The association of SV with viruses (HBV infection, HIV infection, Parvovirus 
B19, Epstein-Barr virus), bacteria (streptococci, staphylococci), fungi (aspergillus), 
drugs, malignant diseases, and systemic diseases of connective tissue was revealed. 
The basis of SV pathogenesis is inflammatory infiltration and necrosis of the 
vessel wall, leading to rupture and hemorrhage in the surrounding tissue, the 
formation of blood clots and ischemic tissue damage. Pathological changes are 
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associated with immune mechanisms mediated by autoantibodies, immune 
complexes, T-lymphocytes. 
With ANCA vasculitis, autoantibodies to specific neutrophil cytoplasm antigens 
are formed - proteinase 3 (PR-3) and myeloperoxidase (MPO). Under the influence 
of pro-inflammatory cytokines, neutrophil cytoplasm antigens move to the cell 
membrane, neutrophils are activated and adhere to vascular endothelial cells. The 
subsequent binding of ANCA to neutrophil enzymes leads to their degranulation, 
release of inflammatory mediators and cytokines, lysis of endothelial cells and 
necrotic vasculitis, accompanied by the formation of granulomas. 
With MPA, ANCA can be detected, but there is no granulomatous inflammation in 
contrast to GPA and EGPA. 
 
Table 25-Current classification of systemic vasculitis (Chapel Hill Consensus 
Conference, 2012), [11] 
Vasculitis with large-caliber vascular lesions 
• Takayasu arteritis (non-specific aortoarteritis) 
•  giant cell arteritis (Horton's disease) and rheumatic polymyalgia 
Vasculitis with lesions of medium-sized vessels 
• nodular polyarteritis 
• Kawasaki disease 
Vasculitis with small-caliber vascular lesions 
      Vasculitis associated with antineutrophilic cytoplasmic antibodies 
(ANCA): 
• microscopic polyangiitis  
• granulomatosis with polyangiitis (Wegener) 
• eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 
    Immunocomplex vasculitis: 
• iseases associated with antibodies to GBM (Goodpasture syndrome) 
• cryoglobulinemic vasculitis 
• IgA-associated vasculitis (hemorrhagic vasculitis, Shenlein-Genoch 
purpura) 
• hypocomplete urticarial vasculitis (anti-C1q vasculitis) 
Variable vasculitis 
• Behcet's disease 
• Cogan syndrome 
Vasculitis with vascular lesions of a single organ 
• cutaneous leukocytoclastic angiitis 
• cutaneous arteritis 
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• primary vasculitis of the central nervous system 
• isolated aortitis 
• others 
Vasculitis associated with systemic diseases 
• vasculitis in SLE 
• rheumatoid vasculitis 
• sarcoid vasculitis 
• others 
Vasculitis associated with certain etiological factors 
• cryoglobulinemic vasculitis associated with hepatitis C virus 
• vasculitis associated with hepatitis B virus 
• aortitis associated with syphilis 
• drug immunocomplex vasculitis 
• medicinal ANCA-associated vasculitis 
• paraneoplastic vasculitis 
• others 
 
Clinical symptoms of systemic vasculitis 
 
Common symptoms: fever, weight loss, general weakness. 
Signs of a systematic pathological process: damage to several organs and systems: 
arthralgia, myalgia, damage to the skin, lungs, cardiovascular system, 
gastrointestinal tract, kidneys, and nervous system. 
Clinic SV significantly varies depending on the location and degree of damage to 
the vessel. The main clinical manifestations of SV depending on the caliber of the 
affected vessel are shown in table 26. 
Clinical symptoms of granulomatosis with polyangiitis (Wegener) 
• A triad of organ damage involving the upper respiratory tract, lungs and kidneys 
is characteristic. GPA may manifest as an isolated lesion of the upper respiratory 
tract or a combination of these lesions. 
 
Table 26 - The main clinical manifestations of SV depending on the caliber of the 
affected vessel 
Affected vessel  Possible clinical manifestations 
Systemic vasculitis of large / medium vessels 
Common carotid 
artery 
Dizziness, headache, syncope 
Maxillary artery Intermittent muscle pain when chewing 
Ocular artery Vision loss 
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Renal artery Hypertension, renal failure 
Mesenteric arteries Ischemic Enterocolitis 
Coronary arteries Angina pectoris, myocardial infarction 
Pulmonary artery Cough, bloody sputum, shortness of breath, pulmonary 
infarction 
SV vessels of small caliber 
Leather Mesh livedo, subcutaneous nodules, purpura, skin ulcers, 
finger necrosis 
Peripheral nerves Mononeuritis 
Muscle Myalgia 
Joints Arthralgia 
Kidney Necrotizing glomerulonephritis 
Gastrointestinal tract Ulcers, bleeding 
Heart Myocarditis, arrhythmia 
Lungs Pulmonary Alveolar Hemorrhage 
Serous membranes Pericarditis, pleurisy 
Eyes Retinal hemorrhages, scleritis 
 
• The upper respiratory tract is most often affected (90%): ulcerative necrotic 
rhinitis, sinusitis, damage to the organ of hearing, trachea, and larynx with the 
formation of sub-follicular granulomas. Perforation of the nasal septum with the 
formation of a saddle-shaped deformation of the nose, destructive pansinusitis with 
the spread of granulomatous tissue into the orbit, hearing loss, stenosis of the 
larynx may develop. 
• Lung damage (50-70%): multiple nodes or infiltrates, prone to disintegration and 
cavity formation, atelectasis, pneumonia. Often, lung damage is asymptomatic. 
• Kidney damage (80-90%): proliferative focal glomerulonephritis with half moon, 
necrosis and thrombosis of individual loops and large segments of glomeruli. 
Acute nephritic syndrome, renal failure, or asymptomatic proteinuria, 
microhematuria, less often macrohematuria may develop. 
• Lesions of the organ of vision (50%): periorbital granuloma, leading to blindness 
in every fifth patient, episiscleritis, optic vasculitis, occlusion of the retinal arteries. 
• Skin lesion (25-35%): hemorrhagic or ulcerative hemorrhagic rashes, reticular 
liver, gangrenous pyoderma. 
• Damage to the peripheral nervous system (20-30%): sensory-motor multiple 
mononeuritis, less commonly distal symmetric polyneuropathy, neuritis V, VII pair 
of cranial nerves. 
• Heart damage (20%): coronary heart disease, high risk of myocardial infarction, 
stroke, peripheral arterial occlusion. 
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• Damage to the gastrointestinal tract (5%): abdominal pain, nausea, vomiting, 
diarrhea, bleeding. 
• With HPA, in comparison with other ANCA vasculitis, the highest risk of 
developing exacerbations and relapses, even at high doses of immunosuppressants. 
 
Clinical symptoms of microscopic polyangiitis 
• Clinical symptoms are similar to GPA, but there is no or minimal upper 
respiratory tract damage, no destructive granulomas in the lungs. 
• In 50% of patients a severe pulmonary-renal syndrome is developed: necrotizing 
alveolitis (antibodies to PR-3 are detected), fibrosing alveolitis (antibodies to 
MPO), kidney damage (40-55% - rapidly progressive glomerulonephritis). 
• Skin lesion (70%): ulcerative hemorrhagic rashes, mesh retinitis, skin and tissue 
necrosis. 
• Lesions of the organ of vision (30%): scleritis and episcleritis. 
• Damage to the nervous system (30%): multiple mononeuritis with damage to the 
peripheral and cranial nerves, cerebral vasculitis. 
• Damage to the gastrointestinal tract (10%): abdominal pain, nausea, vomiting, 
diarrhea, bleeding. 
• A more aggressive course is characteristic than with GPA or EGPA. 
 
Clinical symptoms of eosinophilic granulomatosis with polyangiitis ( Churg-
Strauss) 
• EGPA is combined with eosinophilia, bronchial asthma, allergic rhinitis, nasal 
polyposis, or a combination of both. 
• Clinical development goes through 3 stages. At the first stage for several years 
there are symptoms of bronchial asthma, allergic rhinitis, sinusitis, drug 
intolerance, an increase in the number of eosinophils in the blood. At the 2nd 
stage, eosinophilic pneumonia or gastroenteritis joins, often eosinophilia of blood 
more than 10%. Stage 3 - the development of necrotizing vasculitis. 
• Lung damage (70%): migratory infiltrates (eosinophilic pneumonia) or nodes 
without decay cavities, eosinophilic pleurisy, moderate enlargement of 
intrathoracic lymph nodes. 
• Kidney damage 20-45%: glomerulonephritis. 
• Heart damage (30-50%): pericarditis, endomyocarditis, coronary artery disease, 
heart failure, rhythm and conduction disturbances. 
• Skin lesion (64%): hemorrhagic or ulcerative hemorrhagic rashes mainly on the 
skin of the limbs, urticaria rashes. 
• Damage to the peripheral nervous system (64%): sensory-motor multiple 
mononeuritis. 
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• Damage to the central nervous system (10%): neuritis of the cranial nerves, acute 
cerebrovascular accident, convulsions, coma. 
• Lesions of the organ of vision (30%): scleritis and episcleritis. 
• Damage to the gastrointestinal tract (10%): eosinophilic gastroenteritis, vasculitis 
of the intestinal wall. 
Diagnosis of systemic vasculitis [31, 32, 33] 
Diagnosis of SV is based on a comprehensive assessment of the clinical picture, 
data from laboratory, instrumental, and morphological studies. An exclusion of all 
causes that can lead to the development of secondary vasculitis is required. 
Laboratory indicators specific to SV 
• Complete blood count: normochromic anemia, thrombocytosis, neutrophilic 
leukocytosis, increased ESR, for EGPA, eosinophilia above 1.5 x 109 / l is 
characteristic. 
• Urinalysis: proteinuria, hematuria, cell cylinders. The level of serum creatinine, 
GFR, electrolyte levels are determined, a study of daily urine is conducted, etc. 
• Markers of inflammation - the content of CRP and ESR correlate with the activity 
of the disease. 
Immunological studies for SV diagnosis  
• Detection of ANCA confirms the diagnosis of ANCA-associated vasculitis. 
Antibody content correlates with disease activity. 
• ANCA screening test - IIF response. There are two main types of luminescence 
of ANCA: cytoplasmic (c-ANCA) and perinuclear (p-ANCA). 
• After receiving a positive response in the IIF method, the specificity of antibodies 
is determined by ELISA: cytoplasmic antibodies react with proteinase-3, 
perinuclear antibodies with myeloperoxidase. 
• The frequency of detection of ANCA in ANCA-SV and their specificity are 
different (table 27): 
- in GPA, antibodies to PR-3 (c-ANCA) are detected in most patients in 90% of 
cases, while to MPO (p-ANCA) in only 10% of cases. 
- with EGPA, antibodies to MPO are detected in 50-75% of patients, while to PR-3 
in only 10% of cases; 
- with MP with equal frequency, antibodies to PR-3 and to MPO are detected in 
50% of cases. 
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Other diseases and SV in which ANCA is detected 
• Perinuclear ANCA (p-ANCA) include antibodies to other components of 
neutrophil cytoplasmic granules (elastase, cathepsin, lactoferrin) along with 
antibodies to MPO. Some p-ANCA are not characteristic of vasculitis, but are 
found in other diseases. For this reason, in the diagnosis of vasculitis, obtaining the 
perinuclear type of luminescence in the IIF reaction is always supplemented by a 
study for antibodies to myeloperoxidase using ELISA or a comprehensive study of 
several ANCA. 
• P-ANCA can be detected with IgA-associated vasculitis (hemorrhagic vasculitis, 
in 20-30% of cases), nodular periarteritis (2%), rarely with SLE, RA. 
• P-ANCA (more often for MPO) is found in patients with Goodpasture syndrome 
(10-15%) together with antibodies to the glomerular basement membrane (anti-
BMC). 
• P-ANCA can be detected with rapidly progressive glomerulonephritis (in 50% of 
cases), idiopathic alveolar hemorrhagic syndrome, ulcerative colitis (40-50%), 
Crohn's disease (10-20%), primary biliary cirrhosis, chronic hepatitis, 
paraneoplastic vasculitis. 
The defeat of small vessels of the skin and internal organs is often secondary and 
occurs when the antigen is kept in the body for a long time (infections, tumors, 
drugs, etc.). For differential diagnosis between primary and secondary SV 
(vasculopathy) laboratory, instrumental, histological studies are performed. 
 
Laboratory studies used for SV differential diagnosis: 
• determination of antibodies to dsDNA, ANA, RF, antibodies to phospholipids to 
exclude ARD; 
• determination of concentration of creatinine, liver enzymes, CPK (exclusion of 
inflammatory myopathy); 
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• bacteriological blood test; determination of markers of hepatitis B virus, C, HIV, 
syphilis; 
• electrophoresis of serum and urine proteins, analysis of sternal punctate to 
exclude lymphoproliferative diseases; 
• identification of tumor markers. 
Instrumental research methods used for differential diagnosis of SV: 
• rhinoscopy, laryngoscopy, bronchoscopy, radiography of lungs and sinuses, CT, 
high-resolution CT, MRI; 
• determination of external respiration functions; 
• FGDs, colonoscopy; 
• ultrasound dopplerography of blood vessels, heart, 
• ultrasound of internal organs, 
• angiography of the celiac trunk and renal arteries, 
• MRI of large blood vessels and aorta, 
• electromyography. 
Histological examination in SV. Due to the large number of cases of seronegative 
variants of SV, a biopsy is an obligatory component of diagnosis in ANCA 
vasculitis, giant cell arteritis, and polyarteritis nodosa. A biopsy of the most 
accessible affected tissue is performed. 
Histological signs of vasculitis: 
• Vascular wall infiltration with various combinations of white blood cells and 
lymphocytes. 
• Fibrosis and intimal hypertrophy, secondary thrombus formation, fibrinoid 
necrosis - destruction of all wall layers. 
• Leukocytoclasia - the detection in vessels and around them of small fragments of 
nuclei ("nuclear dust") of destroyed inflammatory cells due to the destruction of 
white blood cells. 
• Perivascular infiltration. 
• There may be (during immunofluorescence research) a small number of deposits 
of immunoglobulins and complement in the walls of blood vessels or their 
complete absence. 
• None of pathomorphological changes is specific to individual vasculitis. 
Interpretation of biopsy data should be done only taking into account the clinic. 
When making a diagnosis of ANCA vasculitis, an analysis is made of the 
compliance of the data from the above studies with classification criteria (table 28). 
An important aspect of diagnostics is the knowledge of age-related priorities of SV 
(table 29). If SV symptoms appear in an age group uncharacteristic for it, 











1. Inflammation of the 
nose and mouth 
Oral ulcers; purulent or bloody 
discharge from the nose 
2. Changes in the lungs 
during x-ray 
examination 
Nodules, infiltrates or cavities 
in the lungs 
3. Changes in urine Hematuria (> 5 red blood cells 
in sight) or erythrocyte 
cylinders in urine sediment 
4. Biopsy data Granulomatous inflammation in 
the artery wall or in the 
perivascular and extravascular 
space 
The presence of 2 or more criteria allows you to diagnose 





1. Bronchial asthma 
 
Difficulty breathing or diffuse 
wheezing when inhaling 
2. Eosinophilia 
 
Eosinophilia> 10% of the total 





polyneuropathy by the type of 
gloves or stockings 
4. Radiological signs of 
pulmonary infiltrates 
Migratory or transient 
pulmonary infiltrates detected by 
x-ray 
5. Pathology of the 
maxillary sinuses 




Accumulation of eosinophils in 
extravascular space 
The presence of 4 or more criteria allows you to diagnose 
with a sensitivity of 85% and a specificity of 99% 
Microscopic 
polyangiitis 





Table 29-Age priorities of systemic vasculitis 
Age of patients Name of systemic vasculitis 
Childhood Shenlein-Genoa vasculitis, Kawasaki vasculitis  
Young age Nodular periarteritis, Behcet's disease, Takayasu disease 
Average age Granulomatous polyangitis (Wegener), microscopic 
polyangiitis, eosinophilic polyangiitis (Churg-Strauss) 
Elderly age Horton's giant cell arteritis, rheumatic polymyalgia 
 
Often there is a need for differential diagnosis of ANCA-associated vasculitis with 
immunocomplex, less often with vasculitis of vessels of medium and large caliber. 




















































IgA detection straight 
immunofluorescence 
Exclude SLE, Sjogren's syndrome, 
viral hepatitis 






Leukocytoclastic vasculitis in the 
upper and lower 
dermis 
 
 Necrotizing vasculitis 
in the lower layers of the dermis and 
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Figure 3 - Algorithm for differential diagnosis of systemic vasculitis 
 
Diagnosis example 
1. Granulomatosis with polyangiitis, chronic course, advanced stage, grade 1 
activity with lung damage (infiltrative lung damage, respiratory failure I), organs 
of vision (right-sided exophthalmos, complete atrophy of the optic nerve of the 
right eye, partial atrophy of the optic nerve of the left eye), kidney (nephropathy, 
chronic kidney disease C3a). 
2. Granulomatosis with polyangiitis (Wegener's granulomatosis), acute course, 
advanced stage, 3 degree activity with damage to the upper respiratory tract 
(rhinitis, purulent hemorrhagic sinusitis), oral mucosa (ulcerative stomatitis), 
hearing organs (ossifying labyrinthitis), organs of vision (bilateral keratitis), lungs 
(infiltrative lung lesion, pleural empyema, respiratory failure III), kidneys 
(nephropathy with progressive renal failure), heart (pericardial effusion), 
gastrointestinal tract (heart attack echeni), nervous system (polyneuropathy), skin 
(hemorrhagic rash), joints (arthritis, functional class II). 
 
Treatment of ANCA-associated vasculitis [18] 
Treatment is carried out in 3 stages. 
• Stage 1 - induction of remission lasting 3-6 months. Used drugs and treatment 
methods: GCS, GCS + cytostatics, cytostatics, immunoglobulins for intravenous 
administration, biological drugs, plasmapheresis, escalation therapy (pulse therapy 
with methylprednisolone + cyclophosphamide + plasmapheresis). 
• Stage 2 - maintaining remission: therapy with cytostatics + GCS for 2-5 years 
(until clinical and laboratory remission is achieved). 
• Stage 3 - treatment of relapses of SV. 
 
To induce remission of generalized ANCA-SV, it is recommended to use a 
combination of cyclophosphamide + GCS (methylprednisolone or prednisolone). 
The tactics of treatment vary depending on the severity of SV and the response to 
the therapy. There are 2 treatment regimens that differ in the way of administering 
drugs - intravenous or oral. 
1 circuit. Cyclophosphamide in pulse therapy: intravenously 15 mg / kg (not more 
than 1 g) at intervals between the first 3 courses of 2 weeks, then every 3 weeks. 
+ Methylprednisolone in pulse therapy mode: intravenously 0.5-1 g / day for 3 
consecutive days, followed by the administration of prednisolone orally 1 mg / kg / 
day (no more than 80 mg) once in the morning until the effect is achieved, usually 
at least a month. After the effect is achieved, they begin to gradually reduce the 
dose of prednisone at 1.25 mg by 25% per month until the dose of prednisolone 
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reaches 20 mg / day, then by 10% every 2 weeks to 10 mg / day. In the future, it is 
possible to reduce the dose of GCs at 1.25 mg every 4 weeks. 
With an increase in serum creatinine or in an elderly patient, lower doses of 
cyclophosphamide are used (Table 30). 
 
Table 30 - modification of intravenous cyclophosphane dose depending on the 
patient's age and serum creatinine level 
Age Creatinine 
<300 mmol / l 
Creatinine 
300-500 mmol / L 
< 60 15 mg / kg / pulse 12.5 mg / kg / pulse 
60- 70 12.5 mg / kg / pulse 10 mg / kg / pulse 
> 70 10 mg / kg / pulse 7.5 mg / kg / pulse 
 
2nd scheme. Cyclophosphamide inside 2 mg kg/day (no more than 200 mg/day) 
with a dose reduction to 1.5 mg/kg/day when remission is achieved (within 3-12 
months). 
In the presence of renal failure, the dose of cyclophosphamide inside should be 
reduced by 25-50%. Additionally, prednisolone is prescribed orally 1 mg/kg/day 
(no more than 80 mg) once in the morning (after eating) until the effect is 
achieved, usually at least a month. After the effect is achieved, a dose reduction of 
prednisolone is carried out according to the scheme described above 
The combination of methotrexate + GCS. It is prescribed for ANCA-associated 
limited vasculitis (local pathology of the upper respiratory tract), without rapidly 
progressing nephritis (creatinine <150 mmol/L) and severe lung damage. The dose 
of methotrexate is 15-25-30 mg week. 
The combination of mycophenolate mofetil + GCS. Mycophenolate mofetil has 
renoprotective properties. Assign 1-2 g/day in one or more doses with a duration of 
at least 6 months. GCS is prescribed in a standard dose. 
A refractory variant of the course of SV is distinguished, in which there is no 
reverse development of the clinical manifestations of the disease or an increase in 
clinical activity is observed, despite standard pathogenetic therapy being carried 
out for 6 weeks. 
 
Treatment of refractory SV and SV with recurrent course 
• Genetically engineered biological drugs. Rituximab is a chimeric monoclonal 
antibody to the CD20 receptor for B-lymphocytes. Dosage regimen: intravenously 
375 mg/m2 once a week for 4 weeks. Treatment is combined with the 
administration of corticosteroids in a standard dose, supporting therapy with 
azathioprine, mycophenolate mofetil. A combination of rituximab and 
cyclophosphamide in a standard dose is possible for one or several months in 
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severe cases of the disease, including the development of rapidly progressive 
glomerulonephritis. 
With the development of relapse after remission induced by rituximab, a second 
course is recommended. Lower doses of rituximab (500-1000 mg) may be 
effective. To reduce the risk of relapse, a preventive prescription of a second 
course of rituximab can be considered. 
It is possible to use infliximab (chimeric antibodies to TNF-α, etanercept 
(antibodies to soluble TNF-α), with EGPA - omalizumab (chimeric antibodies 
against the IgE receptor). 
• Normal human immunoglobulin for intravenous administration is prescribed for 
the refractory course of ANCA vasculitis, if there are contraindications for 
cytostatics (infectious complications, pregnancy, before and after surgery). Dosage 
regimen: slowly intravenously (20 drops per minute) 0.4-2g/kg 1 time/day, 3-5 
days. It is possible to conduct repeated courses once a month for 6 months. Side 
effects: flu-like syndrome. 
• Plasmapheresis. Mechanism of action: suppression of immune inflammation by 
removing antibodies, immune complexes, pro-inflammatory cytokines, 
inflammatory mediators, prostaglandins. 
Dosage regimen: 7-10 procedures for 14 days with removal of 60 ml/kg of plasma 
and replacement with an equal volume of 4.5-5% of human albumin. 
It is attached due to ineffectiveness of induction therapy, in cases of active severe 
illness with an increase in creatinine levels of more than 500 mmol/l, as well as 
with hemorrhagic alveolitis. 
• Escalation therapy: plasmapheresis + GCS + cytostatics. Dosage regimen: 7-10 
plasmapheresis procedures for 14 days (60 ml / kg/day) with plasma replacement 
with an equal volume of 4-5% albumin in combination with pulse therapy with 
methylprednisolone (15 mg kg/day) and cyclophosphamide (10 mg/kg/day). 
Additional drugs. In the complex treatment of ANCA vasculitis, antiplatelet agents 
are used - low doses of acetylsalicylic acid, dipyridamole; anticoagulants (heparin, 
warfarin); vasodilators; ACE inhibitors. 
With gPA in cases with proven carriage Staph. aureus, as well as for the prevention 
of pneumocystis infection in patients receiving cyclophosphamide, 
trimethoprim/sulfamethoxazole is prescribed. 
If the patient has impaired renal function due to severe renal failure, programmed 
hemodialysis is performed. 
The ANCA-associated vasculitis management algorithm developed by the British 
Society of Rheumatology [18] is shown in Figure 4. 
Maintenance of remission 
• The duration of treatment is from 2 to 5 years. 
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• GCS inside 5-10 mg once in the morning (after eating) + azathioprine 2 
mg/kg/day with a possible dose reduction to 1.5 mg/kg/day in a year. If possible, 
the dose of GCS should be reduced as much as possible or completely abolished. If 
you need long-term administration of corticosteroids, calcium preparations, 
vitamin D, bisphosphonates for the prevention of osteoporosis are added to the 
treatment. 
• Instead of azathioprine, you can prescribe leflunomide 20-30 mg/day, or 
methotrexate 12.5-15 mg/week, or mycophenolate mofetil 1-2 g/day in one or 
more doses with duration of at least 6 months. 
In duration of remission of vasculitis during the year against the background of 
maintenance therapy, it is recommended firstly to lower the dose of corticosteroids, 
and then to reduce or cancel immunosuppressive therapy. 
Surgery 
It is indicated for the development of irreversible tissue changes (peripheral 
gangrene), subopharyngeal stenosis, stenosis of the bronchi, etc. A kidney 






















AZA - azathioprine, MMF - mycophenolate mofetil, MT - methotrexate, 




Assessment of disease activity 
Induction therapy 
Severe Life-threatening 
damage to organs and systems 
Creatinine ≥ 500 μmol / L 
No heavy defeat of 
organs and systems 
or  or or RТМ+GCS CP + GCS 






on MT / MMF 
Maintenance therapy 
Continue RTM 
GCS dose reduction 
until canceled 
or 
Cancel RTM MT dose reduction 
or AZA until canceled 
Switching to MT or AZA 
Reducing the dose of GCS 
until full cancellation 
Remaining remission without therapy 
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Figure 4 - Algorithm for management of patients with ANCA-associated 
vasculitis 
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SECTION CONTROL TESTS 
 
1. What is not typical for antiphospholipid syndrome? 
1. The presence of antiphospholipid antibodies 
2. Habitual miscarriage 
3. Thrombocytosis 
4. Arterial thrombosis 
5. Venous thrombosis 
 
2. What does not belong to laboratory diagnostic criteria for antiphospholipid 
syndrome? 
1. Antibodies to cardiolipin IgG or IgM isotypes 
2. Antibodies to β2-glycoprotein 1 IgG and / or IgM isotypes 
3. Lupus anticoagulant in plasma 
4. Extension of blood coagulation time in phospholipid-dependent coagulation 
tests (activated partial thromboplastin time, kaolin test, test with Russell's viper 
venom) 
5. High titer of cryoglobulins in blood serum 
 
3. What is not typical for systemic lupus erythematosus? 
1. Photosensitivity 
2. Raynaud's syndrome 
3. Alopecia 
4. Osteolysis of terminal phalanges 
5. Erythematous dermatitis of the face 
 
4. What is not typical for systemic lupus erythematosus? 
1. Pneumonitis 
2. Lupus nephritis 
3. Cheilitis 
4. Eosinophilic endocarditis 
5. Myocarditis 
 






5. Acceleration of ESR 
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5. Gold preparations 
 







8. The most common manifestation of lupus carditis is: 
1. Myocardial infarction 
2. Damage to all valves 




9. What antibodies reliably indicate the presence of systemic lupus erythematosus 
in a patient? 
1. Anticentromeric antibodies 
2. Antibodies to the J-1 antigen 
3. Antineutrophilic cytoplasmic antibodies to proteinase 3 
4. Antibodies to cardiolipin 
5. Antibodies to double-stranded DNA 
 
10. Name vasculitis that is not granulomatous: 
1. IgA-associated vasculitis (hemorrhagic vasculitis, Shenlein-Genoch purpura) 
2. Granulomatosis with polyangiitis (Wegener) 
3. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 
4. Takayasu arteritis (nonspecific aortoarteritis) 
5. Giant cell temporal arteritis (Horton's disease) 
 
11. Name vasculitis, which is granulomatous: 
1. Obliterating thromboangiitis (Vinivarter-Burger) 
2. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 
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3. Microscopic polyangiitis 
4. Essential cryoglobulinemic vasculitis 
5. IgA-associated vasculitis (hemorrhagic vasculitis, Shenlein-Genoch purpura) 
 
12. What type of systemic vasculitis affects only medium-sized arteries? 
1. Obliterating thromboangiitis 
2. Nodular polyarteritis 
3. IgA-associated vasculitis (hemorrhagic vasculitis, Shenlein-Genoch purpura) 
4. Essential cryoglobulinemic vasculitis 
5. With all the mentioned vasculitis, arteries of only medium caliber are affected 
 
13. What type of vasculitis is characterized by vascular lesions of the 
microcirculatory bed? 
1. Essential cryoglobulinemic vasculitis 
2. Microscopic polyangiitis 
3. Hypocomplementemic urticarial vasculitis 
4. IgA-associated vasculitis (hemorrhagic vasculitis, Shenlein-Genoch purpura) 
5. With all the mentioned vasculitis, the vessels of the microvasculature are 
affected 
 
14. What vasculitis is associated with hepatitis B virus infection? 
1. Nodular polyarteritis 
2. Giant cell temporal arteritis (Horton) 
3. IgA-associated vasculitis (hemorrhagic vasculitis, Shenlein-Genoch purpura) 
4. Obliterating thromboangiitis 
5. With all of the listed vasculitis 
 
15. At what systemic vasculitis antineutrophilic cytoplasmic autoantibodies are 
detected in the blood serum? 
1. Giant cell temporal arteritis of Horton 
2. IgA-associated vasculitis (hemorrhagic vasculitis, Shenlein-Genoch purpura) 
 3. Obliterating thromboangiitis 
4. Takayasu arteritis (nonspecific aortoarteritis) 
5. Microscopic polyangiitis 
 
16. What systemic vasculitis is characterized by anti-neutrophil cytoplasmic 
antibodies to proteinase-3? 
1. Granulomatosis with polyangiitis (Wegener) 
2. Essential cryoglobulinemic vasculitis 
3. Giant cell temporal arteritis (Horton) 
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4. IgA-associated vasculitis (hemorrhagic vasculitis, Shenlein-Genoch purpura) 
5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 
 
17. What systemic vasculitis is characterized by antineutrophilic cytoplasmic 
antibodies to myeloperoxidase? 
1. Essential cryoglobulinemic vasculitis 
2. Nodular polyarteritis 
3. Granulomatosis with polyangiitis (Wegener) 
4. Takayasu arteritis (nonspecific aortoarteritis) 
5. Microscopic polyangiitis 
 
18. In what systemic vasculitis can anti-neutrophil cytoplasmic antibodies to 
myeloperoxidase and proteinase-3 be detected? 
1. Takayasu arteritis (nonspecific aortoarteritis) 
2. IgA-associated vasculitis (hemorrhagic vasculitis, Shenlein-Genoch purpura) 
3. Polyarteritis nodosa 
4. Giant cell temporal arteritis (Horton) 
5. Microscopic polyangiitis 
 
19. What type of vasculitis is characterized by lung damage? 
1. Granulomatosis with polyangiitis (Wegener) 
2. Microscopic polyangiitis 
3. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 
4. With all of the listed vasculitis, the lungs are affected. 
5. With all of the listed vasculitis, lung damage is very rare. 
 
20. Which disease is most characterized by an increase in serum creatine 
phosphokinase? 
1. Reactive Arthritis 
2. Systemic sclerosis 
3. Nodular periarteritis 
4. Dermatomyositis 
5. Rheumatoid Arthritis 
 
21. What signs are typical for polymyositis? 
1. Swelling and skin induction 
2. Sharp muscle weakness 
3. Cataract 
4. Joint deformation 
5. Osteolysis of the nail phalanges of the hands 
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22. The Gottron trait is characteristic of: 
1. Dermatomyositis 
2. Systemic sclerosis 
3. Systemic lupus erythematosus 
4. Essential cryoglobulinemic vasculitis 
5. Hemorrhagic vasculitis (Schonlein-Genoch purple) 
 





5. All of the above 
 
24. What diseases are associated dermatomyositis with? 
1. Bronchial asthma 
2. Sarcoidosis 
3. Crohn's disease 
4. Malignant neoplasms 
5. Urticaria 
 
25. A distinctive symptom of Sjogren's syndrome is: 




5. Optic atrophy 
 
26. For Sjogren's syndrome following is not typical: 
1. Severe dryness of the skin 
2. Damage to the salivary glands (reduced salivation) 
3. Dryness of the mucous membranes of the nose, larynx, pharynx, bronchi 
4. Atrophic gastritis with secretory insufficiency, hypokinetic biliary 
dyskinesia, pancreatitis 
5. All of the above is typical 
 
27. Specific markers of Sjogren's syndrome: 
1. Antibodies to the nuclear antigen Ro (ass-A/Ro) and La (aSS-B/La)  
2. LE cells 
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3. Antibodies to double-stranded DNA 
4. Antineutrophilic cytoplasmic antibodies to myeloperoxidase  
5. Anti-neutrophil cytoplasmic antibodies to proteinase 3 
 
28. What does not apply to the radiological signs of rheumatoid arthritis? 
1. Osteoporosis  
2. Osteophytes 
3. Narrowing of the joint gap 
4. Usource articular surfaces 
5. Ankylosing of joints 
 
29. What complication is most common for rheumatoid arthritis? 
1. Renal amyloidosis 
2. Secondary infection 
3. Antiphospholipid syndrome  
4. Gastric ulcer 
5. Development of Raynaud's syndrome 
 
30. III degree of activity of rheumatoid arthritis is characterized by the following 
clinical and laboratory manifestations, except: 
1. Erythrocyte sedimentation rate 62 mm/h 
2. Pain assessment on a visual analog scale of 8 cm 
3. Morning stiffness during the day 
4. SRP is 3 times higher than normal 
5. The defeat of the periarticular tissues 
 
31. What drug is considered the "gold standard" for the treatment of rheumatoid 
arthritis? 
1. Hydroxychloroquine 
2. Methotrexate  




32. What immunological indicator is most typical for rheumatoid arthritis? 
1. High RF titer 
2. Presence of LE cells  
3. High titer of antistreptolysin O  
4. The presence of antibodies to double-stranded DNA  
5. High titers of antinuclear antibodies 
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33. What immunological indicator is highly specific for rheumatoid arthritis? 
1. Antinuclear antibodies 
2. Anti-neutrophil cytoplasmic antibodies 
3. Antibodies to double-stranded DNA 
4. Antibodies to cyclic citrullinated peptide  
5. Antibodies to the Scl-70 antigen 
 
34. What kind of disease is characterized by deformation of fingers of the hands 
like "Swan's neck" and "button loop"? 
1. Rheumatoid arthritis 
2. Psoriatic arthritis 
3. Systemic lupus erythematosus 
4. Osteoarthritis's 
5. Hemorrhagic vasculitis 
 
35. What is the most common disease that causes hypotrophy of hand muscles? 
1. Osteoarthritis 
2. Rheumatoid arthritis 
3. Systemic sclerosis 
4. Systemic lupus erythematosus 
5. Microscopic polyangiitis 
 











3. Duration of morning stiffness 
4. The severity of pain on a visual analog scale 
5. Uric acid level 
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Task 1. A 55-year-old woman went to the clinic with complaints of a temperature 
of 37.2-37.4 оС for a month, swelling of the joints of the hands, feet, limited 
mobility in them, morning stiffness in the joints of the upper and lower extremities 
up to 14 hours. Notes a slight effect from taking NSAIDs. 
Objective examination: there is a symmetrical lesion of the wrist, 
metacarpophalangeal and proximal interphalangeal joints of the hands (except for 
the 1st metacarpophalangeal joint and the 5th proximal interphalangeal joint), and 
the metatarsophalangeal joints. Above the surface of these joints, there is 
hyperemia of the skin, local hyperthermia. Active and passive movements in the 
joints are limited. 
Data from additional surveys. General blood analysis: red blood cells- 4,6х1012//l, 
HB-118 g / l, white blood cells-- 8,0х109/l, ESR-35 mm / h.  
Radiography of hand joints: periarticular osteoporosis, narrowing of joint slits, 
single usures in the area of proximal interphalangeal joints is determined. 
Questions: 
1. Formulate a preliminary diagnosis. 
2. What additional tests should be performed to verify the diagnosis? 
3. What diseases should be treated with a differential diagnosis? 
4. Determine the tactics of managing patients with this pathology. 
 
Task 2. Patient K., 24 years old, went to the clinic with complaints of a slight 
temperature increase (up to 37.5 оС), pronounced general weakness, pain in the 
joints of the hands, knee and ankle joints, and an increase in axillary lymph nodes. 
She considers herself sick for about six months, and associates the disease with 
hypothermia. 
At objective examination: the state of moderate severity. There is erythema on the 
face, especially on the cheeks and in the area of the back of the nose. Axillary 
lymph nodes are enlarged (size exceeds 15 mm in diameter), dense, painless. There 
is swelling of small joints of the hands, ankle and knee joints, movement in them is 
limited. The heart rate - 108 beats/min, BP - 140/100 mm Hg. All heart tones are 
rhythmic, muted. The borders of the heart are not changed. When auscultation of 
the lungs is determined by hard breathing, in the lower parts - weakened. The 
abdomen is of the usual shape, participates in the act of breathing, and is soft and 
painless when palpated. The liver is not enlarged. The symptom of pounding is 
negative on both sides. Stool and diuresis are normal. Dense edema in the area of 
the feet and shins. 
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Data from additional surveys. General blood analysis: red blood cells-2,9х1012/l, 
Hb-90 g/l, white blood cells-3,1х109/l, platelets-105х109/l, ESR-45 mm per hour.  
General analysis of urine: protein-3.5 g / l, specific weight 1018, white blood cells-
8-10 in the field of view, red blood cells changed-22-24 in the field of view, 
hyaline cylinders-2-4 in the field of view. 
Biochemical analysis of blood: total protein-53 g / l, CRP-16 mg/l, blood urea-11.6 
mmol / l, creatinine-113 mmol / l. 
Questions: 
1. Formulate a preliminary diagnosis. 
2. What additional tests should be performed to verify the diagnosis? 
3. What diseases should be treated with differential diagnostics? 
4. Determine the tactics of managing patients with this pathology. 
 
Task 3. The first-born 26-year-old was admitted to the maternity hospital at full-
term pregnancy. She complained on periodic flashing of flies before the eyes, pain 
in the epigastric region. This third, first, and second pregnancy resulted in a 
spontaneous miscarriage at 17-18 weeks of gestation. During the pregnancy, she 
added 9 kg of body weight. 
On objective examination: there is no edema, and the peripheral lymph nodes are 
not enlarged. When the lungs are auscultated, vesicular respiration is determined. 
The boundaries of the heart correspond to the norm. The heart tones are rhythmic, 
muted. The number of heartbeats is 95 in 1 min. Blood pressure is 115/65 mm Hg. 
The face is symmetrical on both hands. The abdomen is soft, painless, and the liver 
and spleen are not enlarged. The chair is normal. Diuresis is sufficient. 
Data from additional surveys. General blood analysis: red blood cells-4,3х1012/l, 
white blood cells-7,2х109/l, platelets-105х109/l. General urine analysis without 
pathology. 
Biochemical blood analysis: total protein-70 g / l, bilirubin-2.2 mmol/l, urea-3.1 
mmol/l, creatinine-62 mmol / l. Wasserman's Reaction is weakly positive. 
Immunological examination of blood: anti-cardiolipin antibodies and lupus 
anticoagulant in high titers are determined. 
In the emergency room, she was examined by the obstetrician-gynecologist on 
duty: pregnancy of 37-38 weeks, pelvic presentation of the fetus. 
Questions: 
1. Formulate a preliminary diagnosis. 
2. What additional methods of examination should be performed to verify the 
diagnosis? 
3. Make a differential diagnosis. 
4. Determine the tactics of managing patients with this pathology. 
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Task 4. Patient V. 52 years old, was admitted to the Department of rheumatology 
with complaints of severe general weakness, loss of body weight, swelling of the 
skin of hands, tingling sensation in the fingers, paleness and blueness of the fingers 
in the cold, wounds on the fingertips, pain in the joints of the hands and feet. She 
considers herself ill for 3.5 years. The disease began with a tingling sensation of 
the fingertips, whiteness of the fingers in the cold. Over the past few months, the 
patient has been concerned about severe general weakness, swelling of the hands 
and non-healing wounds on the fingertips, and an increase in body temperature to 
37.2-37.4 оС. She was sent to the rheumatological department for verification of 
the diagnosis. 
Under objective inspection: asthenic physique, low nutrition. Expression limitee, 
the mouth slit is narrowed, with wrinkles around. In the area of the hands, there is 
dense swelling and induration of the skin, the brush does not clench into a fist. 
Symptom of a "rat bite" on your fingertips. Muscle tone is lowered. When 
palpated, the muscles are slightly painful. Peripheral lymph nodes are not palpated. 
The number of heartbeats 95 in 1 min. AD-110/70 mm Hg. Borders of the heart 
correspond to the norm. The heart tones are rhythmic, muted. Breathing in the 
lungs is vesicular, crepitation is heard in the lower parts on both sides. The 
abdomen is of usual shape, participates in the act of breathing, is soft on palpation, 
and is painful in the epigastrium. The liver is not enlarged. The symptom of 
pounding is negative on both sides. 
Data from additional surveys. General blood test: red blood cells-3,9х1012/l, Hb-
110 g/l, color. indicator-0.7, white blood cells-9,2х109/l, ESR-51 mm / h. 
General urine analysis: clear, acid reaction, specific gravity 1015, protein- absent., 
1-2 white blood cells in p / s. 
Biochemical blood analysis: total protein-76 g / l, CRP-17.4 mg / l. 
X-ray examination of the hands: areas of calcification in the subcutaneous tissue, 
mainly the end sections of the fingers. Osteolysis of the nail phalanges of the 
fingers of the hands, periarticular osteoporosis. 
Questions: 
1. Formulate a preliminary diagnosis. 
2. What additional tests should be performed to verify the diagnosis? 
3. What diseases should be treated with differential diagnostics? 
4. What are the diagnostic criteria for this disease? 
5. Determine the tactics of managing patients with this pathology. 
 
Task 5. Patient B., 34 years old, came to the clinic with complaints of severe pain 
in the knee, ankle, and foot joints, severe weakness, and pain in the muscles of the 
arms and legs, which made self-care difficult. During the month, she had an 
increased temperature (37.5-37.7 °С), without chills. She considers herself sick for 
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six months, when there was a general weakness, the joints of the upper and lower 
limbs began to hurt and swell. She has redness and peeling of the skin over the 
joints of the hands. After consulting a rheumatologist, the clinic diagnosed 
rheumatoid arthritis and prescribed prednisone at a dose of 15 mg / day. She took 
prednisone for about 4 months with a gradual decrease in the dosage until complete 
withdrawal. She noted a significant improvement in the general condition, joint 
pain decreased, and skin changes began to pass. In the spring, after 
hyperinsulemia, again appeared the above complaints, but more pronounced. The 
patient was unable to get out of bed and had a high fever (38.8 °С). She was taken 
to the hospital by ambulance and admitted to the rheumatology department. 
At objective examination: the state of moderate severity. Body temperature  
37.7 °С. The patient is of correct physique and moderate nutrition. She can hardly 
move, can't keep her arms and legs in the air. Musculature is developed normally. 
Muscle tone is sharply reduced. The muscles of the shoulder and pelvic girdle are 
compacted, enlarged in volume, of a testy consistency, and there is marked pain 
when palpation of the muscles. The joints are not changed, and movements in the 
joints are limited due to pain. Lymph nodes are not enlarged. On the skin of the 
chest in the decollete area, in the area of the back of the neck and shoulders, bright 
erythema, slightly flaking. Erythema and peeling of the skin of the back surface of 
the hands over the proximal interphalangeal and metacarpal joints, redness and 
peeling of the skin of the palms. No pathological changes were detected in the 
cardiovascular system, respiratory system, and gastrointestinal tract. 
Data from additional surveys. General blood analysis: red blood cells-- 4,6х1012/l, 
hemoglobin-139 g / l, white blood cells-15,0х109/l, ESR - 26 mm/h. 
General urine analysis: clear, acid reaction, specific gravity 1015, protein-absent, 
2-3 white blood cells in p / s. 
Biochemical blood analysis: protein-81 g / l, AST-98 IU / l, ALT-100 IU/ l, CFK-
1002 IU / l, cholesterol-5.2 mmol/l, CRP ++, total bilirubin - 12 mmol/l, creatinine 
- 120 mmol/l, urea - 4.52 mmol/l. 
Questions: 
1. Formulate a preliminary diagnosis. 
2. What additional tests should be performed to verify the diagnosis? 
3. What diseases should be treated with a differential diagnosis? 
4. Determine the tactics of managing patients with this pathology. 
 
Task 6. Patient A., 54, complained of dry mouth and eyes, and an increase in the 
size of the parotid salivary glands. 
A few years ago, there was a feeling of "sand" in her eyes. When visiting an 
optometrist, a diagnosis was made: dry keratoconjunctivitis (filamentous keratitis 
OU), hypolacrimia III art. Then, active destruction of teeth with formation of 
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cervical caries began, taste perception decreased, and pain appeared in the joints of 
the hands. About 10 months ago, the left and then the right parotid salivary gland 
began to increase in size. During this period, the patient noted an increase in 
temperature to 37.3-37.5 °C, and her vision began to deteriorate. 
On objective examination: body temperature 37.2°C. Dry skin. Parotid salivary 
glands with palpation are enlarged in size, dense in consistency. The oral mucosa is 
bright red, and there is no free saliva. The tongue is dry, without plaque, there is 
atrophy of the papillae. The conjunctiva of eyes are dry and hyperemic. No 
pathological changes were detected in the respiratory system, cardiovascular 
system, or gastrointestinal tract. 
Data from additional surveys. Sialography of the left parotid salivary gland: there 
is a slight expansion of the parotid duct, single cavities are determined in the 
parenchyma. 
Sialometry-unstimulated saliva secretion <0.1 ml/min. 
Results of biopsy of the small salivary glands of the lower lip: there is a 
preservation of the lobular structure, a decrease in the number of acinuses. In the 
periductal regions with the transition to stroma, lymphohistiocytic infiltration of 
125-250 cells in the field of view is determined. 
Questions: 
1. Formulate a preliminary diagnosis. 
2. What additional tests should be performed to verify the diagnosis? 
3. What diseases should be treated with a differential diagnosis? 
4. Determine the tactics of managing patients with this pathology. 
 
Task 7. Patient V., 29 years old, went to the emergency room of the hospital with 
complaints on difficulty in nasal breathing, nosebleeds, cough with the release of 
viscous sputum mixed with blood, shortness of breath at rest, expressed General 
weakness. The last 4 years he has high blood pressure and a change in the color of 
urine. A few months ago, the weakness and headache increased, and in recent days 
the above-described complaints have appeared. 
At objective examination: the state of moderate severity. The skin is pale, dry, 
there is swelling of the face, minor swelling of the lower extremities. When 
auscultation of the lungs is determined by hard breathing, in the lower parts on 
both sides-small-bubble wet rales. The number of breaths is 26 per minute. The 
borders of the heart are not expanded. The number of heartbeats is 95 per minute. 
The tones are rhythmic, muted.BP 210/110 mm. Hg. The abdomen is soft and 
painless. Diuresis is reduced: drinks 1.5 l, allocates urine-800 ml. 
Data from additional surveys. General blood analysis: red blood cells-2,7х1012/l, 
hemoglobin-96 g / l, white blood cells-9,8х109/l, ESR-45 mm / hour. 
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General urine analysis: specific gravity 1008, protein-1.5 g / l, 3-4 white blood 
cells in the field of view, 12-14 red blood cells in the field of view, 2-4 hyaline 
cylinders in the field of view. 
Biochemical blood analysis: urea - 12.8 mmol/l, creatinine - 126 mmol/l, CRP - 29 
mg/l. 
X-ray of the lungs: deformation of the pulmonary pattern, reduced transparency of 
the lung tissue in the lower parts on both sides. In the projection of the lower lobes 
of both lungs, single areas of infiltration are rounded to 5 cm in diameter. 
Questions: 
1. Formulate a preliminary diagnosis. 
2. What additional examinations should be performed for the patient to verify the 
diagnosis? 
3. Make a differential diagnosis of the disease. 
4. Determine the tactics of managing patients with this pathology. 
 
Task 8. Patient B., 22 years old, went to the clinic to the district therapist with 
complaints of severe headache, rash on the fingertips, palms, nail beds, which 
appeared about a week ago. She feels whiteness and soreness of fingers and toes, 
increased when cooled, persistent redness in the area of the back of the nose and 
cheeks, swelling of the right cheek. About 3 months, there is a subfebrile 
temperature (up to 37.2 °С), pronounced weakness and pain in the area of the 
muscles of the shins, elbow and ankle joints. She associates this disease to stress 
(loss of a relative). 
At objective examination: the state of moderate severity. On the face, erythema is 
defined as a "butterfly", mainly on the cheeks. Slight swelling in her cheeks, 
slightly larger on the right. On the pads of her fingers, palms, and nail beds, there 
is a small-point hemorrhagic rash, the second and third fingers of her hands are red 
and bluish. Movements in the ankle and elbow joints are limited due to pain, slight 
swelling of the affected joints, and their pain is palpated. On a visual analog scale, 
the severity of pain is 90 mm. The general assessment of the disease by the patient 
is 86 mm, by the doctor-74 mm. The number of heartbeats is 102 beats/min. BP is 
130/95 mm Hg. All heart tones are rhythmic, muted. The boundaries of the heart 
are not expanded. No pathological changes were detected on the part of the 
respiratory system and gastrointestinal tract. 
Data from additional surveys. Total blood count: red blood cells-2,6х1012/l, white 
blood cells-3,1х109/l, platelets-101х109/l, ESR-55 mm per hour. 
The general analysis of urine: protein - 1.5 g/l, specific weight 1017, leukocytes 
12-14 in sight, erythrocytes-changed - 12-14 in sight, hyaline cylinders - 4-6 in the 
field of view. 
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Biochemical blood analysis: total protein-76 g / l, CRP-38 mg/l, blood urea-10.5 
mmol / l, creatinine-134 mmol / l. CIC-566 Ed. D-Dimers-650 ng / ml, fibrinogen 
A-5.0 g / l. 
Wasserman's reaction is sharply positive (4+). 
Antibodies to cardiolipin and lupus anticoagulant are detected in the middle titers. 
Questions: 
1. Formulate a preliminary diagnosis. 
2. What additional tests should be performed to verify the diagnosis? 
3. What diseases should be treated with differential diagnostics? 
4. Determine the tactics of managing patients with this pathology. 
 
Task 9. Patient V., 45 years old, was admitted to the emergency department of the 
emergency hospital with complaints of severe abdominal pain, pain in the knee and 
elbow joints, the appearance of a red rash on his legs and arms, an increase in body 
temperature to 38.0° C. He associates his disease with a viral infection about 3 
weeks ago. The listed symptoms developed within a few days. 
An objective examination: patient's condition is moderate. The skin is pale pink, 
there is a small symmetrical hemorrhagic rash on the legs, hips, forearms, slightly 
rising above the skin (palpable), not disappearing when pressed. Some rashes have 
necrosis in the center, covered with hemorrhagic crusts. Symptoms of "pinch" and 
"tourniquet" are negative. Minor edema in the area of the knee and elbow joints is 
determined, passive and active movements in these joints are sharply painful. The 
number of heart contractions is 106 beat/min. BP - 110/70 mm. Hg. Heart sounds 
are rhythmic, muffled. The boundaries of the heart are not extended. Vesicular 
breathing is heard above the lungs. The abdomen during palpation is painful in 
mesogastric pain, there is an increase in pain during palpation. Peritoneal 
symptoms are absent. The liver and spleen are not enlarged. Once there was a stool 
with an admixture of fresh blood, the gases escaped. 
Data from additional surveys. Complete blood count: red blood cells - - 4,7х1012/l, 
hemoglobin - 118 g / l, platelets - 220х109/ l, white blood cells - 11,0х109/l, e - 1%, 
st - 10%, s - 70%, l - 16%, m - 3%, ESR - 48 mm / hour. D-Dimers - 660 ng / ml, 
fibrinogen A - 4.9 g / l. 
Questions: 
1. Formulate a preliminary diagnosis. 
2. What additional examinations are needed to verify the diagnosis? 
3. What diseases should be used for differential diagnosis? 
4. Determine the tactics of managing patients with this pathology. 
 
Task 10. Patient A., 28 years old. She turned to the local therapist with complaints 
of severe pain and swelling, stiffness (up to 11 hours) in her knee, elbow and wrist 
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joints. She has continuous (within 1.5 months) temperature of 37.1ºС - 37.3ºС. She 
feels expressed weakness, serving herself with difficulty. The disease is associated 
with a viral infection. She took NSAIDs for a long time. 
An objective examination: a state of moderate severity. Body temperature 37.2ºС. 
In the area of the right wrist joint there are 4 subcutaneous dense, painless nodular 
formations measuring 0.4x0.3 cm. Moderate swelling of the affected joints and 
skin hyperthermia during palpation are determined. Passive and active movements 
in the knee, elbow and wrist joints are limited due to severe pain. Lymph nodes are 
not enlarged. In the lungs, vesicular breathing, no wheezing. The number of 
breaths is 16 per minute. Heart sounds are muffled, rhythmic. The heart rate is 86 
per minute. BP - 129/80 mm. Hg. The abdomen on palpation is soft, painful in the 
epigastric region. The liver and spleen are not enlarged. 
Data from additional surveys. Blood test: red blood cells - 3,2х1012/l, Hb - 104 g / 
l, white blood cells - 10,1х109/l, platelets - 448х109/l, ESR - 38 ml / hour. CRP - 
22 mg/l, fibrinogen 4.6 mg/dl, serum iron - 15.2 mg/dl. 
X-ray of the knee joints: periarticular osteoporosis, narrowing of the joint gap, 
single usages are determined. 
Esophagogastroduodenoscopy: bright hyperemia of the mucous membrane of the 
antrum of the stomach with single erosions. 
Questions: 
1. Formulate a preliminary diagnosis. 
2. What additional examinations are needed to verify the diagnosis? 
3. Make a differential diagnosis. 
4. Determine the tactics of managing patients with this pathology. 
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ANSWERS TO TASKS 
 
Answer to task 1 
1. Diagnosis: rheumatoid arthritis, seropositive/seronegative (depending on the 
detection of RF in the blood serum), 2nd degree of activity, stage II, FC 1-2. 
2. Additional examination plan: general blood analysis, biochemical blood 
analysis, general urine analysis, determination of rheumatoid factor and antibodies 
to cyclic citrulline peptide in blood serum, x-ray of foot joints. 
3. Differential diagnosis: osteoarthritis, gout, pseudogout.  
4. Treatment: NSAIDs for a short time (until joint pain is reduced): diclofenac 50 
mg, 1 t. 3 times a day (or diclofenac retard 100 mg a day), or nimesulid 100 mg, 1 
t. 2 times a day, or meloxicam 7.5 mg, 1 t. 3 times a day, or etoricoxib 90 mg 1 
time a day. Basic drugs: methotrexate 2.5 mg, prescribed from 7.5-10 mg to 25-30 
mg per week. When the 2nd degree of RA activity is usually prescribed 10-12. 5 
mg per week, the effectiveness of the prescribed dose is evaluated in a month, if 
necessary, it is increased. After achieving clinical and laboratory remission of RA, 
the dose of methotrexate is gradually reduced by titrating according to an 
individual scheme. Folic acid 5 mg / week on days free of methotrexate. With high 
activity of the disease - prednisone 7.5-10 mg / day inside for 1-1. 5 months. 
Treatment of NSAIDs and GCS should be performed in combination with the 
proton pump inhibitor omeprazole at a dose of 20-40 mg/day. It is possible to 
administer GCS in / articulately: kenalog 1 ml (40 mg), or diprospan 1 ml (7 mg). 
 
Answer to task 2 
1. Diagnosis: systemic lupus erythematosus, subacute course, 3rd degree of 
activity, with skin lesions (erythema of the face according to the "butterfly" type), 
lymphadenopathy, polyarthritis, serositis (pleurisy?), lupus-nephritis 
(morphologically unspecified) with nephrotic syndrome, pancytopenia (anemia, 
leukopenia, thrombocytopenia). Symptomatic arterial hypertension. 
2. Additional tests plan: general blood analysis, common urine analysis, daily 
proteinuria, urine analysis according to Nechyporenko, Zimnitskiy, a sample of 
Rehberg. Biochemical blood analysis (ALT, AST, CPK, glucose, urea, creatinine, 
total protein, albumin, CRP, potassium, sodium). Immunological markers of the 
disease: antinuclear antibodies, antibodies to double-chiral DNA, antiphospholipid 
antibodies. X-rays/ultrasound of the affected joints. Echocardiography, ECG, 
ultrasound of the abdominal cavity. Kidney biopsy to clarify the morphological 
variant of nephritis. 
3. Differential diagnosis: rheumatoid arthritis, mixed connective tissue disease 
(Sharpe's syndrome), systemic vasculitis. 
 124 
4. Treatment: pulse therapy: methylprednisolone 1000 mg intravenously for 3 
days, cyclophosphamide 600-1000 mg intravenously once. Then prescribe 
prednisone inside 1 mg/kg/day (no more than 60 mg), cyclophosphamide is 
administered in/in a drip of 600-1000 mg 1 time per month for 6 months. Next, an 
oral cytostatic is prescribed, the prednisolone dose is reduced to 0.15-0.2 mg/kg / 
day. ACE inhibitors and diuretic drugs are shown. 
 
Answer to task 3 
1. Diagnosis: antiphospholipid syndrome: recurrent fetal loss syndrome 
(spontaneous abortions), thrombocytopenia, category I (positive anti-cardiolipin 
antibodies and lupus anticoagulant). Pregnancy 37-38 weeks, pelvic presentation 
of the fetus. 
2. Additional examination plan: determine the dynamics (2 times within 12 weeks) 
of lupus anticoagulant, antibodies to cardiolipin, antibodies to beta-2-glycoprotein 
1, coagulogram. 
3. Differential diagnosis: autoimmune thrombocytopenia, gestosis, systemic 
vasculitis, SLE. 
4. Treatment tactics: small doses of aspirin, low-molecular-weight heparin, 
glucocorticosteroids. The delivery option is determined in conjunction with the 
obstetrician-gynecologist. 
 
Answer to task 4 
1. Diagnosis: systemic sclerosis, 3rd degree of activity, chronic course with skin 
lesions (edema and induration of the skin of the face, hands, digital ulcers in the 
area of the fingertips of the hands), blood vessels (Raynaud's syndrome), joints 
(polyarthralgia), nervous system (polyneuropathy), lungs (interstitial fibrosis?).  
2. Additional tests plan: general blood analysis, common urine analysis, daily 
proteinuria, urine analysis according to Nechyporenko, Zimnitskiy, a sample of 
Rehberg. Biochemical blood analysis (ALT, AST, CPK, glucose, urea, creatinine, 
total protein, albumin, CRP, potassium, sodium). Stop x-ray, chest x-ray with 
esophageal contrast, chest CT, Doppler EchoCG, ECG, coagulogram, FGDs, 
respiratory function test, immunological examination for antinuclear antibodies, 
sclerodermic antibodies, skin and muscle flap biopsy, capillaroscopy. 
3. Differential diagnosis: rheumatoid arthritis, SLE, dermatomyositis/polymyositis, 
focal scleroderma. 
4. Diagnostic criteria for systemic sclerosis. "Large criteria": proximal 
scleroderma; "small criteria": sclerodactyly; scars, tissue defects on the fingertips 
of the hands; basal pulmonary fibrosis on both sides. 
5. Treatment. Immunosuppressive therapy: prednisone orally at a dose of 15-20 
mg/day; kuprenil 250-500 mg every other day. Vasodilator drugs: calcium 
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antagonists (nifedipine 10 mg, 1 t. 3 times a day; or diltiazem 60 mg, 1 t. 2-3 times 
a day). Disaggregants (pentoxifylline-400 mg 3 times a day). 
 
Answer to task 5 
1. Diagnosis: dermatomyositis, subacute course, 3rd degree of activity with 
damage to the muscles of the proximal parts of the upper and lower extremities, 
joints (polyarthralgia, FC II), skin (Gottron erythema, V-syndrome, "shawl" 
syndrome, "mechanic's hand"). 
2. Additional examination plan: general blood analysis, general urine analysis, 
biochemical blood analysis (ALT, AST, CPK), immunological studies (antinuclear 
antibodies, myositis-specific antibodies (to the Jo-1, Mi-2 antigen, etc.), 
electromyography, muscle biopsy, chest x-ray/CT, studies to exclude the 
paraneoplastic process (ultrasound, FGDs, colonoscopy, etc.).  
3. Differential diagnosis: myasthenia gravis, hereditary muscle diseases, drug-
induced myopathy. It is necessary to exclude the tumor nature of the process. 
4. Treatment. NSAIDs to reduce pain. Prednisone 1 mg/kg/day, in the absence of 
positive dynamics for a month, the dose should be increased to 2 mg/kg/day. 
Methotrexate from 25 mg/week inside. Folic acid 5 mg/week on days free of 
methotrexate. If the disease is highly active, pulse therapy, plasmapheresis, and 
intravenous immunoglobulin can be used.  
 
Answer to task 6 
1. Diagnosis: Sjogren's disease, chronic course, activity of the II degree with 
damage to the salivary glands (bilateral mumps) with hypofunction of the II 
degree, the oral mucosa (stomatitis), cervical caries, damage to the lacrimal glands 
(dry keratoconjunctivitis, hypolacrimia of the III art.), joints (polyarthralgia, FC I). 
2. Additional survey plan. General blood analysis, general urine analysis, 
biochemical blood analysis, RF, ANA, double-chiral DNA antibodies, Ro antigen 
antibodies (aSS-A/Ro) and more specific La antigen antibodies (aSS-B/La). 
3. Differential diagnosis: sarcoidosis, parenchymal mumps, lymphoma. 
5. Tactics of treatment. Glucocorticoids and cytostatics (hydroxychloroquine) in 
small doses for a long time. Intraocular artificial tears, cyclosporine, 
corticosteroids. Mouthwash, with the development of infection-antibacterial, 
antiseptic and antifungal drugs. 
 
Answer to task 7 
Diagnosis: granulomatosis with polyangiitis (wegenera), subacute course, 
advanced stage, activity of 3 degrees with damage to the upper respiratory tract 
(rhinitis), lungs (infiltrative lung damage, hemoptysis, DN I), kidneys 
(glomerulonephritis, morphologically unspecified, nephrotic syndrome, chronic 
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kidney disease, C3A - clarification of the stage after determining the glomerular 
filtration rate). Arterial hypertension, grade 3, risk III. Mild anemia. 
Additional survey plan. General blood analysis, general urine analysis, a sample of 
Rehberg. Biochemical analysis of blood: urea, creatinine, uric acid, total protein, 
protein fractions, potassium, sodium, CRP, with a decrease in glomerular filtration 
rate below 60 ml/min – calcium, phosphorus, parathyroid hormone. Immunological 
studies: rheumatoid factor, ANCA, circulating immune complexes, 
immunoglobulins. Computed tomography of the lungs. Biopsy of the affected 
tissues of the upper respiratory tract, kidney biopsy. 
 Differential diagnosis: other systemic ANCA-associated vasculitis (eosinophilic 
granulomatous polyangiitis, microscopic polyangiitis), other systemic vasculitis 
(nodular polyarteritis, hemorrhagic vasculitis, goodpasar's disease), diffuse 
connective tissue diseases, granulomatous diseases (sarcoidosis, berylliosis, 
eosinophilic pneumonia, Leffler syndrome, tuberculosis, syphilis), malignant 
tumors. 
Tactics of treatment. Induction therapy: GCS in combination with 
cyclophosphamide for 3-6 months, with the development of rapidly progressing 
nephritis, combined with plasmapheresis. When refractional for additionally 
prescribe infliximab (or rituximab). Maintenance therapy-GCS and 
cyclophosphamide (or azathioprine, methotrexate) for 2-5 years. 
 
Answer to task 8 
1. Diagnosis: systemic lupus erythematosus, acute course, 3rd degree of activity, 
with skin lesions (erythema of the face according to the "butterfly" type), blood 
vessels (Raynaud's syndrome, capillaries on the fingertips, palms, nail beds), joints 
(polyarthralgia), lupus nephritis (morphologically unspecified), antiphospholipid 
syndrome, category I (antibodies to cardiolipin and lupus anticoagulant), 
pancytopenia (anemia, leukopenia, thrombocytopenia). Symptomatic arterial 
hypertension. 
2. Additional survey plan. General blood analysis, common urine analysis, daily 
proteinuria, urine analysis according to Nechyporenko, zimnitskiy, a sample of 
Rehberg. Biochemical blood analysis: ALT, AST, CPK, glucose, urea, creatinine, 
total protein, albumin, CRP, potassium, sodium. Immunological markers of the 
disease: antinuclear antibodies, antibodies to double-chiral DNA, antiphospholipid 
antibodies (lupus anticoagulant, antibodies to cardiolipin, antibodies to beta-2-
glycoprotein 1) after 12 weeks. X-rays/ultrasound of the affected joints. 
Echocardiography, ECG, ultrasound of the abdominal cavity. Kidney biopsy to 
clarify the morphological variant of nephritis. 
3. Differential diagnosis: rheumatoid arthritis, mixed connective tissue disease 
(Sharpe's syndrome), dermatomyositis, systemic vasculitis. 
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4. Treatment. Pulse therapy: methylprednisolone 1000 mg intravenously for 3 
days, cyclophosphamide 600-1000 mg intravenously once. Then prescribe 
prednisone inside 1 mg/kg/day (but not more than 60 mg), cyclophosphamide is 
administered in / in a drip of 600-1000 mg 1 time per month for 6 months. Next, an 
oral cytostatic is prescribed, the prednisolone dose is reduced to 0.15-0.2 
mg/kg/day. Anticoagulants, antiplatelet agents and vasoprotection are 
recommended. Angiotensin-converting enzyme inhibitors and diuretic drugs are 
shown. 
 
Answer to task 9 
Diagnosis: IgA-associated vasculitis (hemorrhagic vasculitis, Schenlein-Genoch 
purpura), acute course, I attack, active phase, activity of 3 degrees, mixed variant 
(skin, joint and abdominal syndromes). 
Additional survey plan. General blood analysis, common urine analysis, daily 
proteinuria, urine analysis according to Nechyporenko, zimnitskiy, a sample of 
Rehberg. Biochemical blood analysis: ALT, AST, CPK, glucose, urea, creatinine, 
total protein, albumin, CRP, potassium, sodium, coagulogram. X-rays/ultrasound 
of the affected joints. Echocardiography, ECG, ultrasound of the abdominal cavity, 
FGDs, colonoscopy. 
Differential diagnosis: other systemic vasculitis with small vessel damage, 
intestinal obstruction, peritonitis. 
Treatment. Glucocorticoids (prednisolone) and cytostatics (hydroxychloroquine) in 
small doses for a long time. Disaggregants-kurantil 2-4 mg/kg per day, 
pentoxifylline 100-300 mg in 250 ml of 0.9% sodium chloride solution 
intravenously. Heparin in a dosage of 200-300 UNITS/kg of body weight per day, 
divided into 4 subcutaneous injections, is gradually canceled with a decrease in the 
single dose. In severe cases, plasmapheresis is prescribed. 
 
Answer to task 10 
Diagnosis: rheumatoid arthritis: seropositive (in the presence of RF) polyarthritis 
of the II x-ray stage, III degree of activity with systemic manifestations 
(rheumatoid nodules), functional insufficiency of the II art. NSAID-gastropathy. 
Mild anemia. 
Additional survey plan. General blood analysis, biochemical blood analysis, 
General urine analysis, determination of rheumatoid factor and antibodies to cyclic 
citruline peptide in blood serum. X-rays/ultrasound of the affected joints. 
Echocardiography, ECG, ultrasound of the abdominal cavity. 
Differential diagnosis: SLE, primary osteoarthritis. 
Treatment. Selective COX-2 inhibitors for a short time (until joint pain is reduced): 
meloxicam (or nimesulide, or celecoxib) in combination with the proton pump 
 128 
inhibitor omeprazole (20-40 mg/day). Methotrexate 20 mg per week (or 
methotrexate 20 mg per week intramuscularly), the correction of the dose of 
methotrexate is carried out depending on the response to treatment, but not earlier 
than a month. Folic acid 5 mg/week outside of methotrexate. Given the high 
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